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Stellingen 
1. The failure in BMT recipients to accumulate somatic mutations in their VH 
region genes in peripheral blood lymphocytes, correlates with an absence of IgD 
negative cells, and is consistent with a maturational arrest at a fairly late stage of 
differentiation. 
Dit proefschrift 
2. The sequence of events that occur during successful BMT can be regarded as 
a blueprint for immune reconstitution in other clinical settings. However, in the 
description and interpretation of these events, it is important to realize that 
immune reconstitution does not appear to recapitulate human fetal ontogeny. 
Raaphorst, F.M. 1998. Bone marrow transplantation, fetal B-cell repertoire development, and the 
mechanism of immune reconstitution [letter]. 
Blood 92:12, 4873 
3. Oligonucleotide hybridizations are a useful tool for identifying a large 
number of genes and to determine the occurrence of somatic mutations among 
virtually any gene without the need for sophisticated instrumentation. 
Dit proefschrift 
4. Immunodeficiencies common among BMT recipients are not due to an 
abnormal usage of VH gene segments. 
Dit proefschrift 
5. The inability of B cells from BMT recipients to accumulate somatic 
mutations appears to be a B cell autonomous deficit. 
Dit proefschrift 
6. The hematopoietic microenvironment represents a complex network of 
inductive signals, regulatory molecules, and cell-cell interactions that permit the 
simultaneous determination of various hematopoietic cell fates. The interaction 
of notch with multiple components of this regulatory network may allow it to 
function as a master regulator, integrating various signaling pathways to limit 
the number of cells that respond to diverse signals. 
Milner, L.A. and Bigas, A. 1999. Notch as a mediator of cell fate determination in hematopoiesis: 
evidence and speculation. Blood 93:8 2431 
Stellingen behorende bij het proefschrift" B cell autonomous somatic mutation deficit following 
bone marrow transplantation" van Annuska Glas, Wageningen, 2000 
7. The use of HLA-DRB1 genotyping in the early arthritis patient, during the 
initial clinical and laboratory assessment, should be a useful tool to identify a 
subset of patients with a high risk of early joint erosions and consequent poor 
clinical course. 
Nepom, G.T. 1998. Major histocompatibility complex-directed susceptibility to rheumatoid arthritis. 
Adv. Immunol. 68:315 
8. When everything is coming your way, you are in the wrong lane 
Steven Wright 
10. Ergert u niet maar verwondert u zich slechts, dan leeft u langer 
Don't be aggravated but be amazed, you'll live longer. 
12. The generation of random numbers is too important to be left to chance. 
Robert R. Coveyou 
Stellingen behorende bij het proefschrift " B cell autonomous somatic mutation deficit following 
bone marrow transplantation" van Annuska Glas, Wageningen, 2000 
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Introduction 
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The bone marrow consists of a sponge-like reticular framework filled with blood cell 
precursors from stem cells through mature cells of all haematopoietic cell types 
(except T cells), and a fair amount of adipose tissue. It is the major haematopoietic 
organ and is critically involved in the production of all formed blood elements in 
postnatal life. The bone marrow contains rapidly dividing cells from the immune 
system and therefore is sensitive to DNA damaging agents. In certain types of cancers 
where a high dose of radiation and chemotherapeutic agents are needed, a bone 
marrow transplant is necessary to "rescue" the patient from the lethal side effects of 
radiation and chemotherapy. 
More than fifty years have gone by since the first experiments in mice that lead to the 
wide application of human stem cell transplantation. In 1949 Jacobson et al [1] found 
that shielding of the spleen of a mouse during otherwise lethal irradiation permitted 
survival. Further animal studies ranging from mice to dogs and nonhuman primates 
defined the essentials of transplantation biology. The first attempts of bone marrow 
transplantation in patients were mostly unsuccessful in the early 1960s. After the 
discovery of human leukocyte antigens (HLA), which are expressed on the surface of 
essentially all cells, and are held responsible for organ and tissue graft rejection, a 
rational approach for the selection of suitable donors could be taken. The first 
successful HLA-matched marrow transplant was reported in 1968 [2]. Since the first 
grafts in the late 1960s thousands of transplants have been carried out successfully. 
According to data compiled by the International Bone Marrow Transplant Registry 
approximately 45,000 transplants were performed worldwide in 1997 only, of which 
30,000 were autologous transplants and 17,000 were allogeneic transplants, in which 
the donor was a closely matched sibling or unrelated donor [3]. However, marrow 
recipients who survive the initial post-grafting period do not always become fully 
immunocompetent; recovery of immune function takes up to several months for 
autologous transplant recipients and 1 to 2 years for patients receiving allogeneic 
transplants. The experiments described in this thesis are focused on the recovery of 
the B cell compartment following BMT. In order to understand the functional deficits 
that occur after transplant, B cell development in healthy individuals will be discussed 
first. 
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Cells of the immune system. 
Throughout postnatal life, all blood cells are derived from pluripotent stem cells in the 
bone marrow. These stem cells have the capacity to self-renew, and are able to 
differentiate along a number of alternate pathways: the lymphoid, myeloid, 
thrombocytic and erythroid lineages (Figure 1). Cells that develop along the myeloid 
lineages differentiate into neutrophils, monocytes/macrophages, eosinophils, 
erythrocytes, megakaryocytes and mast cells. 
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Figure 1. The hypothetical relationship between blood cells of the various 
lineages. All cells derive from common stem cells. Uncertainties about early steps 
in the process is indicated by dashed lines. The boxed area shows T cell 
differentiation in the thymus; the shaded area shows differentiation in peripheral 
tissue. All other steps take place in the bone marrow. 
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Lymphocytes are derived from haematopoietic stem cells that have developed along 
the lymphoid pathway. This differentiation process is only partially understood. 
Evidence for the existence of a common lymphoid precursor is limited; however, it 
seems reasonable to believe that there is a common lymphoid precursor cell that gives 
rise to the different classes of lymphocytes. Two broad classes can be recognized: B-
and T-lymphocytes; both classes are part of the specific immune system that is 
induced or stimulated by exposure to foreign substances. T lymphocytes can be 
further subdivided into two main, functionally distinct, populations: cytotoxic CD8 T 
cells that lyse cells which produce foreign antigens, and CD4 helper T cells that allow 
B cells to make antibody responses to proteins and other T dependent antigens. 
Further subsets of T cells include y8 T cells, which are a rare population in humans 
and its function is not exactly known, and suppressor T cells, which can down 
regulate the immune response. The other class of lymphocytes, the B cells, is 
responsible for the synthesis and secretion of antibody molecules. A unique feature of 
B lymphocytes is that all B cells together are pre-programmed to create an enormous 
number of antibodies. Each individual B cell creates an antibody that has combining 
sites that differ from antibodies produced by other B cells. This is achieved by 
creative use of immunoglobulin gene segments, and further fine-tuning by somatic 
mutation, which will be discussed below. 
B cell development 
The early maturation steps of B cell development take place in the bone marrow, and 
are accompanied by specific changes in the immunoglobulin structure and mRNA 
expression. The first step 
in the generation of the 
antibody repertoire 
includes combinatorial 
joining of one diversity 
(D) segment to one joining 
(JH) segment with the 
Figure 2. Sequence of human heavy chain rearrangement. V deletion of the intervening 
genes are indicated as V 1-120, D genes as D 1-25, and J 
genes as J 1-6. Gene segments and distances between them DNA, iollowed by the 
are not shown to scale. . . . „ ., 
joining oi one oi many 
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variable (VH) segments to D-JH segments to form the Ig heavy chain V domain in 
precursor pro-B cells [4;5] (Figure 2). Cells that have functionally rearranged VDJ 
regions move on to the pre-B cell stage, where the VDJ forms a pre-B cell receptor 
with a surrogate light chain [6]. In the transition to the immature B cell stage, the pre-
B cell receptor is lost and replaced as surface IgM with a light chain. The cells then 
emerge from the bone marrow as IgM-expressing, short-lived transitional B cells [7], 
and home to peripheral lymphoid organs where they continue the sequence of 
maturational steps that lead to a mature activated B cell stage. However, only a 
relatively small fraction of the transitional B cells enter the mature long-lived 
compartment. This process is thought to be competitive and dependent on survival 
signals that are delivered in secondary lymphoid organs [8;9]. Once the cells are 
recruited into the long-lived compartment, B cells are subject to an antigen dependent 
mutation and selection process that is designed to increase the affinity and functional 
efficiency of the immunoglobulin repertoire. This closely regulated process occurs in 
a specialized microenvironment, the germinal center, is helper-T dependent and is 
thought to be initiated in the T cell rich regions of the secondary lymphoid organs 
[10]. 
Germinal centers (GC) represent a complex interaction between many secreted and 
membrane bound molecules and at least three cell types: T lymphocytes, B-
lymphocytes and follicular dendritic cells (FDCs) [10]. In this tightly regulated 
microenvironment, the cells undergo the process of heavy chain class (isotype) 
switching, and somatic mutation occurs in response to specific signals [11;12] 
(reviewed in [13]). Isotype switching allows the production of antibodies that are 
capable of mediating distinct biological functions but retain the same antigen-
combining specificity. The final step of germinal center B cell development is the 
differentiation of high affinity germinal center B cells towards memory B cells and 
plasma cells. Any self-reactive B cells that are created during B cell development are 
removed from the repertoire at multiple checkpoints during the B cell maturation 
steps (reviewed in [8; 14]). 
Antibody diversity 
Several different mechanisms contribute to the pre-immune diversity of the antibody 
repertoire, such as the random pairing of heavy and light chains, and the use of 
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multiple germline gene segments to be used in recombination of V, D and J elements. 
The inclusion of a D region in heavy chain gene assembly creates a significant 
increase in diversity compared to light chain assembly. Additional diversity is created 
by flexibility of the recombination site. For example, imprecise DNA rearrangement 
in which nucleotides at the 3' end of the VH gene, both ends of the D segment and the 
5' end of the JH gene may be deleted during the recombination event. N-region 
diversification adds non-germline nucleotides to the junctions of rearranged VJ or 
VDJ genes, which is catalyzed by the enzyme TdT [15-17]. Less frequently, extra 
bases are added that are palindromic to the termini of the rearranging gene segments, 
and are called P-nucleotides [18]. These insertions are the result of the opening of 
hairpin ends in an asymmetric position during VDJ recombination and contribute to 
the diversity. 
Somatic mutation 
After antigenic stimulation, the Ig heavy and light chain genes undergo another type 
of structural alteration, namely somatic mutation, which contributes to the generation 
of an even more diverse antibody repertoire. Somatic mutation is a unique feature of 
B cells. It is triggered by T cell dependent responses and is characteristic of a 
germinal center reaction [19]. In the somatic mutation process, random mutations are 
introduced in the variable regions of the immunoglobulin genes to increase the 
affinity and functional efficiency of the immunoglobulin repertoire. 
The somatic mutants undergo affinity selection by antigens presented by FDCs in the 
germinal center. Cells with high affinity immunoglobulin variants pick up antigen 
from the FDCs, process and present the antigen to T cells in the germinal center and 
differentiate into memory B cells and plasma cells. However, random mutations 
introduced in the VH genes can cripple the Ig receptor by altering its structural 
integrity as well. Cells expressing low affinity receptors or crippled receptors fail to 
acquire sufficient antigen and die by apoptosis [20]. 
A number of models have been described that involve DNA repair in somatic 
mutation [21], however the exact mechanism of somatic mutation remains unknown. 
It is known that the accumulation of somatic mutation is highly focused in rearranged 
variable genes [22-24], is primarily composed of point mutations [25;26], and seems 
17 
to occur without regard to receptor affinity [27]. The rate of somatic mutation in Ig 
genes is 10"3 to 10"4 per base pair per generation (reviewed in [28]) and is similar to 
the range of intrinsic errors when DNA polymerase proofreading and mismatch repair 
are absent (reviewed in [21]). 
Several in vitro models have been described that mimic germinal center reactions [29-
33], yet the precise mechanism of activating the somatic mutational process is poorly 
understood. These models however, are valuable for analyzing extrinsic signals, 
enzymes and regulatory mechanisms that are responsible for the somatic mutation 
process. For instance it has been shown that activated T lymphocytes are required for 
somatic mutation to occur [11;27], and activated T cell-associated molecules, CD40 
ligand (CD40L) and CD86, were shown to be important for the formation of germinal 
centers [34-36]. 
Genomic organization of immunoglobulin genes. 
The organization of rearranging Ig receptor gene segments is important in the 
generation of antibody diversity. The use of multiple germline gene segments creates a 
vast number of antibodies with different recombining sites. The human heavy chain 
variable region locus contains approximately 120 VH region gene segments [37-39], 
although haplotypes may vary considerably with respect to numbers of gene segments 
[40-42]. Approximately 40 VH gene segments are functional or transcribed [39]. 
Twenty-five D segments [43] and 6 JH gene segments [44;45] are located downstream 
from the VH gene segments. The estimated combinatorial diversity is approximately 
6000 [39]. This number varies because of allelic variation between individuals. The 
constant regions encoding exons are just downstream of the J regions. 
The genes encoding the human immunoglobulin heavy chain comprise the most 
telomeric locus on the long arm of chromosome 14 (14q32.3) [46-48]. Additional VH 
gene segments, all of which are pseudogenes, are located on chromosomes 15 and 16 
[49;50]. The human VH genes can be grouped into seven distinct families based on 
amino acid [51] or nucleotide sequence similarities [52-57]. Generally, sequence 
identity is >80% within families, but <70% between families. Gene segments 
comprising the human VH families are highly interspersed [53-55;58-63]. The genes 
encoding human immunoglobulin kappa light chains and lambda light chains are 
situated in multi-gene clusters on chromosomes 2, and 22, respectively. 
The expressed repertoire. 
The adult repertoire of antibody specificities has been thought to be derived from the 
random rearrangement (and subsequent selection) of functional VH and VL gene 
segments. The frequency with which members of a gene family were recovered from the 
repertoire was thought to reflect the complexity (or size) of the family [64-67]. 
However, analysis of individual VH3 and VH4 genes in unselected B cells shows that 
the adult repertoire represents a markedly biased sample of the germline repertoire 
[68-80]. Rather than a random assortment, a small number of VH segments dominate 
rearrangements in peripheral B cells (reviewed in [81]). The V3-23 gene for example 
a. 
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Figure 3. Frequency of occurence of individual VH3 and VH4 genes among rearrangements 
from peripheral blood B cells of healthy adults. Frequencies are calculated independently 
for VH3 and VH4 genes. Circles represent individual subjects. Bars represent the mean 
percentage of rearrangements for each VH gene. (From Glas et al, 2000 [81]) 
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is the most commonly expressed VH gene. Its expression is disproportionate among 
randomly assessed B cells and comprises as much as 40% of all VH3 expressing B 
cells [69;70;73;76-78]. V3-30 and V3-33 are also commonly rearranged [73;76;78]. 
Four V region genes, V3-11, V3-15, V3-20, and V3-74, made lesser contributions to 
rearrangements, and the remaining element, V3-64 was rarely represented among 
rearrangements in a population of 12 subjects [73]. Despite this clear-cut pattern of 
biased utilization seen on a population basis, there is considerable variation between 
subjects (Figure 3). 
Similar to the utilization of VH3 gene segments, the utilized VH4 repertoire includes 
over-expressed and under-expressed elements (Figure 3). Three genes (V4-4b, V4-31, 
and V4-34) accounted for more than half of all VH4 rearrangements in four subjects 
[70]. A single gene, V4-34, accounted for more than 25 percent of VH4 
rearrangements [70;75], and gene segment V4-59 accounted for 20 to 28 % of all VH4 
rearrangements [82;83]. Three VH4 gene segments, CH15-8, V4-55, and V4-28 and 
its allele V4-28b, are not or rarely found in rearrangements. Of these genes, segment 
V4-55, is classified as a pseudogene because of a stopcodon in CDR1, but this defect 
should not prevent its rearrangement. It is somewhat surprising, therefore, that V4-55 
is not even represented among non-productive rearrangements [70;84]. It is possible 
that an additional, previously undetected, defect located in the recombination signal 
sequence of this gene precludes rearrangement. Another of these unrearranged gene 
segments, CH15-8, is located outside the VH locus on chromosome 15 [37;50], 
indicating that CH15-8 can not be rearranged by virtue of being an orphon. The third 
gene (comprised of two alleles, V4-28 and V4-28b) is located approximately 500 kb 
5' to JH and maps between V3-30 and V3-23. The reason why this gene is not 
rearranged has not been determined. The sequence of one allele of this locus, 
including 5' and 3' flanking regions, has been reported [39;85] and appears to encode 
a fully functional gene. The absence of this gene in the mature B cell pool does not 
seem to be due to selection processes, since rearranged V4-28 and V4-28b genes are 
absent from the pre-B and pro-B cell pool as well [82;86]. 
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Stability of the expressed repertoire. 
The rearranged VH repertoire in peripheral B cells should be reasonably constant, 
because most of B cells in peripheral blood are pre-immune cells. To determine if the 
repertoire was stable over time, the variability in one donor was assessed by analyzing 
rearrangements in B cells obtained 8 months and two years apart. The relative 
stability of the utilized repertoire was striking, little change was observed with 
representation of most VH3 or VH4 genes increasing or decreasing only slightly 
[70;81]. 
Although one could imagine that in some pathologic circumstances the pattern of VH 
utilization might change, this has not been observed frequently. Some studies have 
suggested a bias in the repertoire in autoimmune and neoplastic B cells [64;69;79;87-
91]. In rheumatoid arthritis (RA) patients, certain heavy chain V genes have been 
found to be preferentially used for encoding autoantibodies [92-98]. However, while 
usage of individual VH genes was highly biased among RA patients, no evidence of a 
distortion in the bias was observed compared to healthy controls [83]. Systemic lupus 
erythematosis (SLE) is an autoimmune disease characterized by the production of 
anti-dsDNA antibodies. In a recent study by Dorner et al [99], no differences were 
found in the repertoire of an SLE patient when non-productive rearrangements were 
analyzed and compared to the repertoire in healthy subjects. However, the VX and the 
VH repertoires in productive rearrangements were markedly skewed, suggesting that 
extreme B cell over-activity drives the initial stages of SLE, leading to remarkable 
changes in the peripheral VH gene usage that may underlie the failure to prevent the 
emergence of autoimmunity [99]. 
Repertoire biases during B cell development. 
The developmental stage in which the bias in the repertoire begins was analyzed using 
pre-B as well as immature B cells from the bone marrow. A strong bias in the usage 
of certain VH3 and VH4 family genes was shown [82], similar to that seen in the 
peripheral repertoire. In these B cell stages however, the bias may reflect both 
rearrangement frequency as well as the contribution of selection occurring at later 
stages of development, e.g. efficiency of |j. chain (surrogate light chain) paring at the 
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pre B cells stage or ligand selection at the immature B cell stage. By studying 
individual VH gene segments among out of frame rearrangements from pro-B cells, the 
frequencies of the individual rearrangements would reflect only processes before 
translation of the u-heavy chain and should not be biased by selection mechanisms. Rao 
et al [86] demonstrated that at the pro-B cell stage some individual VH gene segments 
are more frequently rearranged than others, similar to that seen in mature B cells, 
suggesting that the predominant expression of these genes in peripheral mature B cells 
is determined to a significant degree by their preferential rearrangement during V-DJ 
recombination [86]. 
It was thought that the VH genes used to encode antibodies expressed earliest in 
human and murine fetal development comprised a special subset of the total repertoire 
of VH genes available to the adult, e.g. proximal to the D locus [55;100-103]. Several 
studies have suggested that the single member VH6 family is preferentially used in the 
fetal repertoire [103-105]. However, we now know that the repertoire is more limited 
than previously thought, and the bias seen in the human fetal liver repertoire [55;106-
109] and fetal bone marrow repertoire [86] is similar to that seen in the adult bone 
marrow [82; 110] and adult peripheral blood. However, it appears that the fetal bone 
marrow repertoire resembles the adult repertoire more closely than the fetal liver 
repertoire does [86]. Chromosomal location does not seem to influence rearrangement 
in the fetal repertoire [108;109;111-113]. Nonetheless, analysis of the adult repertoire 
does reveal some differences in composition compared to the fetal liver repertoire. For 
instance, the VH element V3-30.3 was found to be the predominant element in the 
fetal repertoire [55; 106] but is a relatively minor element in the adult repertoire [70]. 
Among the VH4 genes, the genes V4-34 and V4-39, which were not or rarely found in 
the fetal liver repertoire, are predominant VH4 genes utilized in the adult repertoire. 
While the repertoires of the adult subjects differed with respect to a number of genes, 
some of these differences have been directly attributed to the presence or absence of 
specific elements in the germline. Similar germline analysis is not generally available 
for the fetal subjects. 
B cell development following bone marrow transplantation. 
Shortly after the high dose treatment of chemotherapeutic agents and radiation is 
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complete, patients receive the replacement marrow through an intravenous catheter. 
Engraftment of the marrow usually occurs within about 2 to 4 weeks following 
transplantation. Because BMT recipients have to regenerate their immune system 
from the transplanted bone marrow, it is not surprising that patients exhibit 
immunodeficiencies during the first three months after transplant. Both natural and 
specific immunity are affected. Persistent deficits in patients are often associated with 
graft versus host disease (GVHD), which is a frequent complication of allogeneic 
BMT. GVHD is the result of an immune reaction of the engrafted lymphoid cells 
against tissues of the host, impairing their ability to function and increasing the 
patients susceptibility to infection. 
After transplant, B-lymphocytes recover slowly in number and function (reviewed in 
[114]) and approach normal levels or even supranormal levels by 1-2 years following 
transplant [ 115; 116]. Coincident with recovering B cells, serum IgM, IgGi and IgG3 
levels but not IgGi. lgG.t and IgA levels return to normal by 1 year post transplant 
[117-124]. Early post-transplant B-lymphopoiesis is mono- or oligoclonal [125-128], 
and restricted clonality is more frequent in patients with chronic GVHD [129]. Some 
long-term survivors suffer from opportunistic bacterial infections, especially with 
encapsulated bacteria such as Streptococcus pneumoniae and Hemophilus influenzae 
type b [130; 131]. Because immune responses to polysaccharides present in bacterial 
capsules are typically T-independent, at least a portion of the defect is likely intrinsic 
to B cells. The complete reconstitution of B cell immunity in recipients can take 
years. 
The nature of the B cell defect(s) leading to the specific humoral immunodeficiency in 
BMT recipients is uncertain. It has been suggested that B cell development after 
transplant resembles ontogenic B cell development [115-117;132-134] in that 
similarities are seen in BMT survivors and normal infants. For example recovering B 
cell numbers, B cell phenotype, the delay in Ig production, and the use of certain 
immunoglobulin (Ig) genes[l 14-117; 133-137]. But as shall be discussed in Chapter 6, 
evidence based on the usage and diversity of the rearranged heavy chains, indicates 
that post transplant development is different from ontogenic development. 
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This thesis. 
In this thesis experiments are described that are aimed at a further understanding of 
the nature of the B cell defect(s) that contribute to the immune deficiencies following 
BMT. Normal levels of serum IgM and IgG [122; 123] indicate that 
immunodeficiency is not due to a general failure to produce immunoglobulin or an 
overt lack of T cell help in heavy chain class switching. One possibility that is 
addressed in this thesis is that an abnormal usage of the VH genes may contribute to 
the humoral immunodeficiency seen in BMT recipients. The usage of VH families 
following BMT appears to mimic usage during B cell ontogeny [135;136]. Thus, to 
account for the observed immunodeficiencies, it might be expected that during the 
first year post transplant, BMT patients would utilize a more limited set of V genes 
than would healthy adult subjects; this is the subject of Chapter 3. 
The results indicated that the utilization of VH genes was normal after transplant, but 
the accumulation of somatic mutations in peripheral blood B cells was much greater 
among rearrangements in controls than in BMT recipients. To determine the intrinsic 
capacity of transplant recipient naive B cells to acquire somatic mutations, a model 
was developed that mimics a germinal center reaction in vitro and is described in 
Chapter 4. Chapter 5 details the utilization of this model to determine if the somatic 
mutation process in B cells from BMT recipients could be activated in vitro, and to 
determine if the lack of somatic mutation in BMT recipients in vivo is a consequence 
of an intrinsic B cell deficit, or a lack of adequate T cell help. 
To study the VH repertoire in multiple individuals, a fast and reliable technique was 
needed. Nucleotide sequence analysis is useful but provides a relatively small data set. 
To this end, a highly sensitive hybridization technique [41;63;138-140] was adapted 
for identification of VH genes in cDNA libraries and for the analysis of mutation in 
these genes. The use of motif-specific probes to identify individual genes and to 
detect somatic mutation is the subject of Chapter 2. 
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Abstract 
This report describes the correlation between motif-specific hybridization and necleotide sequence as an approach to the 
identification of individual human VH genes using motif-specific oligonucleotide probes, complementary to specific motifs within 
individual VH genes. The sensitivity of the hybridization and post washing processes permits discrimination of single nucleotide 
differences between probe and target. This feature is used both to identify individual genes, as well as to detect mutations in 
genes by sequential hybridization with multiple probes. In addition to the general strategy, specific details are provided for the 
identification of 12 VH3 genes and 14 VH4 genes. © 1999 Elsevier Science Ltd. All rights reserved. 
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1. Introduction 
Analysis of multi-gene families comprised of closely 
related genes, and discrimination between germline 
variation and somatic mutation can be prohibitively 
labor intensive or require sophisticated instrumenta-
tion. We have employed an approach which requires 
no specialized instrumentation and can be performed 
in any moderately equipped laboratory. Essentially, 
the method is to hybridize recombinant libraries con-
taining genes of interest with motif-specific, synthetic 
oligonucleotide probes targeted to unique sequences of 
individual genes. The use of synthetic oligonucleotides 
as probes has been well described (Wallace et al., 1979; 
Wallace et al., 1981; Conner et al., 1983; Verlaan-de 
Vries et al., 1986; Amar et al., 1987; Gitschier et al., 
•Corresponding author. Tel.: +206-223-8840; fax: + 206-223-
7543. 
E-mail address: emilner@vmmc.org (E.C.B. Milner) 
1986; Guillaume et al., 1990; Macintyre et al., 1990). 
Under appropriate hybridization and washing con-
ditions, single nucleotide mismatches between probe 
and target can be readily discriminated from perfect 
matches (Wood et al., 1985; Sasso et al., 1990). 
Therefore, a sequence motif detected by one probe will 
not be detected by another probe targeted to another 
gene or another region of the gene. The method is use-
ful for the analysis of any multi-gene family, where 
discrimination between highly similar elements is 
desired. 
Our particular focus has been on the human immu-
noglobulin heavy chain variable region (VH) genes, 
which comprise a complex multi-gene locus containing 
approximately 100 haploid elements. We have gener-
ated and used synthetic oligonucleotides corresponding 
to human immunoglobulin VH sequences. By using 21 
base pair probes in conjunction with high stringency 
hybridization and washing conditions, it has been 
possible to unambiguously identify individual germline 
VH genes, based on the occurrence of unique sequence 
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motifs, and to identify variation in closely related 
germline genes (Willems van Dijk et al., 1989; Sasso et 
al., 1990; Willems van Dijk et al., 1991; Willems van 
Dijk et al., 1992; Sasso et al., 1992; van der Maarel et 
al., 1993; Willems van Dijk et al., 1993). An outgrowth 
of these studies was the establishment of diagnostic cri-
teria for identification of specific VH elements. These 
criteria have been used in several studies to analyze V-
gene use among peripheral B cells (Suzuki et al., 1995; 
Glas et al., 1995; Suzuki et al., 1996; Milner et a l , 
1995; Huang et al., 1996; Glas et al., 1997; Hufnagle et 
al., 1995; Milner, 1996; Huang et al., 1998; Rao et al., 
1996; Kraj et al., 1997). Similar criteria have been used 
in other studies (Guillaume et al., 1990; Stewart et al., 
1993). 
Because of the high degree of specificity, the unique-
ness of a motif is determined by single nucleotides. 
Probes can be effectively targeted to single nucleotide 
substitutions that distinguish otherwise identical 
sequences. Many of the VH genes have multiple unique 
nucleotides that can be targeted, permitting the gener-
ation of multiple diagnostic probes, each one of which 
detects a distinct motif of that particular gene. 
Motif-specific probes can be used not only to ident-
ify individual genes but to detect somatic mutation as 
well. By sequential hybridization with multiple oligo-
nucleotide probes, mutations in individual genes can 
be detected. For example, if a gene carries three unique 
motifs, the sequence of the particular gene can be 
detected by a probe directed at any one of the three 
motifs. If hybridized sequentially, concordant results 
indicate that the germline sequence has been retained 
through the target region of each probe. However, 
genes that have accumulated mutations in the target 
site of one or more of the probes will display a loss of 
concordance when hybridized (Suzuki et al., 1996). 
Loss of concordance is easily scored and provides an 
index of the acquisition of somatic mutations. In this 
report we show the specificity of the oligonucleotide 
hybridization and its correlation with nucleotide 
sequence. We illustrate the use of the method for iden-
tifying individual VH gene segments in rearrangements, 
and for the detection of somatic mutations. 
2. Materials and methods 
2.1. Cell preparations 
Peripheral blood mononuclear cells (PBMC) were 
isolated from a Ficoll-Hypaque gradient. B cells were 
stained with fluorescein-conjugated anti-IgM or anti-
IgD (Coulter), phycoerythrin-conjugated anti-CD 19 or 
CD20 (Coulter), or appropriately conjugated mouse 
immunoglobulin isotype control antibodies. Viable 
lymphocytes were selected on the basis of forward and 
40 
side angle light scattering criteria. A Coulter Epics 750 
or a Becton-Dickinson Facstar flow cytometer was 
used to sort B cells into positively stained fractions. 
The non-B cell (negative) fraction of each sort was 
also collected. The purity of the sorted B cells ranged 
from 94 to 95%. 
2.2. Rearrangement library construction 
Purified B cells (CD19+ or CD20 + ) were lysed in 
cell lysis buffer (50 mM Tris, pH 8.0, 1 mM EDTA, 
0.5% Nonidet P-40, 0.5% Triton X-100, 0.5% Tween 
80, and 200 ug/ml proteinase K) and incubated at 
50°C for 30 min. Cell lysates were sonicated for 30 s 
using a Sonifier 450 (Branson, Danbury, CT) fitted 
with a cup horn, at 50% duty cycle, 50% output to 
provide more uniform PCR amplification. Proteinase 
K was heat-inactivated by incubation for 10 min at 
95°C. The rearranged VH genes were amplified using 
one of the family-specific 5' primers, E68 (VH3-L), 5'-
CTGAATTCCATGGAGTTTGGGCTGAG-3' or E74 
(VH4-L), 5 '-CCGAATTCATGAAACACCTGTGGT-
TCTT-3', corresponding to the 5' ends of the leader 
sequences of VH3 and VH4 families respectively, and 
the 3' primer E71, 5 -GCTCTAGACT(T/C)ACCTG-
AGGAGACGGTGA-3', complementary to the 3 ' end 
of the 6 JH gene sequences. Restriction sites (EcoRI 
for 5' primers; Xba\ for 3 ' primers) included in the pri-
mers are underlined. An aliquot of lysate containing 
15,000-50,000 cell equivalents was amplified by PCR 
using AmpliTaq DNA polymerase (Perkin Elmer, 
Fostercity, CA) and using cycle conditions to obtain 
amplification in the linear range; a denaturation step 
of 1 min at 95°C, then 30 cycles of 45 s at 94°C, 30 s 
at 60°C, 1 min at 72°C, and a last extension step of 
3 min at 72°C. The DNA polymerase has an error rate 
of 1 x 10~5 per base pair according to the manufac-
turer. The linearity of the PCR reactions has been con-
firmed by electrophoresing [a-32P]dCTP-incorporated 
PCR products of different cycle points on a 2.0% 
agarose gel and quantifying the bands by phosphor 
imaging (data not shown). The PCR products were 
cloned into EcoRl/Xbal digested pBS + phagemid vec-
tor (Stratagene, La Jolla, CA) and the recombinant 
plasmids were used to transform Epicurian Coli XL2-
Blue MRF ' ultracompetent cells (Stratagene). The 
transformants, about 400 per library, were toothpicked 
into wells of a 96-well plate containing Luria-Bertani 
medium with 75 ug/ml carbenicillin or ampicillin. 
Single-stranded DNA was recovered by adding 
(5 x 108 pfu/ml) VCSM13 Interference-Resistant 
Helper Phage (Stratagene). After a 1 h incubation 
period at 37°C, kanamycin was added to 75 ug/ml and 
the cultures were grown for another 16-20 h. 
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Table 1 
Oligonucleotides corresponding to human VH sequence motifs. The probes are listed in 5'-3' orientation and are oriented in the sense direction 
with respect to the coding sequence of the VH gene segment 
Oligonucleotide Sequence Gene Location 
E7 
E8 
E13 
E22 
E35 
E36 
E39 
E41 
E42 
E43 
E44 
E53 
E54 
E56 
E57 
E58 
E83 
E87 
H110 
H139 
M8 
M16 
M18 
M19 
M20 
M24 
M25 
M41 
M42 
M69 
M76 
M84 
M85 
M86 
M91 
M93 
M98 
M99 
M100 
M101 
M105 
M109 
M112 
M122 
TCCATCAGTAGTTACTACTGG 
TCCATCAGCAGTGGTAGTTAC 
TCCGTCAGCAGTGGTAGTTAC 
GCAGTTATATCATATGATGGAAGC 
AGTGACTACTACATGAGCTGG 
AGTGGTAGTACCATATACTAC 
GAAATCCATCATAGTGGGAGC 
GAAATCAATCATAGTGGAAGC 
AGTATCTATTATAGTGGGAGC 
TATATCTATTACAGTGGGAGC 
CGTATCTATACCAGTGGGAGC 
TCAGCTATTGGTGCTGGTGGT 
TCAGCTATTGGTACTGGTGGT 
TACATCTATCATAGTGGGAGC 
GAAATCTATCATAGTGGGAGC 
TACATCTATTACAGTGGGAGC 
AGTAGCAACTACATGAGCTGG 
TCAGCTATTAGTGGTAGTGGT 
CGTATTAAAAGCAAAACTGAT 
TACATCTATTATAGTGGGAGC 
AGCAGCTATGCCATGAGCTGG 
AGTAGCTATGGCATGCACTGG 
GTGAAGGGCCGGTTCACCATC 
GGAAGCAATAAATACTACGCA 
GGAAGTAATAAATACTATGCA 
GGTGGTAGCACATACTACGCA 
TACGCAGACTCCGTGAAGGGC 
GGAAGTAATAAATACTACGCA 
AGCTGTTGGAGTCTGGGGGAG 
TGGTGGAGCTGGGTCCGCCAG 
GCAGTTATATGGTATGATGGA 
AGTAGCTACTGGATGCACTGG 
AGTAGCTACGACATGCACTGG 
GGTGGTTACTCCTGGAGCTGG 
GATGATTATGGCATGAGCTGG 
GTCCGCCAGGCTCCAGGCAAG 
AGTGGTGGTTACTACTGGAGC 
AGTAGTAGTTACTACTGGGGC 
AGCAGTAGTAACTGGTGGGGC 
AGCAGTGGTAACTGGTGAATC 
AGTGGTGATTACTACTGGAGT 
AGTGGTTACTACTGGAGCTGG 
AAGCCTTCGGAGACCCTGTCC 
GGTAGTTACTACTGGAGCTGG 
V4-59, V4-4 
V4-61b 
V4-61 
V3-30.3 
V3-11 
V3-11 
V4-55p 
V4-34 
V4-39 
V4-59, V4-61 
V4-61b 
HC16-11 
V3-47p 
V4-30.2 
V4-4, V4-4b, CHI5 
V4-31, V4-31b, 
V3-53 
V3-23 
V3-15 
V4-28, V4-28b 
V3-23 
V3-30 
V3-23 
V3-30.3 
V3-30 
V3-23, V3-53 
V3-23, V3-53 
V3-30b 
V3-23 
CH15 
V3-33 
V3-74p 
V3-13 
V4-30.2 
V3-20 
V3-30 
V4-31, V4-31b 
V4-39 
V4-28, V4-28b 
V4-55p 
V4-30.4 
V4-34 
V4-30.4 
V4-39, V4-80, CH15, V4-34, V4-4, V4-55p, V4-61, V4-59 
V4-61, V4-61b 
CDR1 
CDR1 
CDR1 
CDR2 
CDR1 
CDR2 
CDR2 
CDR2 
CDR2 
CDR2 
CDR2 
CDR2 
CDR2 
CDR2 
CDR2 
CDR2 
CDR1 
CDR2 
CDR2 
CDR2 
CDR1 
CDR1 
CDR2FR3 
CDR2 
CDR2 
CDR2 
FR3 
CDR2 
FR1 
CDR1FR2 
CDR2 
CDR1 
CDR1 
CDR1 
CDR1 
FR2 
CDR1 
CDR1 
CDR1 
CDR1 
CDR1 
CDR1 
FR1 
CDR1 
2.3. Germline library construction 
VH family-specific germline libraries were similarly 
generated as above from either the negative fraction 
collected from the cell sorts or unsorted PBMC. PCR 
reactions used for constructing VH3 libraries were car-
ried out using the 5' primer E68 and either the 3' pri-
mer E46, 5 -GACTCTAGACAATGACTTCCCCTC-
ACT-3', which is complementary to the 3' flanking 
recombination signal sequence of VH3 genes, or E88, 
5 ' -GACTCTAGATCTCAGGCTGTTCATTTG-3 ' , 
which is complementary to a conserved VH3 FR3 
sequence. PCR reactions used for constructing VH4 
libraries were carried out using the 5' primer E74 and 
either the 3 ' primer E45, 5 -AATTCTAGACTGGG-
CTCACACTCACCTCC-3', which is complementary 
to the 3' flanking recombination signal sequence of 
VH4 genes, or E89, 5 -AATTCTAGAC ACAGAGC-
TCAGCTTCAG-3', which is complementary to a con-
served VH4 FR3 sequence. 
2.4. Library screening 
Multiple replicate filters were prepared by dot blot-
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ting approximately 10 ul of supernatants containing 
phage particles in a 96-well grid on Hybond N + nylon 
membranes (Amersham, Arlington Heights, IL). 
Filters were denatured in 0.5 M NaOH, 1.5 M NaCl, 
neutralized in 0.5 M Tris-HCl pH 7.0, 3 M NaCl, and 
UV cross-linked. Hybridization with a 32P-labeled full 
length probe allowed a determination of the total num-
ber of recombinant clones in each library. The cDNA 
clone 58p2 (Schroeder et al., 1987; Willems van Dijk et 
al., 1991) was used for the VH4 family-specific probe, 
and cDNA clone 56p2 (Schroeder et al., 1987; Willems 
van Dijk et al., 1989) was used for the VH3 family 
specific probe. The probes were labeled by random 
hexamer priming (Feinberg and Vogelstein, 1984). 
Hybridization of the family-specific VH probes to repli-
cate filters was performed in 50% formamide, 
5 x SSC, 1 x Denhardt's, 20 mM NaP0 4 , pH 7.6, 
50 ug/ml salmon testes DNA, 10% Dextransulfate, 
and 50 ug/ml tRNA (50 x Denhardt's is 1 % polyvinyl-
pyrrolidone, 1% Bovine Serum Albumen, 1% Ficoll, 
all wt/vol) for 16 h at 42°C. Final washes after hybrid-
ization were performed in 0.1 x SSC, 0.1% SDS at 
60°C for 1 h. 
The panel of diagnostic oligonucleotide probes listed 
in Table 1 were also hybridized to replicate filters. 
Oligonucleotide probes were end labeled using T4 
polynucleotide kinase in the recommended buffer to a 
specific activity of approximately 1 x 109 cpm/ug. 
Hybridization of oligonucleotides to replicate filters 
was performed in 6 x NET, 5 x Denhardt's, 0.1% 
SDS, 0.05% Nonidet P-40, 5 mM EDTA, 250 ug/ml 
tRNA and 250 ug/ml salmon testes DNA (12 x NET 
is 1.2 M NaCl, 0.3 M Tris, pH 8.0, 12 mM EDTA). 
The filters were prehybridized in the hybridization 
solution for 1-4 h and were hybridized at 5°C above 
the melting temperature (Tm) for 30 min and 5°C 
under the Tm overnight. The Tm is estimated using 
2°C for A + T and 4°C for G + C. After hybridiz-
ation the filters were washed three times at 43°C in 
5 x SSC, 0.5% SDS for a total of 2 h. This was 
followed by a wash in 3.2 M Tetramethylam-
moniumchloride (TMACL) (Aldrich, Milwaukee, WI), 
0.5% SDS, 0.05 M Tris, pH 7.8 for 1 h (modified 
from Wood et al., 1985). The predicted melting 
temperatures of oligonucleotides in TMACL as 
determined by probe length is approximately 62°C 
for 21 base pair probes (Wood et al., 1985). The 
TMACL post wash temperatures were empirically 
determined to be 55°C for probe M99, 57°C for 
probe HI39, 59°C for probes E43 and M69, 61°C 
for probes E22 and E53, 61.5°C for probe M109 
and 62°C for probes M18 and M93. All other 
probes were post-washed at 60°C. The filters were 
exposed for a maximum of 3 h to Kodak X-OMAT 
AR film in metal cassettes at —70°C, with enhancing 
screens. 
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Table 2 
Accuracy of motif-specific hybridization 
Probe 
VH4 E7 
E8 
E13 
E39 
E41 
E42 
E43 
E44 
E56 
E57 
E58 
H139 
M69 
M86 
M98 
M99 
M100 
M101 
M105 
M109 
M112 
M122 
All VH4 
VH3 E22 
E35 
E36 
E53 
E54 
E55 
E83 
H110 
M8 
M16 
M18 
M19 
M20 
M24 
M25 
M41 
M42 
M76 
M84 
M85 
M91 
M93 
All VH3 
Correct 
117 
117 
117 
49 
116 
116 
117 
117 
49 
117 
115 
117 
117 
115 
116 
46 
117 
117 
116 
115 
48 
117 
2288 
38 
21 
88 
38 
38 
14 
36 
88 
75 
70 
93 
88 
36 
37 
38 
74 
5 
87 
36 
71 
36 
72 
1179 
Incorrect 
0 
0 
0 
0 
1 
1 
0 
0 
0 
0 
2 
0 
0 
2 
1 
3 
0 
0 
1 
2 
1 
0 
14 
0 
0 
0 
0 
0 
0 
0 
0 
1 
1 
0 
0 
2 
1 
0 
0 
0 
1 
0 
0 
0 
2 
8 
Percentage correct 
100.0 
100.0 
100.0 
100.0 
99.1 
99.1 
100.0 
100.0 
100.0 
100.0 
98.3 
100.0 
100.0 
98.3 
99.1 
93.9 
100.0 
100.0 
99.1 
98.3 
98.0 
100.0 
99.4 
100.0 
100.0 
100.0 
100.0 
100.0 
100.0 
100.0 
100.0 
98.7 
98.6 
100.0 
100.0 
94.7 
97.4 
100.0 
100.0 
100.0 
98.9 
100.0 
100.0 
100.0 
97.3 
99.3 
2.5. DNA sequence analysis 
DNA sequence analysis was performed using the 
Taq DyeDeoxy Terminator Cycle Sequencing Kit (PE 
Applied Biosystems) on the Applied Biosystems Model 
373A DNA Sequencing System. Sequencing reactions 
were primed with either a universal primer (T7 or T3 
sequencing primers) or oligonucleotide E61, 5'-
CTGTTCACAGGGGTCCTGTC-3', which corre-
sponds to the leader sequence of VH4 gene segments. 
A.M. Glas et al. / Molecular Immunology 36 (1999) 599-610 603 
Additional primers were used to determine the com-
plete sequence of rearrangements, E36, Ml8, M76, 
E99: 5'-AGTTACACCACAGAATACGCC-3', M10: 
5'-ATATGATGGAAGTAATAAAT-3', M22: 5'-
ACTGATGGTGGGACAACAGAC-3', M92: 5 -
TGCATAACCTGTGCTACCACC-3', corresponding 
to motif-specific sequences of V3-11, V3-23, V3-33, 
V3-72, V3-30, V3-15, and V3-20 respectively. 
3. Results and discussion 
3.1. Specificity of the oligonucleotide probes 
Under the appropriate hybridization and washing 
conditions single nucleotide mismatches between probe 
and target can, in principle, be detected (Wood et al., 
1985; Willems van Dijk et al., 1989; Sasso et al., 1990). 
To assess the practical application of this principle, 
and its utility for the analysis of a complex multi-gene 
family, we compared motif-specific hybridization 
results with nucleotide sequences among more than 
200 closely related cloned genes. Recombinant libraries 
were generated as described, and were assessed by hy-
bridization and sequence analysis. The hybridization 
results were then scored as correct or incorrect hybrid-
ization results by comparison to sequence results. Two 
conditions, corresponding to the two concordant poss-
ible outcomes, were scored as a correct hybridization 
result: (1) when a clone was positively identified by hy-
bridization to a specific probe and this result corre-
sponded to the presence of the target sequence, or (2) 
the absence of a hybridization signal corresponded to 
the absence of the exact target sequence. Two con-
ditions were scored as incorrect hybridization: (1) a 
clone was positively identified by hybridization to a 
particular probe, but the target sequence contained at 
least one nucleotide difference from the probe, or (2) 
there was no hybridization signal but the target 
sequence was present, as determined by sequence 
analysis. A total of 210 clones were analyzed by hy-
bridization with 43 probes and by sequence analysis. 
For each individual probe, scoring of hybridization 
results are based solely on homologous combinations, 
i.e., VH3 probes on VH3 clones, and VH4 probes on 
VH4 clones. Results are shown in Table 2. 
The concordance between hybridization data and 
sequence analysis is very high. Nearly two thirds of 
the probes were correct 100% of the time, i.e., yielded 
hybridization results that were in complete agreement 
with sequence data. Among the remaining probes, only 
two were incorrect more than 5% of the time. Overall, 
the probes were correct 99.4% of the time (Table 2). 
When the results of all oligonucleotides are taken 
together, the error incidence was low. Among 3489 hy-
bridization events, 22 errors were detected. Two of 
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Fig. 1. Identification of VH4 gene segments in heavy chain gene re-
arrangement libraries and germline libraries. Recombinant clones 
were picked into 96 well plates and grown overnight in the presence 
of helper phage. Aliquots of single stranded template were trans-
ferred to nylon membranes for hybridization analysis. The filters 
were hybridized with a full-length VH4 probe (top panels) and gene-
specific oligonucleotide probes E41, E58, M98, and M105. 
these errors lead to incorrect identification of a clone, 
e.g. sequence analysis identified a different gene than 
did hybridization analysis. Also two clones were not 
identified by hybridization, but should have been 
identified according to sequence data. The other 18 
errors did not lead to misidentification of clones. In 
total, misidentification of clones using oligonucleotides 
was 1.8%. These results demonstrate that the accuracy 
of the approach is very high, and that mistaken hy-
bridization results are rare, and are a minor source of 
3.2. Identification of individual VH genes contained in 
rearrangements 
We have used these oligonucleotides to analyze 
immunoglobulin VH genes in peripheral blood B cells. 
The frequency of occurrence of individual VH gene 
segments in libraries containing rearranged VH genes 
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c l o n e 3 A 0 - \ . - . , , . . „ » . . ' , , 
C I O D * 4 .•?,. . . . . . . . H A •.-. j j , ' . t i a . , i . . . ' . . 
c l a n * i T , . * C - C 
TCC *TC CSC CAS C*C CC» BOS 
V I - J i b ACT GTC TCT GOT OGC TCC ATC 
Claras S . . . . . . „ . . . . . . . . . . 
TOC ATC CCC CAO CSC CCA 005 
V4-JD.4 *CT CTC TCT GOT CGC TCC ATC » « 
ClOB* 7 . 
c l a n s S , T , . c . 
. l.jrtu 4 .A. f, 
.•I lift* 10 t . . . , , , 
TAC TOO M P TCC ATC CCC CAC CCC CCA CSC 
C , , , . . . , , . 
-T . . . ,*.. . M T . 
., , r . , , , . , , , 
. .? € 
. T . . . . . . . 6 . , 
v4-*ib ACT C K TCT SOT esc tec jwe * » ; *«r a«r *er T*cl 
•.-lone 11 T. « . ' . . , , , C . , 
c l o r . e 12 T . 
I ATC can ChQ SCC :XX :» f l 
V4 41) GCT CTC ?CT SOT «6C TCC hK ASC KJl AST »AC TOO fCf, A f i f . 
Eiar.e 1J . . A . . 5 A. C »T ffl 7TC S,T . . . C 
i t r t i ; CTC CGC CAC CCC CCA 2C.G 
i . . . . , . . , - A T . . • . A 
V4-14 r,:T GTC TAT CCT GOS TCC ?TC ACT 00T TAC TAC TOC ASCC 
clor.« 11 . . . . . . .... . . . . . . . . . . . . . . . . . . . . . . € - . . . , * . (. 
•Tiara 1 S T . . C. • . . . . A C . . . , . , . . . , C . ( 
•:lam i s C T, . . 0 . . . . . . , . . f 
)70C ATC CGC C*G CCC ZCh 33G 
1 . . , . . T 
1 . . . . . . . • , 
) - . . a . . . . •-
Fig. 2. Sequence analysis of 16 unidentified or partly identified VH4 gene rearrangements. The clones are aligned with their putative germline 
sources. Only the V-region sequences are shown, and codons are numbered according to the method of Kabat et al. (1991). Target rshaded, and 
hybridization results are displayed in the margin as ' + ' for a positive identification of the clone by the specific oligonucleotide probe, or a ' - ' , 
which indicates that there was no hybridization to that probe. The sequences reported here are available from the GenBank database under 
accession numbers AF126264-AF126278, and U80165. 
44 
A.M. Glas et al. / Molecular Immunology 36 (1999) 599-610 605 
541 C0S.2 <0 
V4-61 AAG GCA eve SAG TOG A T T K M rar M C W n c A S ? O&G ACC ACC AAC TAG AAC CCC roc e re AAC 
c l o n e i C . , , , A - T T . . . . . . . . . . , , 
V4-3S AA5 GB5 CTG W « 6 ATT WW JUST M S f * S t * f M t «OJ ACC * K TAC T K « C « S t W t K M f i 
else* t . . , . . . , . * C . a i * c . . .s . . . 
v«-n M£ see ore SAB use ATT GGG we M C TAT T*E ACT «s<a ACC ACC TAG TAC AAC CCC TCC CTC A*S 
C l Q D K 3 . . .... - A .. . > . ... -.. ... ... ... 
clace « ... . .T ., . .... .... . .. t ., , >,.€,, .» 
clones . .C ,,.,,_. t. • . . . r -A. 
V*-31fa AAC QOC CTG GAG TOO ATI SCO TAC ATC 5AT SAC ACT CCC ABC ACC VAC TAC AAC CCG TCC CTC AAS 
clone if . > . ... ... ... ... . .. . • . 
V I - J O . 
clou* 
elen* 
cleft* 
.« 
T 
6 
9 
JO 
A W 
... 
SMC 
,c, 
ere 
... 
GAG 
..A 
TOO 
.-C 
ATI 500 TAC 
.C. 
ATC 
w 1 i 
TAT 
». 
TIC AOT 
..A 
aoa 
c. 
•DC 
A. 
ACC 
.It 
TAC 
,-T 
TAC 
... 
AAC 
,,T 
CCC TCC CTC AAC 
V « - « l b AAG GGH E r e SAG TGG ATT SSG CBT B E « W JkCC AST BOS AQC ACC AAC TAC AAC CCC TCC CTC AAG 
dona 11 G B . . . ,C A G , . . 
c l o u s 12 C A O.T C. . -AA . . C G- . . . t t ! 
* 4 - « > AAG « S CIS 6 * 6 f W ATT «SG Silk MIC T A f C M M f t 666 nOC ACC AAC TAC AAC CCS TCC CTC M S 
clone 13 . . . . O . . . -C. . tS . 'BJI ...H I K . . . C T . 0 . 
V4-3 * AAG o s a CTC SAC W C ATT 066 O f t . N I C J U W f l W W B OS* WC ACC AAC I AC AAC CCS fCC CfC AAG 
CI C"H« 14 . . B
 t l = . < -t s S . J * . . . . C . . . • j . — « • X * « r * * * v t- • » * » . . . .* „ * , » i . , . . - - T i . . . i „ - . - - . 
c l o n e 15 C , , , , . . . . . . , . , . , , ,A C O . . . C . . W C BT . . . T . . CC. 
d M e 16 . . . . . . , TT. . 3 . T 
- — to eo 
V4-S1 ACT CGA STC ACC ATA TCA GTA GAG ACQ TCC AAG AAC CAC W C TCC CTC AAG UTS AGC W StS ACS 
£l©fl# I . . . . . . , . . , f . . . . „ , . . , , , , , , . , , . , . . . C . . . . . . . . . . . 0 . 
V I - 1 9 M T CS* GTC ACC ATA TCC GTA GA£ ACC TCC AAC AAC CAG TTC TCC CTC WW' CVS A6C *PC*f STS « X 
a l o j i s 8 , , „ , , 6 C , 6 , . . . . . . . . . . . . , . . . « , . . . . . . . . . . . . . . 
WI-3J AOT CGA CTT ACC ATA TCA GTA «AC ACS TCT WW AAC CAC T?€ ?CC CTS «*S CTC AGC tCT BTC ACT 
el«i» 3 ,., ... ... ... ... ... ... ... .... ... ... ... ... T 
cl oae f ... C ... ... 
clan* 5 ,.. ... .., ft,, ,,. ,, «,A ,,. G ... ..C 
VI-Jill ACT CTft SIT ACC ATA TCA SO, OAC ACS TCT AAO U C CAG TTC E C CTC AAA CTC AGC TCT ST6 AC? 
clones A. .... ... ... , -, -, . ... 8, , ,,, ... ,. , , ,, ,., ,., ... ,.,. 
VI-10.1 AGT DBA BTT ACC ATA TCA GTA GAC ACS FCC AAG AAC CAC TTC TCC CTG AAC CIS HOC 7CV «TC ACT 
<;Jor»« 7 .,, ,,, ,,, ... ... ... .6. ... • ... ... ,,.. ... ... ... ... ... 
clone i ... . i. . C „ ... ... 
claw 9 C C C.C . .C ,.6 ... .«. , . , ,S, ... ..AG.. . .6 ... -GC ... <C. , ,c .C. ... 
clone 10 ... ,,, ,,, BT. ,,G ... A.. ... ..G. . .T .O. ... ..* T 1 
¥*»61b AST CSA OTC AOC ATA TCA OTA SAC ACS TCC W W AAC CAW TTC TCC CTG AAG CTG ASC TCT 6TG ACC 
clone Li . . ... ... , ... ... CG 
clor.e 12 C . ,C T T .C c ... 
V«-«l AGT CGA BIC ACC AT* TCA OTA O K AM K C AAG AAC CAS PPZ TCC CTG AAS CTB ACC TCT GTE ACC 
elan* 13 C . ... ,,, ... C , ,.,*,. ... , ,C ,,6 ... .06 ... C...T. ... S-C ... « 
?*-3* AOT D3L OTC M X ATA TCA GTA GAC ACS TCC AAG AAC CAC TIC TCC CIS AAS CTQ ACC fCT STB ACC 
C l * 3 ! M ! I 1 ! * I * !- t * S i r i t * ' : ! - > ! • • ( ! * i f t t i s i t - > • • t f ' ' r < f ! - i f f •''••. »• t • * » .- • iS-s - . . •. - • . . . 
slOfl# IS , . , . . . .C . . . ^ . „*2 AAG . . . . . . ,G
 4„ . . ! , » , » 4 » G, , ? i t , I * , , ,,, .., 
Fig. 2 (continued) 
45 
606 A.M. Glas et al. / Molecular Immunology 36 (1999) 599-610 
90 
V4-61 GCT GCG GAC ACG GCC GTG TAT TAC TGT GCG AGA 
clone 1 T 
V4-39 GCC GCA GAC ACG GCT GTG TAT TAC TGT GCG AGA 
clone 2 T. ... 
V4-31 GCC GCG GAC ACG GCC GTG TAT TAC TGT GCG AGA 
clone 3 T 
clone 4 ... .Y T T. ... 
clone 5 A.A ... -T 
V4-31B GCC GCG GAC ACG GCC GTG TAT TAC TGT GCG AGA 
clone 6 
V4-30.4 GCC GCA GAC ACG GCC GTG TAT TAC TGT GCC AGA 
clone 7 
clone 8 
clone 9 T T 
clone 10 A T 
V4-61b GCC GCA GAC ACG GCC GTG TAT TAC TGT GCG AGA 
clone 11 .N. .G A C .T 
clone 12 ... .G A C. . 
V4-4b GCC GCG GAC ACG GCC GTG TAT TAC TGT GCG AGA 
clone 13 C T C ... 
V4-34 GCC GCG GAC ACG GCT GTG TAT TAC TGT GCG AGA 
clone 14 
clone 15 T. .G. C.A ... .T C 
clone 16 
Fig. 2 {continued) 
was determined by comparing the number of clones 
that hybridized to each motif-specific diagnostic probe 
with the total detected by the family-specific probe. 
From 300 to 400 individual rearrangements were stu-
died per subject. 
Dot blot hybridization results for five probes on two 
sets of replica filters, one set of rearrangement, and 
one set of germline libraries from one donor are 
shown in Fig. 1. The full length probe detects 72 
clones on the rearrangements filter. Probe E41 corre-
sponds to a unique motif carried by the V4-34 gene. A 
positive hybridization result specifically identifies this 
unique motif and is therefore diagnostic for the pre-
sence of the V4-34 gene. Hybridization to E41 ident-
ified 17 positive clones on the rearrangement filter. 
Thus 24% (17/72) of the clones are derived from re-
arrangement of the V4-34 gene. Probe E58 detects a 
motif that is shared by two genes, V4-30.4 and V4-31. 
Fourteen (19%) positive clones are identified on the re-
arrangement filter, and contain either V4-30.4 or V4-
31 genes. To discriminate between V4-30.4 and V4-31, 
probe M98 is used. Probe M98 corresponds to a 
unique motif carried by the V4-31 gene and is diagnos-
tic for the presence of this gene. Eight (11%) positive 
clones are identified. Probe M105 detects a unique 
motif in the V4-30.4 gene, and is diagnostic for the 
presence of that gene. The six (8%) clones not detected 
by probe M98 were detected by probe Ml05 and are 
identified as V4-30.4. Clones identified by hybridiz-
ation to M98 or M105 should be identified by probe 
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E58 as well. However, six clones showed discordant 
hybridization results, as discussed in the following sec-
tions, each of these clones has acquired a substitution, 
presumably as a result of somatic mutation, in the tar-
get region of one of the probes. 
3.3. Germline libraries 
To compare the germline content of different indi-
viduals, and to verify that all germline genes could be 
identified with the diagnostic probes, libraries were 
generated containing unrearranged genes. Dotblot hy-
bridization results for five probes are shown in Fig. 1. 
The full length probe detects 69 clones on the germline 
filters. Seven clones are identified by hybridization to 
probe E41, and contain a V4-34 gene segment. Probe 
E58 detects 9 clones, which contain a V4-30.4 or a V4-
31 gene segment. Probe M98 detects 7 clones, which 
contain a V4-31 gene segment. Probe M105 detects 3 
clones, which contain a V4-30.4 gene segment. 
The number of positively identified clones by each 
probe reflects the germline complexity. In previous stu-
dies the copy number of the individual genes was 
determined for this donor (Willems van Dijk et al., 
1992; van der Maarel et al., 1993). The hybridization 
results are consistent with the copy number; the 
diploid element V4-34 is detected by probe E41 which 
identified 7 clones (10.1%), the combination of the 
haploid element V4-30.4 and the diploid element V4-
31 is detected by probe E58 which identified 9 clones 
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(13%), the diploid element V4-31 is detected by probe 
M98 which identified 7 clones (10.1%), and the hap-
loid element V4-30.4 is detected by probe Ml05 which 
identified 3 clones (4.3%). These results are consistent 
with a germline repertoire of 10-12 diploid elements as 
previously established (Willems van Dijk et al., 1992; 
van der Maarel et al., 1993). One discordance (between 
E58 and M98) is identified and is discussed in Section 
3.4. 
All clones in the VH4 germline libraries could be 
identified using the VH4 probes, whereas approxi-
mately 80% of clones in the VH4 rearrangement 
libraries could be identified. The unidentified clones 
containing VH4 rearrangements are presumed to have 
accumulated somatic mutations in the regions of the 
probes. That no previously uncharacterized VH4 gene 
segments were amplified was confirmed by analyzing 
the nucleotide sequence of 16 unidentified VH4 re-
arrangements (Fig. 2). 
The sequences in Fig. 2 are compared to the germ-
line counterpart. The target regions of the oligonucleo-
tide probes are shaded. The hybridization results for 
these clones are indicated in the margin of Fig. 2. 
With a single exception (clone 8 CDR1 probe), the 
sequence data confirm the hybridization data, and 
demonstrate that the abrogation of hybridization is 
caused by one or more nucleotide substitutions in the 
target region of the probe. 
3.4. System background 
Faint hybridization occasionally presents difficulties 
in interpretation. In instances where a full length 
probe gives strong hybridization, a very faint signal 
from an oligo probe has usually been found to rep-
resent a contaminant in the well, that is, the motif 
detected by the probe is present but not as part of the 
predominant species. Examples on the germline filter 
are clones A l l and F4 hybridized to M98, and on the 
rearrangement filter clone E7 hybridized to M105. 
These clones were not scored as positive clones. In 
other instances, clones which give a faint signal after 
hybridization, such as on germline filter clone F7 
hybridized to E41, and on the rearrangement filter 
clones A12 and G10 hybridized to probe E58, are con-
sidered positive clones. These scoring decisions require 
careful judgment; however, the error introduced by 
faint hybridization is minor when large numbers of 
clearly hybridizing clones are analyzed. 
When germline genes are analyzed by sequential 
hybridization according to the criteria in Table 3, 
loss of concordance should not occur. However, in 
Fig. 1, on the germline filter, clone H7 is positively 
identified by probe M98, but failed to hybridize to 
probe E58. Because these filters are made from germ-
line libraries, no mutations were expected. Among the 
germline clones the loss of concordance is very unli-
Table 3 
Diagnostic criteria for identification of individual VH genes by oligonucleotide probes 
Gene 
VH3 
Hybridization profile Probe target 
V3-11 
V3-13 
V3-15 
V3-20 
V3-23 
V3-30 
V3-30b 
V3-30.3 
V3-33 
V3-53 
V3-74 
V4-4 
V4-4b 
V4-28 
V4-30.2 
V4-30.4 
V4-31 
V4-34 
V4-39 
V4-55p 
V4-59 
V4-61 
V4-61b 
V4-80 
CH15 
E 3 5 po, i t ive o r gjgposilive 
M85po"i,ive 
H U QPO.it™ 
M 9 j positive 
M 8 po« t ive Q r M 1 8POsLive 
M16p°'i,ive and M76neEative 
M 4 1 po S i t i ve 
M 1 9 p o , i t i » e o r E 2 2posit ive 
M 1 6 p o , i t i v e a n ( j M 7 6 P o s i f v e 
•po^ positive 
M 8 4 p o . i t i v e 
E7positive a n ( J E 4 4posit i»e 
E 5 7 po. i t ive a n ( j M 6 9 n=g . t i ve 
M100positi,e a n d prepositive 
M 8 6 p o » i t i . e o r E 5 6 p o s i t ™ 
M 1 0 5 p o s i t i v e a n j E 5 g po S , t i v c 
M 9 8 pos i t , ve a n d gjgposilive 
M 1 0 9 p o 1 i t i v e o f E 4 jposit ive 
M 9 9 pos , t i ve 0 ] . ^ p o s i t i v e 
M , 0 1 p o S i t i v e o f g j g p o l i ™ 
E 7po,itive a n ( J E 4 3posit ive 
E13PO*i..ve a n ( j E 4 3po,i t iv= 
E 8po„t ive a n ( j E 4 4 po. . t iv C o r M 1 2 2 P ° ' ' ' i v 
M 6 9 p o , i . i . e a n ( j H , 3 9 p o , i t i v e 
M 6 9 p o , i t i v e a n ( j E 5 7 po, i t ive 
CDR1, CDR2 
CDR1 
CDR2 
CDR1 
CDR1, CDR2/FR3 
CDR2, CDR2 
CDR2 
CDR2, CDR2 
CDR2, CDR2 
CDR1 
CDR1 
CDR1, CDR2 
CDR2, CDR1/FR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2 
CDR1, CDR2, CDR1 
CDR1/FR2, CDR2 
CDR1/FR2, CDR2 
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kely to be the result of somatic mutations in the 
regions of the probe, but rather is likely to be the 
result of system errors. Errors in the system could be 
introduced by Taq polymerase, PCR and cloning arti-
facts, and hybridization errors. Predicted concordance 
between oligonucleotide probes differed from the 
observed concordance by 10% on analysis of 
> 15,000 germline clones (results not shown). From 
these results we consider that the system error intro-
duced by amplification, cloning and hybridizing is ap-
proximately 10%. Our procedure assays 42 bp. An 
error for any one nucleotide yields a discordance, 
which is effectively an error for all 42. Thus, an error 
incidence of about 10% is equivalent to a mutation 
incidence of 0.24% per bp, or approximately one sub-
stitution per rearrangement. Other investigators, using 
different methodologies, have reported similar error 
incidences. Klein et al. observed five errors among 11 
control sequences, Pascual et al. observed 28 errors 
among 47 transcripts, and Huang et al. reported 1 
substitution every 300 bp, which led them to calculate 
a Taq error rate of 2 x 10 - 5 per nucleotide incorpor-
ated (Pascual et al., 1994; Klein et al., 1993; Huang et 
al., 1992). 
3.5. The use of oligonucleotides to detect somatic 
mutation in VH rearrangements 
When rearranged genes were analyzed by sequential 
hybridization according to the criteria in Table 3, dis-
cordant hybridization results occurred more frequently 
among rearranged genes than among germline genes. 
For example clones identified by hybridization to E58 
should be identified by probes M98 or M105 as well. 
However, three E58 positive clones (clones A12, Bl, 
and E9 on rearrangement blots in Fig. 1) are not posi-
tively identified by either M98 or M105. Reciprocally, 
three M98 positive clones (clones E6, G5, and H12 on 
rearrangement filters in Fig. 1) are not positively ident-
ified by E58. As predicted by this hybridization result, 
sequence analysis of one of these clones (HI2) con-
firmed the presence of a substitution, presumably 
acquired as a result of somatic mutation, in the target 
region of the E58 probe. 
The accumulation of somatic mutation in individual 
rearrangements is addressed by sequential hybridiz-
ation with multiple probes. We have focused on V3-
23, which is the most frequently rearranged VH3 gene, 
accounting for approximately 15-40% of the total 
VH3 repertoire in peripheral B cells (Logtenberg et al., 
1989; Brezinschek et al., 1995; Suzuki et al., 1995; 
Huang et al., 1996; Rao et al., 1996; Kraj et al., 1997). 
The germline sequence of V3-23 can be detected by 
either of two motif-specific probes. Concordant hy-
bridization of both these probes on rearranged V3-23 
genes indicates V3-23 genes that have retained the 
germline sequence through the targeted motifs. 
However V3-23 genes that have accumulated one or 
more mutations in the target motifs of one or the 
other probe will display a loss of concordance when 
hybridized. 
An example of hybridization results using the V3-23 
specific probes, M8 (CDR1) and M18 (CDR2/FR3) is 
shown in Fig. 3. Probe M8 identifies 14 clones. Probe 
M18 identifies 17 clones including 12 of the M8 posi-
tive clones, and five clones (D9, El , E2, G12, and H4) 
are identified by probe M18, but not by probe M8. 
There are 19 clones identified by probe M8, M18, or 
both. Two clones that gave faint signals (E2 on the 
M8 filter, and H l l on the M18 filter) are not scored as 
positive clones. Therefore these results are scored as 19 
V3-23 rearrangements, of which seven (clones D9, El , 
E2, F7, G12, HI , and H4) are detected by one or 
other probe, but not both, and are scored as mutated 
(37% mutation). These clones are presumed to have 
accumulated one or more mutations in the region of 
the non hybridizing probe. This number is not an 
exact measure of mutation frequency, but does provide 
a very useful, if somewhat arbitrary, index of the 
M18 
i : *t ? n '•} !•• i • i.' 
* * 
• • 
Fig. 3. Detection of somatic mutation m V3-23 rearrangements. Left panel: hybridization of a filter containing rearranged V3-23 gene segments 
hybridized to oligonucleotide M8, which is targeted to a motif specific sequence in CDR1 of V3-23. Right panel: replicate filter hybridized to oli-
gonucleotide Ml8, which is targeted to a motif-specific sequence in CDR2/FR3. 
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amount of mutation among the rearrangements that 
were studied. 
Using this hybridization technique, clones that had 
acquired mutations in both target regions would not 
be detected as clones containing V3-23 rearrangements. 
In such instances, the mutation index as calculated, 
would be an underestimate of the actual somatic mu-
tation incidence. However, sequence analysis of ran-
dom clones showed that clones containing V3-23 
rearrangements rarely had mutations in the M18 target 
region. 
We have found oligonucleotide probe hybridization 
to be useful to identify genes and to determine the 
occurrence of somatic mutation among virtually any 
gene. Judgment is needed when identifying faintly 
hybridizing clones; however, a large number of genes 
can be identified and analyzed in a relatively short 
time span without sophisticated instrumentation. One 
person can easily make libraries and analyze from 
1500 to 2500 recombinant clones in a week. 
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Anomalous Diversification of the 
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ANNL'SKA M. GLAS,* WENDY 0 . HUFNAGLE.* 
IVY SUZUKI.'' LAURIE PFISTER.' P. SAMBASIVA RAO,* 
CAROL NOTTENBURG,' AND ERIC C. B. MILNER M 
"Virginia Mason Research Center 
Seattle. Washington 98101 
I he tied Hutchinson Cancer Research Center 
Seattle, Washington 98104 
''Department of Immunology 
University of Washington 
Seattle, Washington 98195 
Bone marrow transplantation (BMT) is a recognized treatment for certain leuke-
mias, other blood diseases, and some inborn errors of metabolism, and it has 
potential as a vehicle for gene therapy. Nevertheless, patients undergoing BMT 
may remain immunodeficient for several years despite the return to normal IgM 
and IgG levels.1-2 These observations suggest continued defects in both T- and 
B-cell compartments. To determine whether abnormal usage of VH genes may 
contribute to this immunodeficiency, the relative usage of VH genes after marrow 
transplantation has been determined. As a measure of VH gene utilization, re-
arrangements of eight individual VH3 genes were assessed in peripheral blood B 
cells of four BMT recipients and compared to similarly obtained rearrangements 
from two healthy subjects. In addition, rearrangements of 14 individual VH4 genes 
were assessed in peripheral blood B cells of one of the BMT recipients and 
compared to similarly obtained rearrangements from one of the healthy subjects. 
Heavy chain rearrangements were amplified quantitatively, and the resulting PCR 
products were cloned into a phagemid vector. Identification of the VH gene present 
in an individual clone was established by hybridization with a sequence-specific 
oligonucleotide probe. More than 700 independent rearrangements from each 
person were analyzed. 
The pattern of usage of VH genes assessed at 90 days and approximately one 
year after transplant was similar to that observed in healthy subjects and was 
marked by overuse of two elements (V3-23 and V4-34).3 However, the repertoires 
of the BMT recipients were less diversified than the repertoires of the healthy 
subjects. Sequence-specific oligonucleotide probes for 14 individual VH4 genes, 
composing 100% of the germline repertoire, identified more than 99% of the 
rearrangements in the BMT recipient, but only 80% of the rearrangements in the 
healthy subject. Similarly, oligonucleotide probes specific for eight VH3 genes 
detected 75% of rearrangements in the BMT recipients, but only 55% of the 
" This work was supported in part by National Institutes of Health Grant A131241 and 
ACS Grant IM485. 
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rearranged VH3 genes in the healthy subjects. The difference in the percentage 
of identified rearrangements between healthy subjects and BMT patients is pre-
sumed to be the result of somatic mutations in the regions of the probe that 
abrogate hybridization. To assess more directly differences in the occurrence of 
somatic mutations, we determined the nucleotide sequence of 20 randomly picked 
VH3 and 20 randomly picked VH4 rearrangements from one of the BMT recipients 
and from one healthy subject. The BMT recipient exhibited fewer mutations in 
both VH3 gene segments (FIG. 1) and VH4 gene segments (FIG. 2) than did the 
healthy subject. The ratio of replacement to silent substitutions (R/S ratio) in the 
complementarity-determining regions (CDRs) from the BMT recipient was lower 
than in the healthy subject. Somewhat unexpectedly, although the absolute number 
of substitutions was lower in the BMT recipient, the R/S ratio in the framework 
regions in the BMT recipient was much higher than in the healthy subject. The 
significance of this high ratio is not certain, but suggests that the mechanism of 
somatic mutation favors amino acid replacement. 
A high R/S ratio and the selective accumulation of somatic mutations in the 
CDRs is an indicator of antigen-driven responses. The failure in the BMT recipients 
to accumulate somatic mutations is consistent with a defect in antigen-driven 
B-cell responses. This is also consistent with the observation that germinal center 
[••JML^M-JHLiH-JB-. 
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B 
4 
3 
2 
1 
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FR3 
FIGURE 1. Nucleotide substitutions per 100 bp in randomly picked VH3 rearrangements. 
Sequences were determined in both orientations to assess differences in the occurrence of 
somatic mutations. Panel A, healthy subject (VMRC3116); Panel B, BMT recipient 
(UPN5012). 
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FIGURE 2. Nucleotide substitutions per 100 bp in randomly picked VH4 rearrangements. 
Sequences were determined in both orientations to assess differences in the occurrence of 
somatic mutations. Panel A, healthy subject (VMRC3116); Panel B, BMT recipient 
(UPN5012). 
formation is defective in BMT recipients months to years post transplant.4 To-
gether, these data indicate that, although the VH gene content of the repertoire 
has normalized by 90 days post transplant, a defect in B-cell differentiation associ-
ated with antigen activation persists for at least one year after BMT. 
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Immunoglobulin Heavy Chain Variable Region Gene Usage in Bone Marrow 
Transplant Recipients: Lack of Somatic Mutation Indicates 
a Maturational Arrest 
By Ivy Suzuki, Eric C.B. Milner, Annuska M. Glas, Wendy 0 . Hufnagle, Sambasiva P. Rao, Laurie Pfister, 
and Carol Nottenburg 
Many recipients of bone marrow transplant (BMT) make nor-
mal amounts of serum immunoglobulin but are deficient in 
generating specific antibody responses to exogenous stim-
uli. To determine if abnormal usage of VH genes contributes 
to this immunodeficiency, the usage of VH genes was deter-
mined in peripheral blood B cells of four BMT recipients, two 
of whom had developed chronic graft versus host disease. 
The pattern of usage of V„3 or V H 4 genes assessed at either 
90 days or approximately 1 year after transplant was similar 
to that observed in healthy subjects and was marked by 
the over utilization of two elements, one V H 3 and one VH4. 
However, the repertoires of each of the four BMT recipients 
appeared to be less complex than the repertoires of healthy 
subjects. The differences were a consequence of the accu-
mulation of somatic mutations among rearrangements in 
the controls but not in the BMT recipients. The failure to 
accumulate somatic mutations in rearranged VH genes is 
consistent with a defect in antigen driven B-cell responses. 
These results indicate that although the VH gene content of 
the repertoire has normalized by 90 days posttransplant, a 
maturational arrest in B-cell differentiation associated with 
antigen activation persists for at least 1 year after BMT. 
© 7996* by The American Society of Hematology. 
A LL MARROW recipients exhibit immunodeficiencies in 
x m . the first 3 months after bone marrow transplantation 
(BMT). Both cellular and humoral immunity are affected, 
reflecting in part the recapitulation of ontogeny. B cells re-
cover slowly in numbers, in frequency, and in function.1"8 
Impaired function of B cells isolated during the first 90 
days after transplant is apparent in their reduced ability to 
proliferate or to secrete Ig in response to mitogens.3,5'7"9 
These in vitro functions usually approach normalcy by 1 
year after transplant.1"3'5"8"'11 Coincident with recovering B-
cell functions, serum Ig levels also return to normal.51012 
Despite this recovery, marrow recipients who survive this 
initial postgraft period do not always become fully immuno-
competent. Early posttransplant B-lymphopoiesis is mono-
or oligoclonal, and restricted clonality is more frequent in 
patients with chronic graft versus host disease (GVHD). Im-
mune responses to the antigens ipX174 and KLH are meager 
in patients with chronic GVHD.6 As well, some long-term 
survivors suffer from opportunistic bacterial infections, espe-
cially with encapsulated bacteria such as Streptococcus 
pneumoniae and Hemophilus influenzae type b.13'14 Suscepti-
bility to infections is most severe in recipients with chronic 
GVHD; the mortality rate for infections in these patients is 
15% to 40%.I5 Because immune responses to polysaccha-
rides present in bacterial capsules are typically T-indepen-
dent, at least a portion of the defect is likely intrinsic to B 
cells. 
The nature of the B-cell defect(s) leading to this specific 
humoral immunodeficiency is uncertain. Normal levels of 
serum IgM and IgG1012 indicate that immunodeficiency is 
not because of a general failure to produce Ig or an overt 
lack of T-cell help in heavy chain class switching (although 
T-cell function may be impaired to some extent). One possi-
bility is that abnormal restriction of the potential Ig repertoire 
in B cells from BMT patients, possibly because of effects of 
chronic GVHD, contributes to humoral immunodeficiency. 
The Ig repertoire is established by the developmentally 
regulated usage of V genes'617 and the ensuing selection of 
B cells.""" Variable regions of Ig heavy chains are generated 
during differentiation of a B cell by combinatorial associa-
tion of three gene elements, VH, DH, and JH. Approximately 
100 VH genes are organized into seven families based on 
nucleic acid hybridization and DNA sequence similarities.20 M 
The families range in size from one gene (VH6 family)23 to 
approximately 30 to 35 genes (VH3 family).20 
The usage of VH families is not random during develop-
ment25"2' or in phenotypically defined subpopulations of B 
cells.30,31 For example fetal B cells derived from 7 weeks of 
gestation use genes from the VH5 and VH6 families, exclu-
sively. Although all VH families are used by 15 to 18 weeks 
of gestation, VH gene usage may still not be totally random. 
For example, at this time not all genes within the VH3 family 
are used with equal frequency.26'27'29 In adults, although the 
relative percentage of V„ family usage is approximately 
equivalent to the proportion of each family in the genome,31"36 
within VH families certain elements predominate and some 
elements are underrepresented or absent.37 During fetal de-
velopment, unequal usage of the variable region gene fami-
lies has been hypothesized to account in part for the immuno-
deficiency of human neonates,16,27 which lack antibody 
responses to many antigens, including H. influenzae.™ Con-
comitant then with the normalization of the repertoire would 
be the ability to respond to the wide variety of environmental 
antigens typically encountered. At least in adults, although 
the repertoire is not totally random within V gene families, 
immunodeficiencies are not apparent. However, it remains 
unknown if deviation from the normal representation of VH 
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Table 1. Patients Studied 
Patient 
UPN5012 
UPN5007 
UPN4986 
UPN6403 
Sex 
F 
F 
F 
M 
Diagnosis 
Chronic myeloid 
leukemia 
Acute myeloid 
leukemia 
Chronic myeloid 
leukemia 
Chronic myeloid 
leukemia 
Onset of 
GVHD* 
88 
N 
N 
90 
Age at 
Transplant 
28 
54 
37 
45 
Age of 
Donor 
17 
63 
33 
39 
Abbreviation: N, no GVHD present. 
* Number of days following BMT. 
families or genes in B cells after BMT accounts, in part, for 
the observed immunodeficiencies. 
The usage of VH families following BMT appears to 
mimic usage during B-cell ontogeny.3940 Thus, to account 
for the observed immunodeficiencies, it might be expected 
that during the first year posttransplant, BMT patients would 
use a more limited set of V genes than would healthy adult 
subjects. This hypothesis is supported by the results of Storek 
et al40 who found that the B-cell repertoire is restricted to 
fetal-type VH genes early posttransplant. In this report, a 
direct assessment of the B-cell repertoire was made by ana-
lyzing the occurrence of specific VH gene segments in rear-
rangements in peripheral blood (PB) B cells of BMT recipi-
ents at 90 days and 1 year following transplant. The results 
indicated that the pattern of usage of VH genes was similar 
between BMT recipients and healthy subjects. However, 
BMT recipients exhibited a markedly reduced level of so-
matic mutation that is consistent with a maturational arrest 
at a fairly late stage of differentiation. 
MATERIALS AND METHODS 
BMT recipients and control subjects. Four patients (3 women, 
1 man) and their marrow donors were recruited through the BMT 
program of the Fred Hutchinson Cancer Research Center under Insti-
tutional Review Board approval (Table 1). All were white. All re-
ceived marrow from HLA-identical siblings. Two of the patients 
were diagnosed with GVHD within the first 100 days following 
transplant. Two healthy controls recruited from laboratory personnel 
under Virginia Mason Research Center (VMRC) Institutional Re-
view Board approval were studied simultaneously. Analysis of the 
repertoire of these healthy subjects has been published." 
Cell isolations. All patient blood was obtained after approval 
by the Fred Hutchinson Cancer Research Center Institutional Review 
Board. Healthy subject blood was obtained after approval by the 
Virginia Mason Research Center Institutional Review Board. PB 
mononuclear cells (MC) were isolated from a Ficoll-Hypaque gradi-
ent (Pharmacia Biotech, Piscataway, NJ). B cells were stained with 
fluorescein-conjugated anti-IgM or anti-IgD (Coulter, Hialeah, FL), 
phycoerythrin (PE)-conjugated anti-CD 19 or CD20 (Coulter), or ap-
propriately conjugated mouse Ig isotype control antibodies. Viable 
lymphocytes were selected on the basis of forward and side-angle 
light scattering criteria. A Coulter Epics 750 or a Becton Dickinson 
Facstar flow cytometer (Becton Dickinson, Mountain View, CA) 
was used to sort live B cells into positively stained fractions. The 
non-B cell (negative) fraction of each sort was also collected. The 
purity of the sorted B cells ranged from 94% to 95%. Phenotypic 
analyses are shown (see Table 2). 
Rearrangement library construction by VH family-specific primer 
method. Sorted B cells were lysed in cell lysis buffer (50 mmol/ 
L Tris, pH 8.0, 1 mmol/L Na EDTA, 0.5% NP-40, 0.5% Triton X-
100 (JT Baker, Phillipsburg, NJ), 0.5% Tween 80, and 200 ^g/mL 
proteinase K) and incubated at 50°C for 30 minutes. Cell lysates 
were sonicated for 30 seconds using a Sonifier 450 (Branson, Dan-
bury, CT) fitted with a cup horn, at 50% duty cycle, 50% output to 
provide more uniform polymerase chain reaction (PCR) amplifica-
tion. Proteinase K was heat-inactivated by incubation for 10 minutes 
at 95°C. The rearranged VH genes were amplified using one of the 
family-specific 5' primers, VH3-L, 5f-CTGAATTCCATGGAG1TT-
GGGCTGAG-3' or V„4-L, 5'-CCGAATTCATGAAACACCTGT-
GGTTCTT-3', corresponding to the 5' ends of the leader sequences 
of VH3 and VH4 families, respectively, and the 3' primer JHAmp-7, 
5'-GCTCTAGACT(T/C)ACCTGAGGAGACGGTGA-3', comple-
mentary to the 3' end of the 6 JH gene sequences. Restriction sites 
(EcoRL for 5' primers; Xba I for 3' primers) included in the primers 
are underlined. An aliquot of lysate containing 15,000 to 50,000 cell 
equivalents was amplified by PCR using cycle conditions to obtain 
amplification in the linear range. The linearity of the PCR reactions 
has been confirmed by electrophoresing (a-12P]dCTP-incorporated 
PCR products on a 2.0% agarose gel and quantifying the bands 
by phosphor imaging (Molecular Dynamics 400A Phosphorlmager, 
Sunnyvale, CA)." The PCR products were cloned into EcoRVXbal 
digested pBS(M 13+) phagemid vector and the recombinant plasmids 
were used to transform competent DH5aF' (GIBCO-BRL, Gaithers-
burg, MD) or BSJ72.41 The transformants were toothpicked into 
wells of a 96-well plate containing Luria Broth (10 mg/mL bacto-
tryptone, 5 mg/mL bacto-yeast extract, 10 mg/mL NaCl, pH 7) with 
100 /xg/mL carbenicillin or ampicillin, 4 //g/mL kanamycin, and 
viruses containing single stranded DNA were rescued by the addition 
of K07 helper phage. 
Germ-line library construction. VH family-specific germ-line li-
braries were similarly generated as previously described from either 
the negative fraction collected from the cell sorts or unsorted PBMC. 
PCR reactions used for constructing VH3 libraries were carried out 
using the 5' primer VH3-L and either the 3' primer VH3-RS, 5'-
G ACTCTAGAC A ATG ACTTCCCCTACT-3', which is comple-
mentary to the 3' flanking recombination signal sequence of VH3 
genes, or VH3-FR3, 5'-GACTCTAGATCTCAGGCTGTTCAT-
TTG-3', which is complementary to a conserved V„3 framework 
three (FR3) sequence. PCR reactions used for constructing VH4 
libraries were performed using the 5' primer VH4-L and either the 
3' primer VH4-RS, 5 ' -AATTCTAGACTGGGCTCACACTCA-
CCTCC-3', which is complementary to the 3' flanking recombina-
tion signal sequence of VH4 genes, or VH4-FR3, 5'-AATTCTAGA-
CACAGAGCTCAGCTTCAG-3', which is complementary to a 
conserved VH4 FR3 sequence. 
Library screening. Multiple replicate filters were prepared by 
dot blotting 10 ph of supernatants containing phage particles in a 
96-well grid on Hybond N+ nylon filters (Amersham, Arlington 
Heights, IL). Filters were denatured in 0.5 mol/L NaOH, 1.5 mol/L 
NaCl, neutralized in 0.5 mol/L Tris-HCl, 1.5 mol/L NaCl, and UV 
cross-linked. Replicate filters prepared from the libraries were 
probed as previously described.'1243 Hybridization with 32P-labeled 
family-specific VH probes allowed a determination of the total num-
ber of recombinant clones in each library. A panel of diagnostic 
32P-labeled oligonucleotide probes that identify individual VH gene 
segments were also hybridized to replicate filters. The frequency of 
occurrence of each specific VH gene segment was calculated by 
dividing the number of clones hybridizing with an oligo probe by 
the total number of clones hybridizing with the family-specific probe. 
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Table 2. Phenotype of Lymphocytes From BMT Recipients 
90 d Posttransplant 1 yr Posttransplant 
CD5 +• CD20 CD5 + CD19 
% of Total PBL % of Total PBL 
UPN5012 
UPN5007 
UPN4986 
UPNS403 
8.22 
15.1 
5.05 
9.68 (CD 19) 
3.64 
5.3 
2.58 
4.0 (CD19) 
ND" 
ND 
9.6 
4.06 
7.91 
8.94 
13.13 
3.70 
4.36 
2.02 
4.74 
2.43 
2.17 
4.58 
10.39 
1.09 
13.6 
ND 
14.54 
16.62 
6.09 
ND 
6.73 
6.04 
11.7 
ND 
10.24 
12.4 
Abbreviat ion: ND, not determined. 
Oligonucleotide probes. The following oligonucleotide probes 
were used: M8, AGCAGCTATGCCATGAGCTGG44; M76, GCAG-
TTATATGGTATGATGGA4443; Ml6, AGTAGCTATGGCATGCAC-
TGG46; E36, AGTGGTAGTACCATATACTAC; HI 10, CGTAT-
TAAAAGCAAAACTGAT"; M85, AGTAGCTACGACATGCAC-
TGG44; Ml9, GGAAGCAATAAATACTACGCA46; M41, GGA-
AGTAATAAATACTACGCA4445; E42, AGTATCTATTATAGTG-
GGAGC (reverse complement of M1I44 '); M69, TGGTGGAGC-
TGGGTCCGCCAG4 ' ; E57, GAAATCTATCATAGTGGGAGC 
(reverse complement of Ml 15"); Ml09, AGTGGTTACTACTG-
GAGCTGG"; M101, AGCAGTGGTAACTGGTGAATC47; E8, 
TCCATCAGCAGTGGTAGTTAC47; E44, CGTATCTATACCAG-
TGGGAGC (reverse complement of M1214'); E58, TACATCTAT-
TACAGTGGGAGC (reverse complement of M1034'); M105, AGT-
GGTGATTACTACTGGAGT47; El 3, TCCGTCAGCAGTGGT-
AGTTAC"; E7, TCCATCAGTAGTTACTACTGG47; M100, AG-
CAGTAGTAACTGGTGGGGC"; M86, GGTGGTTACTCCTG-
GAGCTGG.4 ' 
RESULTS 
Regeneration ofB cells following BMT. The number and 
percentage of B cells found in PB were determined at inter-
vals after marrow transplant for the marrow recipients and 
before marrow donation for the marrow donors (Table 2). 
Mononuclear cells were stained with a fluorescein-conju-
gated anti-CD20 or anti-CD19, and in separate analysis, with 
fluorescein-conjugated anti-IgM and PE-conjugated anti-
IgD, and analyzed by flow cytometry. For all patients at both 
timepoints, the percent of total lymphocytes that were B 
cells was within normal range. 
Serum Ig levels were assayed at approximately 90 days 
and 1 year after transplant (Table 3). By 90 days, serum 
Ig levels were largely within the normal range. In patient 
UPN5012, IgM was below normal at 90 days and IgA was 
Table 3. Serum Ig Levels of Marrow Recipients 
Patient 
UPN6012 
UPN5007 
UPN4986 
UPN5403 
Norma) 
90 d 
34* 
190 
185 
52 
IgM 
1 v r 
154 
ND 
116 
57 
56-275 
90 d 
846 
899 
705 
784 
IgG 
1 y r 
1,060 
ND 
613 
843 
670-1.700 
IgA 
90 d 1 yr 
90 28 
93 ND 
99 79 
155 125 
70-350 
Abbreviat ion: ND, not determined. 
" mg/dL. 
below normal at 1 year. In patient UPN4986, IgG was 
slightly low at 1 year, and in patient UPN5403, IgM was 
slightly low at 90 days after transplant. 
VH gene-specific analysis. To assess the usage of indi-
vidual genes within VH3 and VH4 families, libraries of rear-
rangements were generated using VH family specific 5' prim-
ers and the consensus JH 3' primer as described previously.37 
This system has been found to amplify approximately 25 
VH3 genes and 10 to 12 VH4 genes," which together account 
for more than 75% of the total expressed VH repertoire.48 
Synthetic oligonucleotide probes that specifically identify 
both germ line and rearranged individual VH elements di-
rectly in genomic DNA and in libraries of cloned V regions 
have been described."•4a-44d6 For this report six VH3 and 11 
VH4 gene segments were selected for analysis based on two 
criteria: (1) the gene could be amplified quantitatively from 
the germline in control experiments, and (2) specific, diag-
nostic oligonucleotide probes were available for the gene. 
The six VH3 elements assessed here account for approxi-
mately 50% to 80% of the VH3 component, and the VH4 
elements assessed account for virtually 100% of the VH4 
component of the expressed repertoire (discussed later). 
Therefore, we estimate that the 17 elements assessed com-
prise from 45% to 60% of the total expressed repertoire. 
Rearrangements of the six VH3 genes were assessed in 
PB B cells of four BMT recipients and compared to similarly 
obtained rearrangements from two healthy subjects. Heavy 
chain rearrangements were amplified quantitatively and the 
resulting PCR products were cloned into a phagemid vector. 
Identification of the VH gene present in an individual clone 
was established by hybridization with a sequence-specific 
oligonucleotide probe. More than 700 independent rear-
rangements from each individual were analyzed. For con-
trols, amplifications, and subsequent identification of nonre-
arranged VH3 and VH4 genes from the same individuals were 
also performed. 
The occurrence of VH3 genes in rearrangements for all 
subjects is shown in Fig 1. The occurrence of rearranged 
VH3 genes assessed at 90 days and approximately 1 year 
after transplant is similar to that observed in the healthy 
controls. The variation between individuals is similar to that 
seen previously in a healthy population.49 One of the healthy 
subjects (Nor4882) and one of the BMT recipients 
(UPN5403) have a deletion of the V3-11 gene and one of 
the BMT recipients (UPN5007) has a deletion of the V3-33 
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Fig 1. VH3 repertoire in BMT recipients and normal subjects. The 
frequency of representation of six Vn3 genes in phagemid clones of 
quantitatively amplified rearranged VH3 genes is shown. Data in each 
panel represent analysis of at least 700 rearrangements. The sample 
used in experiment 2 of subject Nor3116 was obtained 8 months 
after the sample used in experiment 1. {A) indicates that subject has 
a germ-line deletion of this VH element. VH nomenclature is that of 
Matsuda et al.55 except V3-30t which encompasses a complex allelic 
region and may include V3-30, V3-30D, and/or V3-30.4. Data for 
Nor311S and Nor48S5 are from Suzuki et a l . " 
gene (data not shown). These deletions account for the fail-
ure to detect rearrangement of these genes in these subjects 
(Fig 1). 
In addition, rearrangements of individual VH4 genes were 
assessed in PB B cells of one of the BMT recipients and 
from one of the healthy subjects (Fig 2). As was the case for 
VH3 rearrangements, no significant difference was observed 
between the patient and the control. To the extent that these 
results are representative of the entire B-cell repertoire, they 
indicate that the repertoire following BMT contains substan-
tially the same assortment of V„ genes as that found in 
nontransplanted controls. 
The repertoires of the BMT recipients are less complex 
than are the repertoires of healthy subjects. Figure 3 shows 
the percent of rearrangements in which the germline VH gene 
of origin could be assigned by hybridization. Among the 
V„3-containing rearrangements (A), there was a slight trend 
toward increased identification in BMT recipients compared 
to the two healthy subjects (p < .005 for patients v controls). 
This trend was more pronounced among VH4-containing re-
arrangements (B). Sequence-specific oligonucleotide probes 
to 9 VH4 loci (11 distinct gene segments) identified more 
than 99% of the VH4 rearrangements in the BMT recipient, 
but only 80% of the V„4 rearrangements in the healthy sub-
ject (p < 10~5 for patients v control). This observed differ-
ence in the percentage of identified rearrangements between 
healthy subjects and the BMT patients could be because the 
BMT recipients used fewer VH genes. However, extensive 
hybridization and sequence analysis have not revealed the 
presence of additional VH genes rearranged in healthy sub-
jects but not rearranged in BMT recipients (A.M. Glas and 
E.C.B. Milner, unpublished observations, 1994). Alterna-
tively, and more likely, these results suggest that the abroga-
tion of hybridization resulted from the accumulation of so-
matic mutations in the target regions of the probes in healthy 
subjects but not BMT recipients. Therefore the accumulation 
of somatic mutations was assessed in the two groups. 
Detection of somatic mutations by sequence-specific hy-
bridization. The accumulation of somatic mutations in 
BMT recipients and healthy subjects was addressed directly 
in the following manner. Somatic mutations in one VH3 gene, 
V3-23, can be detected by sequential hybridization with mul-
tiple probes. The germ line sequence of V3-23 can be de-
tected by either a CDR1 probe or a FR3 probe. Hybridization 
of both of these probes on rearranged V3-23 genes indicate 
which have retained the germ-line sequence through the tar-
get regions. However, rearranged V3-23 genes that have 
accumulated one or more mutations in the target site of one 
or the other probe will display a loss of concordance when 
hybridized. Figure 4 shows the percent of V3-23 rearrange-
ments that have lost concordance for one of the probes in 
the four BMT patients and the two healthy subjects. Among 
the BMT recipients, the percent of V3-23 rearrangements 
isolated from CD19* or CD20* B cells that have acquired 
mutations ranged from < 1 % to approximately 10%. For 
patients UPN5403 and UPN4986 the percentage was similar 
between samples taken 90 days and 1 year posttransplant. 
The distribution of somatic mutations in the healthy subjects 
was assessed in different B-cell populations. In one of the 
healthy subjects, rearrangement libraries were constructed 
from three B cell populations: (1) CD19+ B cells (all B 
cells), (2) CD19+, lgD+ B cells (preimmune B cells), and 
(3) CD19+, IgD" B cells (antigen-driven B cells). Among 
CD19+ B cells, approximately 30% had acquired mutations 
in CDR1 of V3-23 (Fig 4). When the CD19* B cell popula-
tion was further fractionated on the basis of IgD expression, 
it was found, as expected, that the vast majority of mutations 
could be attributed to the IgD~ population. More than 70% 
of V3-23-containing rearrangements from IgD~ cells had 
detectable mutations. In contrast, approximately 10% of rear-
rangements from IgD+ cells had detectable mutations, a 
value that is comparable to that observed among the BMT 
recipients. In a second experiment, B cells from another 
healthy subject were sorted for IgM. Approximately 20% of 
V3-23-containing rearrangements from IgM+ cells in this 
subject had acquired mutations. This value is approximately 
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Fig 2. V H 4 repertoire in a BMT recipient and a 
normal subject. The frequency of representation of 
nine V H 4 loci (11 elements) in phagemid clones of 
quantitatively amplified rearranged VH4 genes is 
shown. Data in each panel represent analysis of at 
least 700 rearrangements. The sample used in 
Nor3116 experiment 2 was obtained 8 months after 
the sample used in experiment 1. (A) indicates that 
subject has a germline deletion of this VH element. 
Data for Nor3116 are from Suzuki et at.37 
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VH4 Gene 
twice the frequency of occurrence of mutations among the 
BMT recipients. Together, these results indicate that utiliza-
tion and diversification of VH genes in the peripheral B-cell 
repertoire of BMT recipients is similar to the utilization and 
diversification of VH genes in the preimmune component of 
the peripheral B-cell repertoire of healthy subjects. 
DISCUSSION 
In this report, the usage of VH3 and VH4 genes in four 
BMT recipients was assessed. In this regard, the frequency 
of rearrangements that contained each of 6 distinct VH3 loci, 
and 9 VH4 loci (11 gene segments) was determined among 
PB B cells of these subjects. We have previously found that 
healthy adult subjects exhibit a biased but highly reproduc-
ible pattern of VH gene utilization in rearrangements.37'49 
NOC3116 
N«3116 (8 mo) 
Norf882 
UPN500790d 
UPN501290d 
UPN5012 lyr 
UPN496890d 
UPN49661yr 
UPNS403 90d 
UPN5403iyr 
B 
NOT3116 
Nor3116(8mo) 
UPN501290d 
UPN5012 1yr 
Identified VH rearrangements (percent) 
Fig 3. Germ-line complexity of the amplifiable VH3 (A) or Vn4 (B) 
repertoires. Bars represent the percent of rearrangements in each 
library for which the germ-line gene of origin could be assigned by 
sequence-specific hybridization. 
The results reported here indicate that, compared to healthy 
subjects, there were no apparent differences in the spectrum 
of genes used at either 90 days or approximately 1 year after 
transplant among the BMT recipients. We interpret these 
observations to mean that the processes involved in generat-
ing the antibody repertoire are largely functional within the 
first few months following BMT. Furthermore, these results 
indicate that the immunodeficiencies common among BMT 
recipients are not likely because of the failure to use appro-
priate V region genes in generating the preimmune antibody 
repertoire. 
UPN5012 90d 
UPN5012 1 yr 
UPN4986 90 d 
t5 UPN4986 1 yr 
J=T UPN5403 90d 
CO UPN54031yr 
Nor4885 lgM+ 
Nor3116lgD+ 
Nor3116lgD-
Nor3116CD19+ 
20 40 60 
Percent Mutation 
Fig 4. Analysis of somatic mutation in rearranged V H 3 genes from 
BMT recipients and normal subjects. The accumulation of somatic 
mutations in one V H 3 gene, V3-23, was assessed by sequential hy-
bridization with the probes, M8 and M18, as described in Materials 
and Methods. Clones that have accumulated one or more mutations 
in the target site of one or the other probe will display a loss of 
concordance when hybridized. Each instance of discordant hybridiza-
tion is recorded as a single mutation. The results are presented as 
the percent of V3-23 rearrangements that have acquired a mutation 
(ie, lost concordance for one of the probes). 
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As for the specific immunodeficiency of BMT recipients, 
our results provide indications of possible mechanisms con-
tributing to poor antibody responses. Strikingly, rearranged 
VH genes exhibited much less somatic mutation in BMT 
recipients than did similar rearrangements obtained from 
healthy subjects. In contrast to healthy subjects, more than 
90% of peripheral B cells from BMT recipients are pheno-
typically CD19+, IgM+, IgD+. This phenotype is characteris-
tic of preimmune B cells. When we stratified the peripheral 
B cell compartment from the healthy subjects, as expected, 
somatic mutations were found preferentially among the IgD" 
population, a population that is all but nonexistent among 
BMT recipients. The frequency of mutations among the IgD+ 
population, and, to a lesser extent, the IgM+ population, was 
similar to that seen in the BMT patients (Fig 3). Thus, by 
both cell-surface phenotype and extent of somatic diversifi-
cation, the B-cell repertoire of BMT recipients resembles 
the preimmune component of the B-cell repertoire of a 
healthy adult, but lacks features of a mature B-cell repertoire. 
The accumulation of somatic mutations is a characteristic 
of T cell-dependent antigen-driven responses.50 Conversely, 
the absence of a somatically diversified B-cell population 
suggests an absence of antigen-driven processes. The failure 
in the BMT recipients to accumulate somatic mutations in 
rearranged VH genes is consistent with a defect in antigen-
driven B-cell responses. However, not all aspects of antigen-
driven responses are defective in BMT recipients. For exam-
ple, BMT recipients are able to make high titers of antibodies 
and to exhibit class switching, processes that are also depen-
dent on the presence of functional CD4+ T cells. As such, 
the data are most consistent with a maturational arrest, which 
may be limited to the stage of B-cell differentiation during 
which somatic mutation occurs. 
As somatic mutation and affinity maturation are thought to 
occur primarily in lymph node germinal centers, one attractive 
hypothesis is that a failure of germinal center processes prevents 
the normal accumulation of somatic mutations following immu-
nization in BMT recipients. Consistent with this hypothesis are 
the observations that germinal centers are generally absent from 
lymph nodes on histologic analysis for months to years in BMT 
recipients,51 and that the reconstitution of CD4+CD8" T cells 
(but not CD4CD8* T cells) is similarly delayed.52 In contrast 
to BMT recipients, germinal centers are present in neonates 
from about 1 month of age.53 
Although GVHD is a potent suppressor of immune func-
tion, the presence of GVHD cannot be the direct cause of 
the apparent maturational arrest observed in these studies 
because two of the patients were free of GVHD. Signifi-
cantly, there were no observable differences in the diversifi-
cation of the antibody repertoire between patients with or 
without GVHD. 
Although the data presented here provide an explanation 
for the specific immunodeficiencies after BMT, further study 
is needed to determine the parameters of recovery of the 
capacity to mount an effective antibody response. In this 
regard, analysis of the cause and effect relationship between 
ineffective antibody responses and germinal center forma-
tion in BMT recipients is likely to be especially illuminating. 
It may be, for example, that the pretransplant conditioning 
regimen disrupts a critical cellular function, or destroys a 
critical population of cells, that is not restored by marrow 
transplant. In addition, a more comprehensive analysis of 
recovery of T-cell function might provide insights. Neither 
T-cell phenotype nor functional analysis was available for 
the patients studied here. In general, recovery of normal 
numbers of CD4+ T cells is slow and may not be achieved 
for more than 1 year posttransplant.54 
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SUMMARY 
Haematopoietic stem cell transplantation has been used for the treatment of many different malignant 
and non-malignant diseases. The immune system of transplant recipients must be regenerated from the 
transplant inoculum, and it is not surprising that many transplant recipients are deficient in generating 
specific antibody responses to exogenous stimuli. This B cell immunodeficiency in these patients is 
associated with clinically significant infections, although the underlying mechanism remains unknown. 
We have previously shown that the pattern of usage of VH genes was similar between healthy subjects 
and BMT recipients, indicating that the immunodeficiency was not due to a dramatic imbalance in VH 
utilization. However, motif-specific hybridization analysis indicated that the accumulation of somatic 
mutations was much greater among rearrangements in controls than in BMT recipients. The failure of 
BMT recipients to accumulate somatic mutations in rearranged VH genes correlates with an absence of 
IgD~ B cells, and is consistent with a defect in antigen-driven B cell responses. In the current study, 
which extends those findings, we have determined the nucleotide sequences of 68 heavy chain 
rearrangements from one patient as well as 39 rearrangements from a healthy control. Analysis of 
these sequences made possible a more precise definition of variable region configuration and of the 
status of somatic mutation in this BMT recipient. The results validate the hybridization data and support 
the conclusion that, although somatic hypermutation and, by inference, antigen-driven responses are 
detected in BMT recipients, they are deficient compared with healthy subjects as late as 1 year after 
transplant. 
Keywords somatic mutation immunoglobulin bone marrow transplant diversity segment heavy 
chain variable region 
INTRODUCTION 
Haematopoietic stem cell transplant, using either bone marrow or 
mobilized peripheral stem cells, is characterized by a prolonged 
period of humoral immunodeficiency, reflecting in part the 
recapitulation of ontogeny [1]. Results suggest that the humoral 
immunodeficiency that exists post-transplant is the result of either 
a B cell defect, a monocyte defect, or a B cell/T cell cooperation 
defect which, in some patients, may be correctable with the addition 
of a cytokine [2]. T cell defects, including lack of helper activity 
and elevated suppresser activity, as well as B cell defects, are 
commonly observed [2-4J. B cells recover slowly in numbers, 
possibly because the post-transplant bone marrow microenvironment 
is deficient in supporting the proliferation and/or differentiation of 
B cell precursors [5], in frequency, and in function [6-13]. 
Impaired function of B cells isolated during the first 90 days 
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after transplant is apparent in their reduced ability to proliferate 
or to secrete immunoglobulin in response to mitogens [8,10,12-14]. 
These in vitro functions usually approach normalcy by 1 year after 
transplant [3,6-8,10-13,15]. Coincident with recovering B cell 
functions, serum immunoglobulin levels also usually return to 
normal [3,10,16], with normal levels of IgM returning at 6 
months, IgG at 12 months, and IgA after 2 years [17]. However, 
some patients who survive the initial post-grafting period do not 
become fully immunocompetent [18,19]. 
B cell and CD4 T cell numbers are low for at least 3 months; 
this is followed by fast recovery of B cell numbers (by 6-12 
months) and slower recovery of CD4 T cells [7,20,21]. Between 1 
month and 1 year after transplantation, in most patients there is 
a marked increase in the percentage of B cell precursors in the 
marrow, which probably accounts for the normalization or even 
overshooting of blood B cell counts within 1 year after transplant. 
However, these early emerging blood B cells have some features of 
immaturity, such as large size, a high surface expression of IgD, 
IgMandCD38 [7,13,15,20]. 
Early post-transplant B lymphopoiesis is mono- or oligoclonal, 
© 1997 Blackwell Science 
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and restricted clonality is more frequent in patients with chronic 
graft-verms-host disease (GVHD). Immune responses to the 
antigens bacteriophage tpXHA and keyhole limpet haemocyanin 
(KLH) are meagre in patients with chronic GVHD, as is antibody 
formation against pneumococcal polysaccharides [11], Post-trans-
plant infections are a well documented complication among 
transplant patients [22]. Some long-term survivors suffer from 
opportunistic bacterial infections, especially with encapsulated 
bacteria such as Streptococcus pneumoniae and Haemophilus 
influenzae type b [23,24]. Susceptibility to infections is most 
severe in recipients with chronic GVHD; the mortality rate for 
infections in these patients is 15-40% [25]. In an analysis of 443 
patients with chronic myelogenous leukaemia (CML) in chronic 
phase given human leucocyte antigen (HLA)-matched sibling 
(n = 251) or mismatched/unrelated (« = 192) marrow since 
1987, 1553 episodes of infection developed after day 120: 60 
patients had no episodes; 160 had one to two episodes; 125 
had three to five episodes; and 98 had six or more episodes [22]. 
With the use of routine antibiotic prophylaxis of penicillin and 
trimethoprim-sulfamethoxazole, encapsulated bacteria are now less 
frequent isolates than previously reported. Fungal and Gram-negative 
organisms are now more frequently observed. 
It seems likely that a heterogeneous collection of defects is 
responsible for the humoral deficiencies following marrow trans-
plant. The evidence cited above is consistent with a variety of 
mechanisms. For example, B cell dysfunction could be secondary 
to T cell dysfunction, either due to inadequate T cell help or to 
suppression; accessory cell (e.g. follicular dendritic cell) function 
could be defective; disturbance of the bone marrow microenviron-
ment could lead to abnormalities of B cell differentiation [5]; the 
disruption of secondary lymphoid tissue architecture could lead to a 
failure to supply an adequate microenvironment for peripheral B 
cell differentiation [26,27]. This latter possibility may be important. 
Although studies are limited to autopsy, the evidence indicates that 
germinal centres recover slowly in many patients [28], In a study 
of 40 patients 70-458 days following transplant, only two 
had recovered germinal centres. In another study, no patients 
recovered mesenteric lymph node germinal centres before day 
133 post-transplant (reviewed in [29]). 
One possibility, which we have explored, was that disruption of 
the programme of selection of the antibody repertoire in B cells 
from BMT patients contributed to humoral immunodeficiency 
[30,31]. This was based on the observation that usage of VH 
families following BMT appears to mimic usage during B cell 
ontogeny [32,33]. Thus, to account for the observed immunodefi-
ciencies, it might be expected that during the first year post-
transplant, BMT patients would utilize a more limited set of V 
genes than would healthy adult subjects. Additional support for this 
hypothesis came from the observation that the B cell repertoire is 
restricted to fetal-type VH genes in the very early post-transplant 
period [33]. 
In a previous study, we analysed the occurrence of specific VH 
gene segments by motif-specific hybridization in over 4900 
rearrangements in peripheral blood B cells of two healthy subjects 
and four BMT recipients at 90 days and 1 year following transplant 
[31]. The results indicated that the pattern of usage of VH genes 
was similar between BMT recipients and healthy subjects. These 
observations suggested that the processes involved in generating 
and selecting the antibody repertoire are largely functional within 
the first few months following BMT [31]. Furthermore, these 
results indicated that the immunodeficiencies common among 
BMT recipients are probably not due to the failure to utilize 
appropriate V region genes in generating the pre-immune antibody 
repertoire. However, the results did provide some indication of 
possible mechanisms contributing to poor antibody responses in 
BMT recipients. Using a highly sensitive hybridization technique, 
we found that rearrangements in BMT recipients exhibited 
much less somatic mutation than did rearrangements of the same 
gene, V3-23, obtained from healthy subjects. The failure in BMT 
recipients to accumulate somatic mutations in rearranged VH genes 
in peripheral blood lymphocytes (PBL) correlated with an absence 
of IgD~ B cells, and is consistent with a maturational arrest at a 
fairly late stage of differentiation. 
In this study, to define more precisely the status of somatic 
mutation among BMT recipients, and to discriminate between 
quantitative and qualitative differences, we determined the nucleo-
tide sequence of randomly selected rearrangements representing 
the spectrum of VH3 and VH4 genes utilized in one patient. The 
results show that the number of somatic mutations in the BMT 
recipient was significantly lower than in the healthy subject. The 
complexity of the CDR3 (third complementarity determining 
region) and DH and JH utilization further supports the conclusion 
that variable region configuration is normal in BMT recipients. The 
ratio of replacement to silent substitutions, and the finding that 
the specific pattern of substitutions deviated from the pattern 
characteristic of unselected mutations induced by the mutator 
mechanism, suggest that the few observed mutations were the 
result of antigen-driven responses. The results validate the hybri-
dization data and support the conclusion that, although somatic 
hypermutation and, by inference, antigen-driven responses are 
detected in BMT recipients, they are deficient compared with 
healthy subjects as late as 1 year after transplant. 
PATIENTS AND METHODS 
BMT recipients and control subjects 
We have previously reported VH utilization and accumulation of 
somatic mutations among four BMT patients (three female, one 
male) [31]. One of the patients, UPN 5012, who was diagnosed 
with GVHD within the first 100 days following transplant, was 
selected for additional analysis in the current study. One of the 
healthy controls (VMRC donor 3116) was also studied further. All 
samples were obtained under Institutional Review Board approved 
informed consent. 
Cell isolations, library construction and oligonucleotide hybri-
dization were performed as described [31,34]. 
DNA sequence analysis 
DNA sequences were determined with Taq DyeDeoxy Terminator 
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) on 
the Applied Biosystems Model 373 A DNA Sequencing System. 
Sequencing reactions were primed with either a universal primer 
(T7 or T3 sequencing primers) or oligonucleotide E61, 5'-
CTGTTCACAGGGGTCCTGTC-3', which corresponds to the 
leader sequence of VH4 gene segments, or additional primers 
corresponding to the CDR2 and FR3 regions of different genes 
were used to sequence CDR3 regions: M10, 5'-ATATGATG-
GAAGTAATAAAT-3'; M18, 5'-GTGAAGGGCCGGTTCAC-
CATC-3'; M22, 5'-ACTGATGGTGGGACAACAGAC-3'; E99, 
5'-AGTTACACCACAGAATACGCC-3'; M76, 5'-GCAGTTA-
TATGGTATGATGGA-3'; M92, 5'-TGCATAACCTGTGCTAC-
CACC-3'; E36, 5'-AGTGGTAGTACCATATACTAC-3'. For each 
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sequence, the V, D, and J germ-line counterparts were identified. 
Initially 20 randomly drawn clones from each library were studied. 
Of those, complete VDJ sequences were obtained from 68 heavy 
chain rearrangements from the BMT recipient and 39 heavy chain 
rearrangements from the healthy subject. 
RESULTS 
VH segment mutation 
To determine if there were qualitative differences in number of 
mutations or differences with respect to distribution and kind 
of substitutions in BMT recipients, we analysed the complete 
nucleotide sequences from randomly selected clones from those 
previously analysed libraries of one BMT recipient and compared 
these with nucleotide sequences determined for randomly chosen 
rearrangements obtained from a healthy control. Clones were 
chosen for analysis by random drawing from each of the VH3 
and VH4 libraries. A total of 107 clones comprising 99 independent 
rearrangements were analysed. The results of sequence analysis 
are summarized in Table 1. The germ-line source of each of 
the rearrangements was determined by comparison with known 
germ-line gene sequences, including some sequences from germ-
line libraries made from the bone marrow donor, some sequences 
previously published by us [34,35], and some sequences extracted 
from GenBank. Comparison of CDR3 sequences was used to 
establish the independence of rearrangements. In control experi-
ments, in which rearrangements were amplified from B cell 
lines, we found that as many as two nucleotide substitutions per 
rearrangement can be introduced by the process of generating 
the rearrangement libraries (data not shown). The number of 
substitutions in combined FR and CDR is shown separately for 
replacement (R) and silent (S) interchanges. The ratio of R/S 
was calculated for each group of sequences in Table 1. Somewhat 
surprisingly, R/S was higher in the BMT sequences than in the 
normal subject sequences. However, the number of mutations in 
BMT rearrangements was significantly lower when compared with 
the normal subject (P<0001). As shown in Table 2, the differ-
ences are very significant when rearrangements with one, two or 
three or more mutations are compared between BMT recipient and 
healthy subject (P < 10~5). 
Analysis of independent substitutions both in the normal 
subject and the BMT recipient showed that transitions (=>55% of 
all substitutions) occurred more often than transversions, although 
it should be noted that transitions are the most frequent misincor-
poration events of Taq-polymerase [36,37]. In agreement with 
previous reports, there were more mutations of purines than 
pyrimidines in the healthy subject [38-42]. Three clones (BMT 
clone 9, normal clones 90 and 103) which contained high numbers 
of mutations were treated separately in the analysis shown in 
Table 3. 
Table 1. Features of heavy chain rearrangements analysed* 
Substitutions 
Donor Clone DH Framet 
FR CDR 
(R/S) 
BMT V„3 90 days 
BMT V„3 1 year 
1 
2 
3 
4 
5 
6 
7 
8 
9§ 
10-151 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
V3-07 
V3-11 
V3-11 
V3-13 
V3-13 
V3-15 
V3-23 
V3-30 
V3-30 
V3-30 
V3-11 
V3-11 
V3-15 
V3-20 
V3-23 
V3-23 
V3-23 
V3-23 
V3-23 
V3-30 
V3-30 
V3-30 
V3-30 
V3-30 
V3-33 
V3-33 
V3-72 
ND* 
DXP1 
DXP1 
D N lb 
ND 
DH21S10 
DK1 
DLR2 
DLR2 
DLR5, DH21S9, DIR4** 
DN1 
DLR2 
D„21S10 
DXp'l 
ND 
DLR2, D N l i nv t t 
D„21S10 
D N lb 
DXP4 
DXp'l 
ND 
D N lb 
DN1 
ND 
D N lb 
DN1 
DNEW 
4 
4 
3 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
6 
4 
2 
4 
6 
3 
4 
4 
3 
4 
4 
4 
0/1 
0/0 
0/1 
1/0 
0/0 
0/0 
1/0 
0/0 
16/10 
1/1 
l -0 t t 
0/0 
0/0 
0/0 
1/0 
0/1 
2/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/1 
0/0 
0/0 
1-5M 
0/0 
0/0 
6/0 
0/0 
0/0 
1/0 
2/0 
0/0 
14/8 
3/0 
12-OM 
0/0 
0/0 
0/0 
0/0 
0/0 
4/1 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
4-0tt 
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Table 1. Cont. 
D„ Framef (R/S) 
BMT VH4 90 days 
BMT VH4 1 year 
Normal VH3 
33 
34 
35 
36 
37 
38 
39-401 
41 
42 
43 
44 
45 
46-471 
48 
49 
50 
51 
52 
58 
54-551 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 
76 
77 
78 
79 
80 
81 
82 
83 
84 
85 
86 
87 
88 
V4-30.2 
V4-31 
V4-31 
V4-31 
V4-31 
V4-34 
V4-34 
V4-34 
V4-34 
V4-34 
V4-34 
V4-34 
V4-34 
V4-39 
V4-4 
V4-4b 
V4-55 
V4-31 
V4-31 
V4-31 
V4-31 
V4-31 
V4-34 
V4-34 
V4-34 
V4-34 
V4-34 
V4-34 
V4-4 
V4-4 
V4-4b 
V4-4b 
V4-61 
V3-11 
V3-15 
V3-20 
V3-20 
V3-23 
V3-23 
V3-23 
V3-23 
V3-23 
V3-23 
V3-23 
V3-23 
V3-30 
V3-30 
V3-30 
V3-30 
V3-33 
V3-33 
V3-33 
V3-74 
D N lb , DlR5inv 
DH21S9 
DXP4 
D1R, DX P 
DXP4 
DH21S9 
Dxp 1. DXp 
ND 
D N I 
ND 
DH21S9 
DXP'1 
DN1 
DH21S9 
D N lb 
DK4, DLRlinv 
DXp 1. DNEW 
DXP1 
D„21S9 
D N lb 
DXp 
D A lb 
D N lb 
D N lb 
DXP'1 
D,.R4 
D A lb 
ND 
D„21S9 
DN1 
D N lb 
ND 
D A lb 
D[.R4 
DXP4 
D N lb 
DXP4 
DH21S9 
DNEW 
D N 4 
DNEW 
DK4, DH21S9inv 
DH21S9 
ND 
DXP4 
DH21S9 
DLR2, D X P 
D N lb 
DN1 
D L R l ,D X P l / 4 
DK1 
D X P 4 ,D N lb 
ND 
4 
1 
4 
4 
4 
4 
4 
3 
4 
4 
6 
4 
4 
5 
4 
4 
4 
6 
3 
4 
4 
4 
4 
6 
4 
4 
4 
4 
1 
4 
4 
6 
6 
6 
4 
5 
6 
4 
6 
4 
5 
4 
4 
4 
4 
4 
5 
4 
3 
3 
4 
4 
4 
1/0 
0/0 
1/0 
1/1 
0/1 
0/0 
0/0 
0/0 
1/1 
0/0 
1/0 
0/0 
0/0 
1/0 
0/0 
1/0 
0/1 
175« 
0/0 
0/0 
0/0 
0/0 
(I/O 
(I/O 
(I/O 
I/O 
l/ll 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
1/1 
0/0 
1/0 
0/0 
0/0 
0/0 
0/0 
0/0 
0/0 
2.0M 
0/0 
0/0 
0/0 
(I/O 
(I/O 
(I/O 
(I/O 
I/O 
(l/ll 
: / i 
5/0 
9-Oii 
0/0 
0/1 
0/0 
1/2 
2/0 
1/0 
0/0 
0/0 
4/4 
0/0 
2/0 
0/0 
0/2 
9/3 
3/5 
0/0 
3/3 
2/2 
1/0 
4/2 
133M 
(I/O 
:m 
MIS? 
0/0 
0/0 
0/0 
0/0 
2/0 
0/0 
0/0 
0/0 
5/3 
0/0 
4/2 
0/0 
0/0 
2/1 
1/3 
0/0 
3/0 
0/0 
0/0 
7/4 
1-85H 
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Table 1. Cont. 
Substitutions 
FR CDR 
Donor Clone VH D„ Framef (R/S) 
Normal VH4 89 
90§ 
91 
92 
93 
94 
95 
96 
97 
98 
99 
100 
101 
102 
103§ 
104 
105 
106 
107 
V4-30.2 
V4-30.4 
V4-30.4 
V4-31 
V4-31 
V4-31b 
V4-34 
V4-34 
V4-34 
V4-34 
V4-34 
V4-39 
V4-39 
V4-39 
V4-39 
V4-4b 
V4-4b 
V4-61b 
V4-61b 
D N l b ,D X P l 
DXP1 
DNEW 
DH21S9 
ND 
DLR3 
DLR 
DLR2, DK4 
DA l /4 
DLR4 
D„21S9 
DAl/4inv, DNlinv 
D„21S9 
DXP4 
D X P ' l ,D A l / 4 
DA l /4 
DLR4 
DNEW 
DLR4 
1/1 
2/15 
0/0 
1/0 
3/2 
3/0 
1/0 
0/0 
0/0 
1/0 
0/0 
2/1 
1/0 
0/0 
1/13 
0/0 
0/0 
0/0 
0/0 
5-75H 
3/1 
8/5 
0/0 
0/0 
3/0 
1/0 
1/0 
0/0 
0/0 
0/0 
0/0 
3/1 
1/0 
0/0 
11/6 
0/0 
0/0 
0/0 
0/0 
6-Ott 
•Sequences are available in Genbank: accession nos. /i8OO83-80182. 
fProductive rearrangement shown as +, non-productive rearrangements shown as -
$Not determined. 
§Highly mutated clones not included in total R/S calculation. 
^Identical clones counted as one rearrangement. 
**In some rearrangements multiple D segments were used. 
ttlnverted D segments in the rearrangements are indicated by 'inv'. 
t^Total R/S ratio for each group. 
The distribution of substitutions of coding strand nucleotides 
generated by the intrinsic action of the hypermutation mechanism 
in the absence of selection by antigen has been found to be 
asymmetric [42,43]. In the absence of selection, the proportion 
of all substitutions involving each nucleotide is: T = 0*13, 
C = 0-21, A = 0-29, and G = 0-37 [42]. Deviations from these 
proportions can be indicative of selection. In our analysis, sub-
stitutions in rearrangements from the BMT recipient did deviate 
from the predicted proportions in that there was a relative increase 
in substitutions of T (which are less commonly substituted by the 
hypermutation mechanism) and a relative decrease in substitutions 
Table 2. Numbers of mutations among rearrangements 
Number mutations 
0 
1 
2 
3 or more 
Normal* 
16 
5 
3 
15 
BMT 
35 
13 
4 
8 
*The number of rearrangements with the indicated 
number of somatic mutations is given. For all arrange-
ments, P < 0-00001 for BMT versus normal 
of A, on the coding strand (Table 3). This deviation was significant 
whether raw data or normalized data were compared with the 
predicted values. None of the other comparisons revealed signifi-
cant differences from the values predicted for the hypermutation 
mechanism. 
The distribution of substitutions among the highly mutated 
clones (BMT clone 9, normal clones 90 and 103) was generally 
typical of the distribution generated by the antibody hypermutation 
mechanism in the absence of selection, although there was a slight 
increase in transversions (Table 3). Compared with the cumulative 
BMT or normal sequences, BMT clone 9 and normal clone 90 had 
an increase in A to C substitutions, and normal clone 103 had 
increased T to A substitutions (Table 3). 
CDR3 complexity 
D segments were identified (according to the criteria of Klein et al. 
[44]), either (i) by identity to a known DH or DIR region over a 
stretch of seven consecutive basepairs, or as (ii) having a single 
basepair difference at least two basepairs from the 5' or 3' end in a 
stretch of eight basepairs otherwise identical to a known DH or DIR 
element [45-48]. By these criteria, the germ-line source of D 
segments in =92% of rearrangements from the BMT recipient 
and 85% of rearrangements from the healthy subject could be 
identified. 
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Table 3. Distribution of coding strand substitutions among rearrangements 
Distribution of substitutions* Cumulative substitutions 
BMTt 
BMT 
Clone 9 
Normal 
clone 90 
Normal 
clone 103 
Preferences!! 
From'1 
T 
C 
A 
G 
From1' 
T 
C 
A 
G 
From71 
T 
C 
A 
G 
From7' 
T 
C 
A 
G 
FromT< 
T 
C 
A 
G 
From11 
T 
C 
A 
G 
0-42 
013 
010 
0-5 
0 
0-23 
0-60 
0-27 
006 
0-5 
0 
0-23 
0-31 
011 
0 0 0 
0-74 
0-29 
0 0 9 
C 
0-53 
-
013 
0-35 
C 
0-6 
-
0-42 
0-31 
C 
0-44 
-
0 0 9 
0-43 
C 
0-6 
-
0-42 
0-31 
C 
0-57 
-
011 
0-25 
C 
0-52 
-
0 1 9 
0-32 
A 
0-29 
0-25 
-
0-55 
P versus 
A 
0-2 
0-2 
-
0-46 
P versus 
A 
0-25 
0-25 
-
051 
P versus 
A 
0-2 
0-2 
-
0-46 
P versus 
A 
0-43 
0-23 
-
0-75 
P versus 
A 
0-31 
0 0 9 
-
0-59 
G 
0-18 
0-33 
0-75 
-
predicted 
G 
0-2 
0-3 
0-58 
-
predicted 
G 
0-31 
015 
0-64 
-
predicted 
G 
0-2 
0-3 
0-58 
-
predicted 
G 
0 0 0 
0-46 
0-78 
-
predicted 
G 
017 
0.17 
0-52 
-
nt 
17 
12 
8 
20 
000075 
5 
10 
12 
13 
0-9088623 
16 
40 
33 
47 
01109961 
5 
10 
12 
13 
0-9088623 
7 
13 
9 
12 
0-2481294 
Normalized§ 
20.29 
11.00 
8.95 
16.76 
6 . 4 x 1 0 " ' 
5-72 
8-36 
13 56 
12-32 
0-8497228 
19-448 
38-488 
38-216 
39-712 
01164651 
5-72 
8.36 
13-56 
12-32 
0-8497228 
8-487 
11-111 
10-742 
10-66 
0-2563223 
Predicted^ 
7.41 
11.97 
16.53 
21.09 
5.2 
8-4 
11-6 
14-8 
17-68 
28-56 
39-44 
50-32 
5-2 
8-4 
11-6 
14-8 
5-33 
8-61 
11-89 
15-17 
*Proportion of total substitutions of each germ-line base contributed by each of the other three bases. 
flncludes all BMT sequences from Table 1 except clone 9. 
tTotal number of coding strand substitutions for each base. 
§Number of coding strand substitutions normalized for base composition, calculated as normalized ={slt){nl4m), where s ~ number of substitutions of m, 
/ = total number of substitutions, n = total number of nucleotides analysed, and m = total occurrence of each nucleotide. 
^Predicted number of substitutions calculated as: predicted =/Nf, based on intrinsic substitution frequency ( / ) where/T = 0-13,/c = 0-21, fA = 0-29, and 
/ G = 0-37 [42], and t = total number of substitutions. 
**Includes all sequences from the normal subject from Table 1, except clones 90 and 103. 
ttlntrinsic base substitution preferences of the somatic mutational mechanism [42]. 
Some of the D families were frequently used in both subjects, 
e.g. D X p. Other families were less frequently used or not used at all. 
No rearrangements of D Q 5 2 were observed in either subject. 
Overall, D H gene usage in both subjects was consistent with 
previous reports [ 4 9 - 5 2 ] . Rearrangements involving D - D joining 
or D - D I R joins accounted for 6% of rearrangements in the 
patient 1 year after transplant, and 2 3 % of the rearrangements 
90 days after transplant. In the healthy subject, rearrangements 
involving D - D joining accounted for 19% of rearrangements. No 
DIR segments were used in rearrangements from the healthy 
subject. 
In both the healthy subject and the B M T recipient, all three 
reading frames of the D segments were used, and about 7-5% of 
the D segments used were inversions, which is consistent with 
previous results [50,51]. Furthermore, the healthy subject and the 
B M T recipient generally used similar D segment reading frames, 
although some individual V genes exhibited an apparent prefer-
ence for reading frame 2; in the 14 clones containing V 4 - 3 4 , 
13 used a D segment in reading frame 2. Also, consistent with 
earlier results [50,51], some of the D segments used a specific 
reading frame, e.g. D segments from the D N family preferentially 
used reading frame 2. 
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Novel D segments 
Three different sequence motifs were identified in both subjects 
which could not be assigned to any of the published DH or DIR 
region element. The first motif, a 20 bp sequence, GTATAG-
CAGTGGCTGGTACG, which includes 7 bp previously identified 
by Yamada et al. [51], was found in 12 independent rearrangements. 
This sequence belongs to the DN family, differing by two nucleo-
tides from DN1, and is designated DN1 b. The second motif, a 16 bp 
sequence, ATAGTGGGAGCTACTT, was found in seven rearran-
gements. The first seven nucleotides of this sequence are identical 
to bases 7-13 of DK1. This new segment could be part of a novel 
DH or DIR region element. Part (13 bp) of this D segment is also 
used in rearrangements reported by Klein et al. [44], where it was 
designated DNEW . The third motif, a 12mer, GACTACGGTGAC, 
was found in five rearrangements. This D belongs to the DA family, 
differing from DA1 and DA4 by two nucleotides, and is designated 
DAlb. 
JH distribution 
The most frequently used JH segments were JH4 (56-8% healthy 
subject, 66-7% BMT recipient) and JH6 (21-6% healthy subject, 
16-7% BMT recipient) in both BMT recipient and control. 
Productive versus non-productive rearrangements 
In the healthy subject, 75-7% of the randomly picked sequences 
were in frame, compared with 76-3% in the BMT recipient. The 
length of CDR3 from productive rearrangements ranged from 13 bp 
to 69 bp in the healthy subject (mean 42 bp) and from 15 bp to 
91 bp in the BMT recipient (mean 39-4 bp). 
DISCUSSION 
In this study, qualitative differences with respect to distribution 
and kind of substitutions resulting from somatic mutation of 
immunoglobulin variable region genes in recipients of bone 
marrow transplant were evaluated by sequence analysis. To this 
end, the complete nucleotide sequences from randomly chosen 
rearrangements from a BMT recipient were compared with nucleo-
tide sequences from randomly chosen rearrangements obtained 
from a healthy control. As predicted from prior hybridization data 
[31], rearrangements from this BMT recipient exhibited far fewer 
somatic mutations than did rearrangements from the healthy 
subject, although the difference was more dramatic in the VH3 
gene family than in the VH4 gene family. The complexity of CDR3 
regions was similar in the BMT recipient and healthy subject, 
further supporting the conclusion that the antibody repertoire is 
generated normally following BMT. 
The generation of high-affinity, somatically mutated antibodies 
in response to antigenic challenge is the hallmark of a protective, 
secondary antibody response. In the absence of somatic mutation, 
high-affinity antibodies are rarely produced. Individuals who have 
a compromised ability to generate somatically mutated antibodies 
will have a compromised ability to clear viral and microbial patho-
gens and opportunistic infectious agents. Antibodies that have been 
antigen-driven may have numerous mutations (20-40 substitutions 
per variable region are not uncommon). They usually display a 
ratio of replacement/silent (R/S) substitutions in the CDRs that is 
greater than that expected of random mutation, whereas R/S in FR 
is frequently less than that expected of random mutation [53,54]. In 
general, R/S > 4-7 is taken as indicating antigen-driven mutation, 
and R/S < 1-5 [54] or < 1-9 [53] is taken as indicating unselected 
(random) mutation. In rearrangements obtained from the BMT 
recipient, R/S within CDRs was elevated (R/S = 11 -5 for all BMT 
sequences). By comparison, R/S in rearrangements obtained from 
the healthy subject was 2-4, which is similar to the values for the 
framework regions in both subjects (20 in healthy subject and 2-2 
in BMT recipient). These values are close to the value of 1-5 
predicted by Shlomchik et al. [54], or 1-9 predicted by Reynaud 
et al. [53] for unselected substitutions. The relatively low R/S in 
CDRs in the healthy subject is somewhat unexpected, but has been 
reported before [55]. The high mutation frequency of thymidines, 
and the high R/S in the BMT recipient should be cautiously 
interpreted, because most of the rearrangements displayed only 
one or two nucleotide substitutions from the germ-line. Because 
the overall incidence of mutation in the BMT recipient fell in the 
range of system background, the high incidence of thymidine 
substitutions could be a consequence of an in vitro bias. To the 
extent that this is true, the data represent an overestimation of the 
amount of somatic mutation. 
The pattern of the observed mutations was suggestive of 
antigenic selection and differed from the expected pattern for the 
intrinsic hypermutation mechanism in immunoglobulin V regions 
[42], in that there was a high incidences of thymidine substitutions, 
and an elevated R/S ratio in CDR1. This pattern provides evidence 
that at least some antigen-driven B cells are present in the 
circulation of BMT recipients. It is uncertain if these B cells 
resulted from immune responses generated in the patient or if 
they represent donor-derived memory cells. The observation that 
there were more mutations at 90 days than at 1 year post-transplant 
suggests the persistence of donor-derived memory B cells. In this 
regard, several studies have shown that adoptively transferred 
immunity persists in recipients for years post-grafting [1,56], and 
may be a consequence of peripheral blood contamination of bone 
marrow preparations [57]. 
The B cell phenotype following BMT is consistent with several, 
not necessarily mutually exclusive, functional deficits. For example, 
B cell dysfunction could be secondary to T cell dysfunction, either 
due to inadequate T cell help or to suppression. Alternatively, the 
disruption of secondary lymphoid tissue architecture could lead to 
a failure to supply an adequate microenvironment for peripheral 
B cell differentiation. The last possibility is intriguing. It is thought 
that recruitment of naive B cells into a long-lived preimmune B cell 
pool depends upon receipt of survival signals delivered in second-
ary lymphoid organs [58]. The disruption of secondary lymphoid 
architecture may preclude efficient delivery of these signals. Thus, 
BMT recipients may have an elevated short-lived B cell compart-
ment and a reduced long-lived compartment. The failure to recruit 
and maintain a long-lived B cell population could account for an 
overall reduced ability to mount an effective antibody response. 
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SUMMARY 
The acquisition of somatic mutations in the rearranged immunoglobulin V regions in B cells occurs 
within the tightly regulated microenvironment of a germinal centre. The precise mechanism responsible 
for turning on the mutational process is unknown. To dissect the role of different components of the 
germinal centre in this mechanism, we have used in vitro cultures of normal human IgD+ peripheral 
blood B lymphocytes co-cultured with activated CD4+ T cells, or with resting CD4+ T cells, or with 
CD40 ligand and IL-4. We observed that if the cultures included activated CD4+ T cells, then up to 
100% of VH transcripts on day 14 were somatically mutated. Transcripts were found to carry from one to 
36 substitutions (median five). In contrast, in the absence of activated T cells, transcripts contained only 
background levels of somatic mutation irrespective of the presence of resting T cells or CD40 ligand and 
IL-4. Cell-cell contact was required for mutation because mutations were not detected when B cells 
were separated from activated T cells by a membrane. 
Keywords B lymphocytes T cell-B cell collaboration antibodies generation of diversity 
INTRODUCTION 
Somatic mutation of rearranged immunoglobulin V region genes is 
a powerful diversifier of the antibody repertoire and an important 
requisite in the formation of memory B cells. Although the 
underlying mechanism remains to be fully elucidated, somatic 
mutation has been found to be highly focused on rearranged 
variable regions (V) of immunoglobulin genes [1-3]. The possible 
start site for immunoglobulin mutator activity has been suggested 
to be located in the vicinity of the promoter or leader sequence 
[4,5]. Both the 3'-enhancer and the intron-enhancer/matrix attach-
ment region seem to be necessary for effective hypermutation 
S.-C.H. current address: Promega Corp., 2800 Woods Hollow Road, 
Madison, Wl 53711-5399, USA. 
S.P.R current address: Department of Pathology and Laboratory Med-
icine, University of Pennsylvania School of Medicine, Philadelphia, PA 
19104, USA. 
G.V.P. current address: Mississippi State University of Mississippi 
State, MS 39762-5759, USA. 
Correspondence: Eric C. B. Milner PhD, Immunology Program, Virginia 
Mason Research Center, 1000 Seneca Street, Seattle, WA 98101, USA. 
E-mail: emilner@vmmc.org 
© 1999 Blackwell Science 
[6-8], but the requirement for a specific promoter sequence is 
less certain [8]. 
In vivo, somatic mutation appears to involve an active process 
that occurs normally in response to specific signals transmitted 
within the tightly regulated microenvironment of a germinal centre 
(reviewed in [9,10]). Although germinal centres appear by day 4 
following immunization, mutation is generally not observed in 
germinal centre B cells until day 8 post-immunization; thereafter, 
point mutations favouring asymmetrical transversions accumulate 
until day 14 [11]. Activated T lymphocytes were shown to be 
required for the somatic mutation to occur [11,12], and an activated 
T cell-associated molecule, CD40 ligand (CD40L), was shown to 
be important for the formation of germinal centres [13]. The 
mechanism responsible for 'switching on' somatic mutation, 
however, remains enigmatic. 
An in vitro system of studying the mutation progression in 
murine B cells has been established, and it has been found that T 
cell-derived signals are necessary for progression of somatic muta-
tion [14]. In the human system, Denepoux etal. [15] have reported 
that somatic mutations can be induced in a lymphoma B cell line 
in vitro upon surface immunoglobulin cross-linking by anti-IgM and 
co-culturing with an activated T cell clone. Evidence showing the 
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induction of somatic mutation in human tonsillar B cells by 
activated T cells was provided by Lebecque and colleagues [16]. 
Here we show, using an in vitro culture system originally 
described by Lipsky and colleagues [17], the accumulation of 
somatic mutations among freshly isolated human B cells from 
peripheral blood. B cells (CD19+/IgD+) were isolated from 
peripheral blood lymphocytes (PBL) of a normal individual and 
were co-cultured with either activated autologous CD4+ T cells, or 
with resting autologous CD4+ T cells, or with CD40L and 
cytokines. After 2 weeks of culture, the occurrence of somatic 
mutations was examined among immunoglobulin VH transcripts 
containing the V3-23 gene, the most frequently represented VH 
gene in PBL B cells [18-21]. 
MATERIALS AND METHODS 
Reagents and cell line 
Murine monoclonal anti-human CD19 (IgGl), goat polyclonal 
anti-human IgD and goat preimmune IgG, unconjugated or con-
jugated to FITC, and goat anti-human IgM (unconjugated), were 
purchased from Becton Dickinson (Mountain View, CA). Purified 
CD40L (a soluble trimeric form [22]) was a kind gift of Drs R. J. 
Armitage, M. K. Spriggs and W. C. Fanslow (Immunex Corp., 
Seattle, WA). Recombinant human IL-4 was purchased from R&D 
Systems (Minneapolis, MN). CDW32L (L cells), a murine fibro-
blast line stably transfected with human FcyRII [23], was obtained 
from Dr E. Clark (University of Washington, Seattle, WA) and 
cultured as described [24]. 
Lymphocyte separation 
PBL were isolated from peripheral blood of a healthy adult male 
Caucasian, VMRC donor 3116. B cells were isolated from PBL by 
anti-CD 19 coated immunomagnetic beads, and detached using 
'detachabead' CD19 reagent (DynaBeads; Dynal, Inc., Lake 
Success, NY). Naive B cells (CD19+/IgD+) were further purified 
from the CD19+ B cells either by anti-IgD-coated immuno-
magnetic beads according to the manufacturer's instructions 
(Dynal) or by anti-IgD (FITC-conjugated) sorting on a FACSort 
(Becton Dickinson Immunocytometry Systems, San Jose, CA). 
The resulting population was >95% CD19+IgD+IgM+. Auto-
logous CD4+ T cells were isolated using anti-CD4-coated 
immunomagnetic beads (Dynal). The CD4+ T cells were detached 
from the beads using 'Detachabead' reagent (Dynal) according to 
the manufacturer's protocol. The purity of T cells as determined by 
FACS analysis was > 99% following isolation. Isolated cells were 
resuspended in RPMI1640 (GIBCO, Grand Island, NY), 10% fetal 
bovine serum (FBS; GIBCO), 2mM glutamine, 1% sodium pyruvate, 
lOOU/ml penicillin and 100 fig/ml streptomycin (RPMI). 
Cell culture 
B cells (103 per well) were cultured in flat-bottomed microplates 
(Costar, Cambridge, MA), in RPMI supplemented with IL-4 
(lOOU/ml). Other additions depending on the experiment were 
anti-IgM (1 Mg/ml), CD40L (1 /ig/ml), CDW32L cells (L cells) (104 
per well), resting or activated CD4+ T cells (105 per well). L cells 
and T cells were irradiated before initiation of the cultures (70 and 
30 Gy, respectively). To activate T cells, wells were pre-coated as 
described [17] with 64.1 antibody, a murine monoclonal anti-
human CD3 (IgGl) which was a generous gift of Dr E. Vitetta 
(University of Texas South-western Medical Center, Dallas, TX). 
Some 64.1 antibody was also obtained through Dr E. A. Clark 
(University of Washington, Seattle, WA). In some experiments, B 
cells were separated from T cells by a membrane (3 fim pore size, 
Transwell; Costar). Cell growth was monitored daily by light 
microscopy. Cumulative immunoglobulin production in the 
cultures was detected by ELISA essentially as described [25]. 
Construction ofcDNA libraries containing rearranged VH3 genes 
Total RNA was extracted from the cells using RNAzol (Tel-Test, 
Friendswood, TX) and cDNA was made as described [26]. VH3-
containing transcripts were amplified in a 31-cycle polymerase 
chain reaction (PCR) with AmpliTaq DNA polymerase (Perkin 
Elmer, Foster City, CA), using a VH3-specific 5' leader primer and 
either a consensus JH 3' primer, a Cy primer, or a C/x primer as 
described [20,21,26]. The PCR-amplified transcripts containing 
VH3 genes were cloned into a phagemid vector and libraries were 
constructed as described [20,21]. In some experiments, colonies 
were lifted directly onto nylon filters. In other experiments, single 
strand phages were rescued in 96-well plates by addition of K07 
helper phage (Stratagene, La Jolla, CA) and 10/al of supernatant 
from each well were dot-blotted on multiple replicate nylon filters 
[20,21], Dot blotted filters were used in the hybridization analysis 
for gene identification and detection of mutation. 
Detection of somatic mutation by differential oligonucleotide 
probe hybridization 
The V3-23 gene is the most frequently rearranged VH3 gene, 
accounting for 20-40% of the total VH3 repertoire in peripheral 
B cells [18-21,27]. Identification of clones carrying transcripts of 
the V3-23 gene and occurrence of somatic mutations were esti-
mated by differential hybridization using oligonucleotide probes M8 
and Ml 8 as described [20,28,29]. M18 (GTGAAGGGCCGGTT 
CACCATC) is targeted at a region overlapping FR3/CDR2 of 
V3-23 [29], and M8 (AGCAGC TATGCCATGAGCTGG) is tar-
geted at CDR1 of V3-23 [30]. Hybridization was conducted by an 
overnight incubation of the filters with 32P-labelled M8 or M18 at a 
temperature of 61°C. Filters were washed with 5x SSC, 0-5% SDS, at 
43°C once for 1 h, then twice for 30 min each, followed by 3.2 M 
tetramethylammonium chloride (TMACL; pH 7-8) containing 0-5% 
SDS for 1 h at 60°C (M8) or at 63°C (M18) [20,31]. Hybridization 
results were visualized by autoradiography. Occurrence of somatic 
mutations was estimated by loss of concordant hybridization of the 
V3-23-specific probes as described [29,32]. 
DNA sequence analysis 
Supernatant (5 /d) from selected phage clones carrying VH3 cDNA 
was used for PCR amplification of the insert by M13(-20) and M13-
reverse primers (Stratagene). PCR products were purified using the 
QIAquick PCR purification kit (Qiagen Inc., Valencia, CA) and 
sequences were determined using the Dye Terminator cycle sequen-
cing kit (Perkin Elmer) on the Applied Biosystems model 373A 
DNA sequencing system using universal T3 and T7 primers. The 
comparison and alignment of DNA sequences of the rearranged VH3 
genes with the germ-line sequence of the donor was performed using 
the Lasergene analysis package (DNASTAR Inc., Madison, WI). 
RESULTS 
B cells co-cultured with activated T cells but not with CD40L 
accumulate somatic mutations 
Although activated T cells were shown to induce Ig V hyper-
mutation in human B cells [15,16], the exact role of T cells, as well 
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Fig. 1. Detection of somatic mutation in V3-23 rearrangements. Upper left panel: hybridization of a blot containing VH3 cDNA clones with 
oligonucleotide probe M8, which is targeted to a sequence motif spanning CDR1. Upper right panel: replicate blot hybridized to probe Ml8, 
which is targeted to a sequence motif which extends from CDR3 into FR2. Concordant hybridization is scored as unmutated; discordant 
hybridization is scored as mutated. Bottom panels: nucleotide sequences of M8 (left) and M18 (right) targeted motifs corresponding to clones 
identified in upper panels. 
as of other components of the germinal centre, in the induction 
of somatic hypermutation in normal B cells is not yet estab-
lished. To address this role, we cultured highly purified IgD+ 
peripheral blood B cells as described above, and estimated the 
accumulation of somatic mutations among B cells expressing 
the V3-23 gene. We took advantage of motif-specific oligo-
nucleotide probe hybridization to screen a large number of 
icDNA clones containing V3-23 transcripts and to obtain an 
(estimate of the number of transcripts carrying mutations in the 
probe-targeted sequences. 
VH3 cDNA clones were screened for hybridization to the 
iprobes M8 and Ml 8. Each instance of discordant hybridization 
of these probes was scored as one mutation. The specificity of this 
scoring is illustrated in Fig. 1. The left panel of Fig. 1 shows 
hybridization of a 96-dot blot array of cloned VH3 cDNAs with 
the probe M8, which is targeted to a sequence motif which spans 
CDR1 of V3-23. A replica of the filter is shown in the right panel, 
Ihybridized to the probe M18 which is targeted to a sequence motif 
that extends from CDR2 into FR3. DNA sequences of the targeted 
motifs are shown below each filter. Clones that hybridize to both 
iprobes are scored as unmutated (e.g. F9, F l l , and Gl). The 
nucleotide sequences (bottom panel) verify the nucleotide identity 
between probe and target for all hybridizing clones, and reveal at 
least one substitution in the targeted motif, for all non-hybridizing 
clones. 
Similar analysis was performed on a large number of recombi-
nant VH3 clones and is summarized in Fig. 2. As shown in Fig. 2, 
an extremely high frequency of discordance (i.e. mutation) was 
observed among V3-23 clones obtained from cultures that con-
itained B cells, activated T cells and anti-IgM. In contrast, a low 
frequency of discordance, comparable to background levels of 
mutation found in pre-culture B cells, was observed in cultures that 
contained B cells, purified CD40L and CDW32L but not activated 
T cells. 
To estimate more accurately somatic mutations, nucleotide 
sequences were analysed among independent V3-23 transcripts 
selected from T cell-supported B cells and from CD40L-supported 
B cells (Fig. 3). T cell-supported cultures produced at least five-
fold more mutations (0-36 substitutions, median = 5, mean = 71) 
than did CD40L-supported cultures (0-6 substitutions, median= 1, 
mean = 11). All mutations were single nucleotide substitutions, no 
insertions or deletions were observed. The ratios of replacement to 
silent substitutions (R/S) in CDRs and FRs from T cell-supported 
cultures were 6-5 and 1-2, respectively, and from CD40L-
supported cultures were 6 0 and 1-8, respectively. Individual 
substitutions occurred largely at sites comprised of the motif 
Pre-culture B cells 
B cells, CD40L, IL-4 
B cells, T cells 
(resting) 
B cells, T cells 
(activated) 
40 60 80 
Percent mutated 
100 
Fig. 2. Mutations accumulate in activated T cell-supported B cell cultures. 
Bars indicate percentage of rearrangements carrying mutations (± s.d. of 
three independent experiments). Libraries were made from pre-culture. 
purified B cells (top bar), or from 14 day B cell cultures which included 
either CD40L and IL-4 (second bar), resting T cells (third bar), or anti-CD3-
activated T cells (bottom bar). V3-23 cDNA transcripts were identified by 
hybridization to probes M8 and/or M18. Mutation was scored as discordant 
hybridization to these probes. Each bar represents the analysis of at least 
1000 V3-23 transcripts. 
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A temporal increase in the proportion of mutated B cells 
To determine the kinetics of accumulation of somatic mutations, 
wells were harvested for analysis 7, 10 and 14 days after initiation 
of culture. At day 7, the percentage of transcripts that had acquired 
somatic mutations was similar to that seen in pre-culture B cells 
(Table 1). However, by day 10 the percentage of transcripts that 
had acquired somatic mutations had increased to twice back-
ground, and in one experiment was more than four-fold over 
background on day 14. 
Table 1. Somatic mutations among VH transcripts on 
different days of culture 
Day 
0 
7 
10 
14 
Experiment 1 
n 
2037 
1393 
599 
165 
Percent 
mutated 
16-3 
2 0 0 
31-6 
661 
Experiment 2 
n 
1455 
229 
288 
2533 
Percent 
mutated 
16-7 
16-6 
32-3 
42-5 
Cultures contained RPMI1640, 10% fetal bovine serum 
(FBS), lOOU/ml IL-4, 1 (ig/ml CD40L, anti-IgM, 1 x IO3 B 
cells, and 1 x IO5 irradiated (30Gy) CD4+ T cells. Cultures 
also contained anti-IgD-coated immunomagnetic beads. 
Plates were coated with anti-CD3 antibody to activate T 
cells. 
n, Number of transcripts assayed. 
Somatic mutations did not accumulate in B cells co-cultured 
with resting T cells 
To determine if activation of CD4+ T cells is required for the 
induction of somatic mutations in B cells, the accumulation of 
somatic mutations was compared between activated T cell-sup-
ported cultures and resting T cell-supported cultures. Initial experi-
ments showed that resting T cells could not support B cell growth, 
presumably because resting T cells do not express CD40L [33] and 
secrete little, if any, IL-4. To test if addition of IL-4 and CD40L, 
perse, would modulate the accumulation of somatic mutations in 
activated T cell-supported cultures, experiments were performed in 
which somatic mutations were compared in activated T cell-
supported cultures in the presence or absence of additional added 
IL-4 and CD40L. Results from two independent experiments 
showed no difference in the accumulation of somatic mutations 
(not shown). In subsequent experiments, CD40L and IL-4 were 
added to cultures supported by resting T cells. As shown in Fig. 2, 
the accumulation of somatic mutations was significantly higher 
among activated T cell-supported cultures compared with resting 
T cell-supported cultures (76% versus 21%, respectively; P < 0-001). 
This difference was not compensated by the addition of CD40L 
© 1999 Blackwell Science Ltd, Clinical and Experimental Immunology, 116:441-448 
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Table 2. Somatic mutation is not induced across a Transwell membrane 
Upper 
Chamber 
Lower 
B cells Activated T cells 
B cells 
Pre-culture B cells 
Experiment 1 
n 
161 
153 
95 
Percent 
mutated 
161 
131 
150 
Experiment 2 
n 
16 
36 
138 
Percent 
mutated 
18-8 
13 9 
19 5 
Cultures contained RPMI1640, 10% fetal bovine serum (FBS), 100U/ 
ml IL-4, 1 ,ig/ml CD40L, anti-IgM, 5xl0 3B cells, and if present, 5 x 105 
irradiated (30 Gy) CD4+ T cells. Cultures also contained anti-IgD-coated 
immunomagnetic beads. T cells were activated by coating plates with anti-
CD3 antibody. 
n, Number of transcripts assayed. 
plus IL-4 (not shown). Somatic mutations were not significantly 
elevated in cultures supported by resting T cells compared with 
pre-culture B cells (P = 0-23). 
Induction of somatic mutation probably requires cell-cell 
contact 
It has been suggested that cross-linking of B cell antigen receptor 
. and T cell-derived signals as well as soluble factors from T cells 
are important for progression of somatic mutation [14], To deter-
mine if cell-cell contact between B and T cells was necessary for 
the induction of somatic mutations in human B cells, we utilized a 
culture system in which B cells were separated from activated T 
cells by a Transwell membrane. IgD+ B cells (5 x 103) were plated 
in the upper chamber and the activated CD4+ T cells (5 x 10s) were 
plated in the bottom chamber. CD40L and IL-4 were added to the 
i medium to promote B cell proliferation. Results from two inde-
pendent experiments demonstrated that if the B and T cells were 
separated by a Transwell membrane, the level of mutation in the B 
cells was low and similar to that from B cells cultured in the 
absence of activated T cells (Table 2). 
Table 3. Soluble products from cellular interaction between B and T cells 
are not sufficient for induction of somatic mutations 
Conditions 
Upper chamber Lower chamber 
B cells Activated T cells 
B cells 
B cells B cells, activated T cells 
B cells, activated T cells 
Upper 
chamber 
Percent 
n mutated 
556 8-5 
1700 10-9 
1195 9 1 
Lower 
chamber 
Percent 
n mutated 
1777 52-3 
2325 53-9 
An additional experiment was performed to determine if 
soluble products generated as a result of B cell-T cell contact 
might be responsible for the induction of somatic mutations. To 
address this question, B cells were plated in both chambers of the 
Transwell plate, while activated T cells were plated only in the 
lower chamber. The results, shown in Table 3, demonstrated that B 
cells that had direct contact with activated T cells in the lower 
chamber acquired somatic mutations, but that B cells in the upper 
chamber did not. Thus, physical contact between activated T and B 
cells appears to be necessary. If soluble factors are important for 
the induction of somatic mutation, they function only in the context 
of cell-cell contact. 
Somatic mutations accumulate in both IgM and IgG transcripts 
To address the possibility that the mutator mechanism is more 
active during IgG production than during IgM production, IgM and 
IgG transcripts were assayed independently following in vitro 
culture. Results from the analysis of > 660 IgG and > 2400 IgM 
transcripts from two independent experiments (each performed in 
duplicate) are presented in Fig. 4. The proportion of transcripts 
with detectable mutation in the 14 day cultures was largely 
independent of isotype, but was clearly dependent on culture 
conditions (Fig. 4). Thus, in the CD40L-supported cultures, the 
proportion of transcripts with detectable mutation was not above 
background in either IgM or IgG transcripts. In the activated T cell-
supported cultures, however, the proportion of transcripts with 
detectable mutation ranged from 351% to 48-7% among IgMs and 
from 514% to 53-1% among IgGs. These results indicate that 
neither selective mutation of IgG nor selective expansion of 
mutated IgG-expressing cells can explain the accumulation of 
somatic mutations in these B cells. 
60 r 
50 
S 40 
30 
JP 20 
10 
Cultures contained RPMI 1640, 10% fetal bovine serum (FBS), 100 U/ 
ml IL-4, 1 (jg/ml CD40L, anti-IgM, 5 x 103 B cells, and if present, 5 x 105 
irradiated (30 Gy) CD4+ T cells. B cells were sorted with anti-IgD antibody 
and the antibodies were left undetached. The percentage of mutations in 
pre-culture B cells was 16-7%. T cells were activated by coating plates with 
anti-CD3 antibody. 
n, Number of transcripts assayed. 
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Fig. 4. Somatic mutations in IgM and IgG transcripts. Results from two 
independent experiments are presented. IgM and IgG transcripts were 
separately amplified from the same total RNA samples in independent 
reverse transcriptase-polymerase chain reaction (RT-PCR) reactions. 
Analysis was performed on > 3000 V3-23 transcripts (1201 IgM transcripts 
from pre-culture B cells, 674 IgM transcripts and 89 IgG transcripts from 
activated T cell-supported cultures, 568 IgM transcripts, and 577 IgG 
transcripts from CD40L-supported cultures). As expected, no IgG tran-
scripts were recovered from pre-culture IgD+ B cells. D, Experiment 1; • , 
experiment 2. 
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DISCUSSION 
In this study we describe the accumulation of somatic mutations in 
cultures of freshly isolated human naive B cells. In all, > 10 000 VH 
transcripts were assayed for mutation by differential hybridization 
with motif-specific oligonucleotide probes. Among B cells 
obtained from cultures containing activated autologous CD4+ T 
cells, 43-100% of the analysed transcripts had acquired somatic 
mutations by the end of the 14-day culture, suggesting that the 
mutator mechanism had been turned on in these B cells. In contrast, 
B cells cultured in the presence of purified CD40L, but without 
activated T cells, proliferated vigorously and isotype-switched but 
showed only a background level of mutation. These data further 
support the notion that a combination of CD40 and IL-4 signalling 
is able to induce clonal expansion and isotype switching in naive B 
cells but is unable to induce somatic mutation [34-36]. 
Our laboratory has exploited a method of detection of individual 
VH genes by hybridization with oligonucleotide probes targeted 
to unique motifs contained in CDRs and FRs of VH genes 
[20,21,30,37-42]. The stringency of the analysis is such that a 
single substitution at any position of the probe target results in 
virtually complete loss of signal. We have used this approach to 
study the accumulation of somatic mutations in rearrangements of 
VH3 genes among peripheral blood B cells [29,32]. By comparison 
of hybridization profiles of multiple, non-overlapping gene-
specific oligonucleotide probes, the presence of somatic mutations 
within probe-targeted regions can be revealed by the loss of 
concordance (relative to the hybridization profile on germ-line 
clones) of one or more probes. In our analysis, each instance of 
discordant hybridization was scored as a mutation. The results are 
expressed as the percentage of transcripts that exhibited discordant 
hybridization. 
The reliability of this assay has been confirmed in numerous 
experiments comparing results from DNA sequence analysis and 
motif-specific hybridization [32]. No discrepancies between the 
sequence analysis and hybridization analysis were found among 
> 120 clones analysed. In all instances of hybridization, the target 
sequence was identical to the probe sequence. In each instance of 
discordan hybridization or non-hybridization, however, clones had 
one or more nucleotide substitutions in the discordant probe-
targeted region. No erroneous false-positive hybridization patterns 
were identified. We have previously demonstrated the exquisite 
specificity of motif-specific hybridization and sensitivity to 
single nucleotide substitutions within the targeted sequences, by 
modified Southern analysis on restriction-digested genomic DNA 
[30,37-42]. 
In this study we have used both differential hybridization and 
DNA sequence analysis to estimate somatic mutations. To date, 
CD19+ IgD+ B cells have been used. This population, which is 
>95% pure, is primarily comprised of naive, unmutated B cells 
[43]. Analysis of somatic mutation performed on this population 
prior to culture is taken as system background. System background 
includes artefacts from all sources as well as a potential contri-
bution from any pre-existing mutated B cells in the population. 
Contaminating IgD~ cells (which are not necessarily B cells) 
comprise <5% of the population and cannot account for the 
background. In the CD40/IL-4 cultures the frequency of mutated 
rearrangements does not increase over this background, and often 
shows a slight decrease. The background level of mutations as 
detected by differential hybridization in this study was about 
15%, which is similar to that found in our previous studies 
[29,44,45]. Because 42 bp/transcript are actually assayed, a 15% 
background calculates to approximately three mutations per 
1000 bp, or one mutation per complete VDJ transcript. This is 
a little high compared with two mutations per lOOObp esti-
mated by Pascual etal. [43], but is not excessive considering 
that this frequency includes all sources of background, includ-
ing Taq polymerase error, PCR-mediated cross-overs (which are 
common among PCR products of VH genes) and hybridization 
scoring errors, in addition to bonafide somatic mutations pre-
existing in the population. 
A population of IgD+IgM" B cells that are highly mutated has 
been identified in human tonsillar lymph node germinal centres 
[46]. This population was not found in the peripheral blood. 
However, it cannot be excluded that the system background that 
we observe is, in part, due to the presence of a population of 
somatically mutated IgD+ B cells present in peripheral blood. 
Results from the Transwell experiments showed that physical 
contact of B cells with activated T cells appeared to be necessary 
for the increase in mutations to occur, indicating that a signal for V 
gene somatic mutation is delivered to B lymphocytes by mole-
cule(s) associated with activated T cells distinct from CD40 
signalling. Engagement of CD40 by CD40L can not substitute 
for the T cell contact in this pathway. Further, our data (Table 3) 
suggest that soluble products generated as a result of the interaction 
between B and T cells are not enough to trigger the mutational 
process. 
Results from DNA sequence analysis showed that R/S in CDRs 
and FRs from the B cells co-cultured with activated T cells were 
6-5 and 1-2, respectively, and from B cells co-cultured with 
CD40L, 6 0 and 1-8, respectively. Based on several analyses 
[47,48], these findings might be interpreted as suggesting that 
antigen-driven processes are involved in both culture conditions. 
However, individual substitutions mostly occurred within Ser 
codons AGT or AGC, which are more common in CDRs than in 
FRs. Substitutions in these codons have been considered as a result 
of intrinsic action of hypermutation mechanism in the absence of 
antigenic selection [49,50]. Furthermore, the pattern of substitution 
among non-productive rearrangements, which cannot have been 
antigen-driven, has been found to be similar [51]. 
It has been suggested that IgG rearrangements are a better 
substrate for the mutator mechanism than are IgM rearrangements 
[52,53]. This suggests the hypothesis that an increased rate of 
isotype switching is responsible for the high level of accumulation 
of somatic mutation among B cells cultured in the presence of 
activated T cells, compared with the low-level accumulation 
among B cells cultured in the presence of CD40L. The prediction 
would be that IgG transcripts would have more mutation than IgM 
transcripts regardless of culture conditions, but the fraction of 
transcripts that were IgG would be significantly higher in activated 
T cell-supported cultures. The results are incompatible with this 
prediction, because no increase over background, or over IgM 
transcripts, was detected among IgG transcripts from CD40L-
supported cultures. Initial populations were highly purified IgD+ 
cells (>95% purity), and, as expected, there was essentially no IgG 
mRNA obtained from these cells. Therefore, the background level 
of mutation is a reflection primarily of IgM-expressing B cells, 
along with artefacts from all sources. Thus, neither selective muta-
tion of IgG, nor selective expansion of mutated IgG-expressing cells, 
can explain the accumulation of somatic mutations in these B cells. 
Therefore the only tenable hypotheses remaining are that either (i) T 
cells regulate the differential outgrowth of mutated (or mutating) 
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B cells compared with unmutated B cells, or (ii) T cells induce 
activation of the mutator mechanism in B cells that grow in these 
cultures. 
Differential outgrowth might account for the observed accu-
mulation of somatic mutations in vitro. For this to be true, we have 
to postulate that a small population of B cells, which previously 
acquired mutations in vivo, or is constitutive for the mutational 
mechanism, is selectively permitted to proliferate in the T cell-
supported cultures, but has no growth advantage in the CD40/IL-4 
cultures. Calculations based on our current results suggest that this 
is an unlikely explanation for the accumulation of mutations in 
culture. In most experiments, 1000 B cells were plated. The plating 
efficiency ranged from 10% to 30% ([54] and G. V. Pinchuk and 
E. C. B. Milner, unpublished data), therefore 100-300 B cell clones 
would grow out. As many as 50% of B cells express a VH3 heavy 
chain, therefore there would be 50-150 VH3-expressing clones. 
From 20% to 40% of VH3 are derived from the V3-23 gene, 
therefore 10-60 V3-23 clones should grow out. If, as seems likely 
based on the known purity of the starting B cell population, mutations 
were confined to a minor subset (e.g. 1%) of B cells, then from 0 1 
to 0-6 (i.e. not more than one) mutated V3-23 clone should be 
found to account for the entire set of mutated rearrangements. 
The results are inconsistent with this prediction. When nucleo-
tide sequences were determined for V3-23 transcripts, 9/12 indepen-
dent clones carried mutations, substantially exceeding the number 
predicted by the differential outgrowth hypothesis (Fig. 3). The 
only scenario under which this number of mutated clones does not 
substantially exceed the number predicted by the differential 
outgrowth hypothesis would be if the entire 15% background were 
due to pre-existing somatic mutation. In view of the fact that a 
background of approx. 15% mutation is obtained in a variety of 
control experiments, this explanation is very unlikely. 
In view of these results and the demonstration that somatic 
mutation can be induced in tonsillar B cells by activated T cells 
[16], it is very likely that the first hypothesis is incorrect and that 
the second hypothesis is correct, i.e. T cells induce activation of the 
mutator mechanism in B cells that grow in these cultures. 
The burning question that remains, of course, is what is the 
signal(s) that results in activation of the mutator mechanism by B 
cells? At this juncture the answer remains unknown, although the 
prospects of solving one of the remaining great immunologic 
mysteries are bright. Signalling through CD40/CD40L is required 
but not sufficient. CD28 signalling is required for the formation of 
germinal centres [55] and is therefore at least indirectly required 
for somatic mutation. Whether a heretofore unknown receptor-
counter receptor is required is a possibility but not a certainty. 
Perhaps the answer will lie among familiar players acting in a 
novel context. 
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Hematopoietic stem cell transplantation 
is characterized by a prolonged period of 
humoral immunodeficiency. We have pre-
viously shown that the deficiencies are 
probably not due to the failure to utilize 
the appropriate V regions in the pre-
Immune repertoire. However, a striking 
observation, which correlated with the 
absence of immunoglobulin IgD - cells 
and was consistent with a defect in 
Introduction 
antigen-driven responses, was that rear-
rangements in bone marrow transplant 
(BMT) recipients exhibited much less 
somatic mutation than did rearrange-
ments obtained from healthy subjects. In 
this paper, we present evidence suggest-
ing that naive B cells obtained from BMT 
recipients lack the capacity to accumu-
late somatic mutations in a T-cell-
dependent manner compared with healthy 
subjects. This appears to be a B-cell-
autonomous deficit because T cells from 
some patients, which were not able to 
support the accumulation of mutations in 
autologous naive B cells, were able to 
support accumulation of mutations in 
heterologous healthy-subject naive B 
cells. (Blood. 2000;96:1064-1069) 
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Hematopoietic stem cell transplantation is a recognized treatment 
for certain leukemias, other blood diseases, and some inborn errors 
of metabolism and has potential as a vehicle for gene therapy. 
However, hematopoietic stem cell transplant, using either bone 
marrow or mobilized peripheral stem cells, is characterized by a 
prolonged period of immunodeficiency affecting both B-cell and 
T-cell compartments (reviewed in Storek et al1)- B-cell counts are 
low but usually approach normalcy by 1 year after transplantation.1 
Coincident with recovering B cells, serum immunoglobulin IgM, 
IgGl and IgG3 levels but not IgG2 and IgA levels return to normal 
by 1 year posttransplantation.2"5 Thus, marrow recipients who 
survive the initial postgrafting period do not always become fully 
immunocompetent. Many recipients are deficient in generating 
specific antibody responses to exogenous stimuli. The complete 
reconstitution of B-cell immunity in recipients can take years. 
The nature of the B-cell defect(s) leading to this specific 
humoral immunodeficiency is uncertain. Normal levels of serum 
IgM, IgGl, and IgG35 indicate that immunodeficiency is not due to 
a general failure to produce immunoglobulin or an overt lack of 
T-cell help (although impaired T-cell function may be an important 
factor). Evidence indicates that the processes involved in generat-
ing and selecting the primary antibody repertoire are largely 
functional within the first year following bone marrow transplant 
(BMT) and that the immunodeficiencies common among BMT 
recipients are probably not due to the failure to utilize appropriate 
V region genes in generating the pre-immune antibody reper-
toire.6'7 The complexity of the CDR3 (third complementarity 
determining region) and DH and JH utilization is similar in BMT 
recipients and healthy subjects 1 year posttransplantation, further 
supporting the conclusion that the primary antibody repertoire is 
generated normally following BMT.8'31 However, a striking obser-
vation was that rearrangements in BMT recipients exhibited much 
less somatic mutation than did rearrangements obtained from 
healthy subjects.6"8 The failure in the BMT recipients to accumulate 
somatic mutations in rearranged VH genes is consistent with a 
maturational arrest at a fairly late stage of differentiation. This 
deficit could be a consequence of either an intrinsic B-cell deficit or 
a lack of adequate T-cell help. In this paper, we present evidence 
suggesting that, in contrast to healthy-subject B cells, B cells 
obtained from transplantation patients 1 year posttransplantation 
lack the capacity to accumulate somatic mutations in a T-cell-
dependent manner. This appears to be a B-cell-autonomous deficit, 
because T cells from some patients were able to support accumula-
tion of mutations in heterologous healthy-subject B cells but not in 
autologous B cells. 
Patients, materials, and methods 
Patients and donors 
Blood samples were obtained under Institutional Review Board-approved 
protocols, and written consent was always obtained. Blood mononuclear 
cells were separated by density-gradient centrifugation, with the use of 
Ficoll-Hypaque (1.077 kg/L) (Amersham Pharmacia Biotech, Piscataway, 
NJ). We studied 9 recipients of allogeneic hematopoietic cell transplants at 
approximately 1 year after grafting (median, 378 days; range, 354-432 
days) in combination with 6 healthy subjects. The median age at transplan-
tation was 42 years (range, 29-52 years). No patient had a history of 
splenectomy. All patients were transplanted for hematological malignan-
cies. They were usually conditioned with cyclophosphamide (120 mg/kg) 
and fractionated total body irradiation (12.0 to 13.2 Gy). The hematopoietic 
cell donors for BMT1, 2, 3, 7, 8, and 9 were siblings matched for HLA-A, 
HLA-B, and HLA-DR, and the donors for patients BMT4, 5, and 6 were 
unrelated volunteers matched for HLA-A, HLA-B, and HLA-DR. Seven 
patients (BMT1, 4, 5, 6, 7, 8, 9) received unmodified marrow; 1 patient 
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(BMT3) received unmodified filgrastim-mobilized blood progenitor cells; 
and 1 patient (BMT2) received filgrastim-mobilized blood progenitor cells 
positively enriched for CD34+ cells. Graft-versus-host disease (GVHD) 
prophylaxis typically consisted of methotrexate (day 1, 3, 6, and 11) and 
cyclosporine (day — 1 through 180).9 Grade 2 to 3 acute GVHD occurred in 
7 patients (BMT2, 3, 5, 6, 7, 8, and 9); it was usually treated with oral 
prednisone (1 to 2 mg/kg/d). Prior to the 1-year posttransplantation 
evaluation, clinical limited chronic GVHD developed in 4 patients (BMT2, 
5, 6, and 8) and clinical extensive chronic GVHD in 3 patients (BMT1, 3, 
and 9). 
At the time of the 1-year posttransplantation evaluation, the patients 
were thoroughly tested for potential relapse of the hematological malig-
nancy and for chronic GVHD status. Eight patients were in complete 
remission; 1 patient (BMT2) was in early relapse (patient with IgG-lambda 
multiple myeloma who had 12% plasma cells in marrow and 16.0 g/L 
monoclonal IgG-lambda in serum at 1 year posttransplantation). All 9 
patients were complete chimeras defined by more than 99% donor cells in 
marrow and/or blood, with the use of Y-chromosome in situ hybridization 
or variable nucleotide tandem repeats.'011 Two patients had clinical 
extensive chronic GVHD (BMT3 and 9), and the remaining 7 patients had 
no clinical GVHD at the 1-year posttransplantation blood draw. One patient 
(BMT1) was on oral prednisone (50 mg/d), and the remaining 8 patients 
were on no systemic immunosuppressive drugs. Patients had received no 
biological response modifiers such as interferon and no intravenous 
immunoglobulin (IVIG) within 2 months prior to the 1-year posttransplan-
tation evaluation, except for 1 patient (BMT2) who received IVIG 
approximately 6 weeks prior to the 1-year posttransplantation evaluation. 
Each patient sample was tested in parallel with a volunteer control (age 
20 to 50) recruited from employees of the Virginia Mason Research Center 
or the Fred Hutchinson Cancer Research Center. 
Flow cytometry and sorting 
The enumeration of B cells and CD4 T cells was done with the use of 
3-color flow cytometry as described.1213 For sorting, blood mononuclear 
cells were stained with fluorescein isothiocyanate (FITC)-conjugated 
goat-antihuman IgD antibody (F(ab')2> (Caltag, Burlingame, CA) and 
phycoerythrin (PE)-conjugated mouse-antihuman CD4 antibody (Becton 
Dickinson, Franklin Lakes, NJ, or Coulter-Immunotech, Fullerton, CA) and 
sorted on a FACS Vantage (Becton Dickinson). Forward- versus side-scatter 
gate was set to encompass primarily lymphoid cells and only a small 
fraction of monocytoid cells. CD4 T cells were defined as CD4hl^h cells; 
IgD+ B cells were defined as IgDhLgh cells. Sorted fractions were more than 
91% pure. 
For the major histocompatibility complex (MHC) control experiments, 
B cells were isolated from peripheral blood lymphocytes (PBL) by 
anti-CD 19-coated immunomagnetic beads (DynaBeads, Dynal, Lake Suc-
cess, NY) according to the manufacturer's protocol. Naive human B-cells 
(CD19+/IgD+) were further purified from the CD19+ B cells by anti-IgD 
(FITC-conjugated) sorting on a FACS Vantage. The resulting population 
was more than 95% CD19+IgD+IgM+. Autologous CD4+ T cells were 
isolated with the use of anti-CD4-coated immunomagnetic beads (Dynal) 
according to the manufacturer's protocol. The purity of CD4 T cells as 
determined by FACS analysis was greater than 99% following isolation. 
Cell culture 
In vitro cultures for analysis of somatic mutation were performed as 
described.14 In brief, B cells (103 per well) were cultured in flat-bottomed 
microplates in RPMI 1640 medium supplemented with interleukin (IL)-4 
(100 U/mL) and anti-IgM (1 ug/mL). Other additions, depending on the 
experiment, were CD40L (1 ug/mL), CDW32L cells (L cells) (104 per well), 
resting or activated CD4+ T cells (105 per well). L cells and T cells were 
irradiated before initiation of the cultures (70 and 30 Gy, respectively). To 
activate T cells, wells were precoated with 64.1 antibody, a murine 
monoclonal antihuman CD3. 
Complementary DNA library construction 
Complementary DNA (cDNA) libraries were constructed as described.14-15 
Polymerase chain reactions (PCRs) used for constructing the libraries were 
performed with the use of the family-specific 5' primers, E310 (VH3-L), 
5'-CTGAATTCCATGGAGTTTGGGCTGAGCTG-3', corresponding to tbe 
5' ends of the leader sequence of Vn3 family, and a 70:15:15 mixture of the 
3' primers E311, 5'-GACTCTAGACT(CT)ACCTGAGGAGACGGT-
GACC-3', complementary to the 3' ends of JHI, 4, 5, and 6 gene sequences; 
E312, 5' -GACTCTAGACT(CT)ACCTGAGGAGACAGTGACC-3', com-
plementary to the 3' end of JH2 gene sequence; and E313, 5'-GAC-
TCTAGACT(CT)ACCTGAAGAGACGGTGACC-3', complementary to 
the 3' end of JH3 gene sequence. Restriction sites (EcoRI for 5' primers; 
Xbal for 3' primers) included in the primers are underlined. For amplifica-
tion of VH3 transcripts Pfu or Taq DNA polymerase (Promega Corp, 
Madison, WI) was used in a 30-cycle program. 
Detection of somatic mutation 
Replicate dot blot filters were made from the libraries and were hybridized 
as described.1415 Occurrence of somatic mutations was estimated by loss of 
concordant hybridization to VH-specific probes and DNA sequence analysis 
as described.714 16 
Semiquantitative PCR 
cDNA was amplified with the use of Taq DNA polymerase (Promega) and 
primers for VH3 expressing IgM (E310 and E213, 5'AATTCTAGATCA-
CAGGAGACGAGGGGGAAAAG- 3') and IgG transcripts (E310 and 
E212, 5'-AATTCTAGAGGGGAAGTAGTCCTTGACCAGGCA-3')- As 
an internal control, B-actin primers were included (E376, 5'-GGTGGG-
CATGGGTCAGAAGGATT-3' and E377, 5'-CCAGAGGCGTACAGG-
Table 1. Lymphocyte subsets by flow cytometry 1 year following transplantation 
Sample 
identification 
BMT1 
BMT2 
BMT3 
BMT4 
BMT5 
BMT6 
BMT7 
BMT8 
BMT9* 
Median 
Normal ranget 
Abs MNC 
(X106/L) 
3070 
550 
2750 
1120 
1940 
810 
1510 
2010 
1725 
%B 
cells 
7 
3 
22 
26 
33 
18 
14 
28 
20 
AbsB 
(XIO/VL) 
215 
17 
605 
291 
640 
146 
211 
563 
253 
94-561 
% lgD+ 
91 
87 
93 
95 
95 
98 
93 
96 
94 
62-95 
%T 
cells 
57 
30 
46 
50 
30 
36 
57 
41 
44 
% CD4 
13 
48 
53 
47 
57 
53 
31 
54 
51 
% OD8 
53 
23 
44 
42 
34 
30 
51 
25 
38 
Abs CD4 
(X106/L) 
227 
79 
670 
263 
332 
155 
267 
445 
265 
400-1313 
Abs CDS 
(x106/L) 
927 
38 
557 
235 
198 
87 
439 
206 
221 
Abs, absolute; MNC, mononuclear cells. 
"No flow data available for BMT9. 
tNormal ranges were defined as 5th to 95th percentiles of at least 91 adult healthy volunteers analyzed at the Fred Hutchinson Cancer Research Center. 
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Figure 1. Flow cytometric analysis and gating of 
blood B cells showing the relative lack of lgD~ B 
cells In a BMT recipient 1 year after grafting. Both 
specimens, normal and patient, were processed concur-
rently. Ficoll-isolated mononuclear cells (MNCs) were 
stained with anti-lgD-FITC (goat F{ab')2 antihuman 
delta chain), anti-(CD4, CD8, CD14, CD16J-PE, and 
anti-(CD19, CD20)-peridinin chlorophyll protein. Data 
were acquired on FACSCAN cytometer. For analysis, 
first the MNC gate {R1, R4) was drawn on the forward-
versus side-scatter dot plots (left). Then, B cells were 
gated on the CD19/CD20 versus CD4/CD8/CD14/ 
CD16 dot plots (R2, R5), excluding non-B cells binding 
anti-CD19/CD20 nonspecifically, "B cell + non-B cell" 
doublets, and CD20'™ T cells (middle). Finally, CDI9/ 
CD20 versus IgD dot plots were created exclusively of 
the cells falling within the MNC gate and the B-cell gate, 
ie, R1 and R2 in the normal and R4 and R5 in the 
patient (nght). To calculate the percentage of IgD B 
cells, regions R3 and R6 were set so as to encompass 
the B cells showing only background FITC fluores-
cence. In this example, 18% of B cells in the normal 
were IgD" versus 4% of B cells in the patient. 
GATAGCAC-3'). The PCR products were size-fractionated on a 1.5% 
agarose gel and stained with ethidium bromide. 
Results 
It was not certain if the previously reported lack of somatically 
mutated B cells in peripheral blood of transplant recipients was a 
result of an actual deficit in the somatic mutational process or if it 
was the product of population dynamics. Our approach to investi-
gating this issue was suggested by the observation that a high 
incidence of mutations was observed in VH transcripts obtained 
from healthy-subject B cells following a 14-day coculture with 
activated CD4+ T cells.14 We hypothesized that if there was an 
actual deficit in the mutational process, then BMT B cells would 
not accumulate mutations in cocultures with activated CD4+ T 
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Figure 2. Incidence of somatically mutated VH transcripts in lymphocyte 
cocultures is dependent primarily on the source of B cells. Accumulation of 
somatic mutation was assessed by sequential hybridization as described.714-16 The 
results are presented as the percentage of VH transcripts that have acquired 1 or 
more mutations in either of two 21-base-pair (bp) target sequences.71415 In the 
Figure, h indicates healthy subject; p, BMT patient, ( - ) , T cells replaced by CD40 
ligand and L cells. Closed circles indicate sources of transcripts selected for 
sequence analysis (see also Figure 4). 
cells. Furthermore, we reasoned that if an intrinsic B-cell deficit 
existed, then neither healthy-subject T cells nor BMT-recipient T 
cells would support the accumulation of somatic mutations in 
BMT-recipient B cells in culture. Alternatively, if the deficit was 
only in the T-cell compartment, then healthy-subject T cells should 
support the accumulation of mutations among BMT-recipient B 
cells. To test these hypotheses, B cells and CD4+ T cells obtained 
from transplant recipients and from healthy subjects were cocul-
tured, and accumulation of somatic mutations was assessed. 
In this study, 9 recipients of allogeneic bone marrow transplants 
were studied. At the time of the 1-year posttransplantation evalua-
tion, the number and percentage of B cells and T cells in peripheral 
blood were determined (Table 1). The median CD4+ T-cell count 
was 265 X 106/L, which was below the normal range. The B-cell 
counts were normal or supranormal, except for 1 patient in whom 
the B-cell count was subnormal; the median count was 253 X 106/ 
L, which fell in the normal range. The percentage of cells 
expressing membrane IgD was determined as described in Figure 
1; it tended to be above normal, although the median fell within the 
normal range (Table 1). 
Autologous combinations of BMT-recipient lymphocytes had 
poor cell growth, and as shown in Figure 2 (Group 1), yielded a low 
incidence of somatic mutation. As expected, autologous combina-
tions of healthy-subject lymphocytes yielded a high incidence of 
mutation (Figure 2, Group 2). These results indicate a deficit 
among BMT-recipient lymphocytes that might be a consequence of 
poor growth or a failure to activate BMT-recipient T cells. 
Heterologous combinations of BMT-recipient B cells and 
healthy-subject T lymphocytes yielded background levels of 
Table 2. HLA-class II typing of healthy donors 
Sample 
ID 
HS1 
HS2 
HS3 
HS4f 
HS5t 
HS6t 
DRB1* 
0101,0404 
0701,0701 
0701,0101 
DQA1* 
0101,0301 
0201, 0201 
0201,0101 
DQB1-
0501,0302 
0201,0201 
0201, 0501 
DPB1* 
0402,0601 
0402,1101 
0201,0402 
*HLA-class II loci. 
fMHC typing unavailable. 
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Figure 3. Incidence of somatically mutated VH transcripts in lymphocyte 
cocultures of healthy subjects with disparate MHC loci. Each data point 
represents the average of duplicate cultures. For each point, an average of 724 VH 
transcripts were analyzed (range 476-885, median 731). Accumulation of somatic 
mutation was assessed as in Figure 2. 
mutation in all but 1 experiment (Group 3). Thus, neither healthy-
subject T cells nor BMT-recipient T cells were consistently able to 
induce the accumulation of somatic mutation in BMT-recipient B 
cells, suggesting that BMT B cells had an intrinsic inability to be 
driven to accumulate somatic mutations. The inability of healthy-
subject T cells to induce mutation in heterologous culture combina-
tions is probably not due to MHC mismatch between BMT-
recipient B cells and healthy-subject T cells; B cells in heterologous 
combinations of lymphocytes from HLA-disparate healthy donors, 
shown in Table 2, accumulate mutations as well as B cells in 
autologous combinations (Figure 3). That resting T cells, even if 
supplemented with CD40L, did not induce somatic mutations in 
these cultures suggests that the accumulation of somatic mutation 
in this system is not driven by an allogeneic reaction. 
In 3 of 6 experiments, T cells from BMT recipients were able to 
support mutation in heal thy-subject B cells, indicating that T 
lymphocytes from some BMT recipients can give adequate T-cell 
help (Figure 2). This finding is consistent with previous reports that 
posttransplantation CD4 T cells appear qualitatively normal.1720 
To estimate the accumulation of somatic mutation more accu-
rately, we analyzed nucleotide sequences among transcripts se-
lected from 2 B-cell cultures (Figure 4). In 1 culture, BMT-
recipient B cells (BMT5) had been cocultured with autologous T 
cells (Table 3, exp 4). In the other culture, healthy-subject B cells 
(HS4) had been cultured with BMT-recipient T cells (BMT5) 
(Table 3, exp 4). These cultures are also indicated by filled circles 
in Figure 2. The sequences from the first set have an average of 
0.2% mutation (median 0.17%). In contrast, the sequences from the 
second set have on average 3.1% mutation (median 1.7%), mote 
than 10-fold higher. The different percentages of mutated VH 
transcripts seen in Figure 2 reflect both quantitative differences in 
the number of mutations among the VH transcripts and differences 
in the incidence of transcripts with any mutation. The correlation 
between mutation detected by hybridization and that detected by 
nucleotide sequence analysis has been reported.1415 
To determine if the lack of somatic mutation in BMT recipients 
correlated with the inability to differentiate in culture, IgG messen-
ger RNA (mRNA) production (an indicator of differentiation21) 
was estimated with the use of a semiquantitative PCR (Figure 5). 
Except for lane 1 in Figure 5A and 5B, in which poor cell growth 
was observed, an IgG PCR product was obtained from all healthy 
subjects as well as all BMT recipients, suggesting that in these 
cultures isotype switching has occurred. As expected, no IgG PCR 
product was obtained from preculture IgD+ cells (data not shown). 
In addition, secreted IgG was detected by enzyme-linked immuno-
sorbent assay in culture supernatants from T-cell-supported cul-
tures irrespective of somatic mutation (data not shown). 
Discussion 
We have previously shown that BMT recipients fail to acquire 
somatic mutations in rearranged VH genes in PBL68 and have low 
memory B-cell counts.22 In the current study, we wished to 
determine the intrinsic capacity of transplant recipient naive B cells 
to acquire mutations. Several models have been described that 
mimic germinal center reactions in which somatic mutation takes 
place. l4-2-V26 We used an in vitro system in which activated CD4+ T 
cells drive B-cell differentiation over a 14-day culture period. In 
this system, healthy-subject B cells accumulate large numbers of 
V-segment mutations, presumably as a consequence of activation 
of the somatic mutator mechanism.14 In contrast, we found that B 
cells obtained from BMT recipients 1 year posttransplantation 
failed to accumulate mutations. This deficit could not be overcome 
by coculture with healthy-subject T cells, although T cells from 
certain patients were able to drive the accumulation of mutations in 
healthy-subject B cells. 
Figure 4. DNA sequence analysis of V3-23 tran-
scripts from T-cell-activated B-cell cultures. B-cell 
cultures from BMT-recipient B cells supported by autolo-
gous activated T cells (sequences 1 -1 -1 -5) and healthy-
subject B cells supported by BMT-recipient T cells 
(sequences 4-1-4-7). Repeated isolation of the same 
cDNA clone is indicated by parentheses. Sequences 
1-1-1-5 are taken from BMT5; sequences 4-1-4-7 are 
taken from HS4 (indicated by the filled circles in 
Figure 2). 
3 G*GCTGC'aa^mG6MrrUTGGGiaaiGGCTTO^AC^^ T a « T a ^ [ J C G C T C C B G a j A * a g K ™ j l l ^ ^ ^ 
IBS 
iTCCTT3^AlX*CTTaCT*CgWaCTIXXreW»yraXO^C«CATCTCCW^^ 
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Table 3. Incidence of somatically mutated VH transcripts in lymphocyte cocultures is dependent primarily on the B-cell donor 
Experiment 
Source of 
B cells 
Source of 
T cells 
Number of transcripts Mutated 
transcripts* (%) 
Nucleotide 
substitutes! (%) 
Exp1 
Exp 2 
Exp 3 
Exp 4 
Exp 5 
Exp 6 
Exp 7 
BMT1 
BMT1 
HS1 
HS1 
BMT2 
BMT3 
BMT3 
BMT4 
HS3 
HS3 
BMT3 
BMT4 
HS3 
BMT6 
BMT5 
BMT6 
BMT5 
HS4 
HS4 
BMT6 
BMT5 
HS4 
BMT7 
BMT7 
HS5 
HS5 
BMT7 
HS5 
BMT8 
BMT8 
HS6 
HS6 
BMT8 
HS6 
BMT9 
BMT9 
HS4 
HS4 
BMT9 
HS4 
BMT1 
HS1 
BMT1 
HS1 
HS1 
BMT3 
HS3 
HS3 
BMT3 
HS3 
— 
— 
— 
BMT6 
BMT5 
HS4 
HS4 
BMT5 
HS4 
— 
— 
— 
BMT7 
HS5 
BMT7 
HS5 
— 
— 
BMT8 
HS6 
BMT8 
HS6 
— 
— 
BMT9 
HS4 
BMT9 
HS4 
— 
— 
nd3 
nd 
nd 
nd 
344 
nd 
374 
>354 
712 
>375 
726 
482 
381 
461 
922 
412 
>742 
620 
491 
570 
789 
86 
647 
751 
601 
754 
745 
820 
353 
664 
681 
736 
784 
683 
345 
331 
288 
>1320 
684 
697 
161 
100 
138 
155 
151 
53 
99 
54 
37 
11 
206 
59 
20 
74 
254 
109 
98 
273 
74 
155 
163 
12 
152 
212 
171 
137 
139 
168 
90 
87 
90 
164 
130 
153 
58 
70 
142 
194 
98 
176 
12 
13 
57 
13 
10 
12 
0 
7 
28 
21 
19 
33 
23 
20 
82 
7 
33 
Nd indicates not determined; BMT, bone marrow transplant; HS, healthy subject. Dash indicates that no T cells were added but that B-cell cultures were supported by 
L cells supplemented with CD40L {1 ug/mL). 
•Percentage of V3-23 transcripts with mutation detectable by hybridization. 
-(•Incidence (%) of nucleotide substitution per base pair (bp) based on 290 bp/transcript of sequence shown in Figure 4. 
Among the patients studied here, the only striking difference 
was in the capacity of patient T cells to support mutation in 
healthy-subject B cells. All 3 of these patients (BMT3, 5, 8) had 
normal levels of CD4+ T cells and supranormal levels of B cells, 
suggesting that recovery of the immune system was more robust in 
these patients. 
Unmutated, naive B cells have the phenotype CD19+ IgM+ 
IgD+. This phenotype is exhibited among healthy subjects by 
approximately 80% of B cells, and among BMT recipients by more 
than 95% of B cells.12 Thus, by both cell-surface phenotype and the 
extent of somatic mutation, the B-cell repertoire post-BMT re-
sembles the pre-immune component of the B-cell repertoire of a 
healthy adult. Simply because of population dynamics, it would 
seem logical that the B-cell repertoire post-BMT would be 
primarily naive. However, our finding that these B cells cannot be 
driven to acquire somatic mutations suggests that additional 
processes are at work. The failure of the cells to accumulate 
1 2 3 4 5 6 7 8 9 
M G M G M G M G M G M G M G M G M G 
Figure 5. Presence of IgM and IgG mRNA in 14-day B-cell cultures of BMT 
recipients and healthy subjects. cDNA from B-cell cultures from 9 recipients and 7 
healthy subjects was amplified with the use of 5' primers specific for VH3 and 3' primers 
specific for either IgM or IgG. Resurts are representative of analysis of triplicate cultures. As 
an internal control, p-actin mRNA was used. Lanes M were amplified with the use of Cu 
primers, lanes G with the use of C7 primers. (A) BMT recipients. (B) Healthy subjects. 
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somatic mutations did not seem to parallel a failure to switch class. 
Taken together, the data are most easily explained by postulating 
that there is a deficit in the capacity of BMT-recipient B cells to 
respond to signals to activate the somatic mutator mechanism. 
Because the marrow donors are themselves healthy subjects 
whose B cells are capable of acquiring mutations, this posttransplan-
tation deficit must be developmentally determined. All patients 
received cyclosporine for the first 180 days after transplantation, 
and this immunosuppressive treatment might be expected to delay 
recovery of immunocompetency. However, ongoing immunosup-
pressive therapy cannot explain the results because cyclosporine 
was terminated at least 180 days prior to our studies for all but 1 
patient (BMT1), who was receiving immunosuppressive therapy at 
the time of this study. 
Another possibility is that during the pretransplantation condi-
tioning regimen, a critical cellular function is disrupted and is not 
restored by marrow transplant. One such function, for example, 
could be the delivery of survival signals. In normal B-cell 
differentiation, newly formed transitional B cells are recruited into 
a long-lived pre-immune B-cell pool, in a process thought to be 
dependent on survival signals delivered in secondary lymphoid 
organs.27-28 Because the pretransplantation conditioning regimen 
may disrupt lymphoid tissue architecture (particularly follicular 
dendritic cells),29 the survival signals may be missing in the 
transplant recipients. As a result, BMT recipients may fail to select 
a long-lived naive B-cell compartment. The implication of this is 
that the B-cell compartment in BMT recipients is composed 
primarily of transitional B cells, which are short lived and have 
newly emerged from the bone marrow.30 We postulate that this 
transitional B-cell population can participate in primary immune 
responses and can be driven to differentiate into plasma cells, but 
does not participate in a germinal center reaction and does not 
acquire mutations. 
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During the decade prior to the mapping of the VH locus and identification of 
essentially all of the of VH genes, multiple reports showed biased utilization of 
specific VH genes in particular situations, ranging from biases in the fetal repertoire to 
association of particular VH genes with autoantibodies and predominant utilization of 
individual genes in specific antibody responses. We now know that some of these 
apparent biases were a reflection of the fact that the VH repertoire was more limited 
than previously thought. Although one could imagine that in some disease situations 
the pattern of VH utilization might change, this has not always been the case. In the 
study described in this thesis, bone marrow transplant (BMT) recipients were studied 
because the recipients regenerate their immune system from the grafted 
haematopoietic stem cells, and exhibit immunodeficiencies following marrow 
transplantation. The exact nature of the B cell defects contributing to the humoral 
immunodeficiency is unknown. 
VHgene usage after BMT 
One of the possibilities that we have explored is that an abnormal restriction of the 
potential antibody repertoire in B cells from BMT recipients contributes to the 
humoral deficiency. It has been suggested that the reconstitution of the humoral 
immune system follows ontogenic development [1-6]. The usage of VH families 
following BMT appears to mimic usage during B cell ontogeny [7;8], and was 
thought to be restricted to fetal type VH genes early post transplant [6-9].Thus, to 
account for the observed immunodeficiencies, it was to be expected that during the 
first year post transplant, BMT patients would utilize a more limited set of V genes 
than would healthy adult subjects. This hypothesis was supported by the fact that 
early post transplant B cell lymphopoiesis is mono- or oligoclonal [10-13], and thus 
might have a limited diversity. However, analysis of rearrangements in peripheral 
blood B cells of healthy subjects [14-16] and BMT recipients at 90 days and 1 yr 
following transplant indicated that the pattern of usage of VH genes was similar 
between BMT recipients and healthy subjects [Chapter 5; 17-19]. Thus the processes 
involved in generating the antibody repertoire are largely functional within the first 
few months following transplant. Furthermore, these results indicated that the 
immunodeficiencies common among BMT recipients probably are not due to the 
failure to utilize appropriate V region genes in generating the pre-immune antibody 
repertoire. The complexity of the CDR3 (third complementarity region) and DH and 
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JH utilization is similar in BMT recipients and healthy subjects 90 days and one year 
after transplant [Chapter 3; 19] and [10], and thus further support the conclusion that 
the primary antibody repertoire is generated normally following BMT by 90 days 
[Chapter 3; 17;18]. 
B cell development after BMT vs ontogenic development 
As mentioned above, it has been suggested that the immune reconstitution after BMT 
resembles the developing repertoire. This is based on similarities between long-term 
survivors without graft versus host disease (GVHD) and normal infants. For example, 
compared to adult B cells, B cells from both neonates and BMT recipients are larger 
in size [3;20]. In both infants and BMT recipients B cell numbers are low at first, but 
then tend to overshoot normal adult values and return to normal [5;6;21-25]. After 
BMT as well as in neonates the B cells have an immature phenotype, IgD lg ,IgM lg 
and CD38high [3;22;24;26;27]. In fetal and cord blood and BMT recipients the 
accumulation of somatic mutation in rearranged VH gene segments is low or absent 
[Chapter 3; 17-19;28-31] (and AM Glas and E.C.B. Milner unpublished results). In 
BMT recipients and infants the sequence of achieving normal adult levels of serum 
isotypes is similar, first IgM, IgGi and IgG3, then IgG2, IgG4 and IgA [6]. In vitro 
function of BMT recipients' B cells and B cells from neonates is abnormal in the 
production of IgG and IgA when compared to adult B cells [5;32-36]. Both neonates 
and BMT recipients are susceptible to encapsulated bacteria [37]. There are a few 
differences after BMT and normal B cell ontogeny such as most cord blood cells are 
L-selectin negative, while a high proportion of BMT recipient B cells are L-selectin 
positive. In fetal spleen, liver and bone marrow and in neonates CD5 B cells are 
abundant [38-41], however the percentage of CD5 B cells after BMT is inconsistent. 
Some studies report high percentages of CD5 B cells [5;22], while in other reports the 
number is low or similar to adult levels of CD5 B cells [38;42;43]. Some 
discrepancies were also found in the expression of CD21, CD23, and CD38 [3-
5;22;42]. These differences may be due to the differences in the flow cytometry 
techniques [3]. 
The restriction to fetal type VH genes early post transplant suggested that the VH 
repertoire parallels ontogenic development as well. The current understanding that the 
spectrum of VH gene segments used in the fetal repertoire resembles the adult 
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repertoire contradicts the old notion that the fetal repertoire was comprised of a 
special subset of the repertoire available to adults. The repertoire is more limited than 
once thought, and a few genes dominate both the fetal repertoire and adult repertoire 
(reviewed in [44]). Hence, the repertoire following BMT is similar to that seen in 
adults [Chapter 3; 17;18]. 
B cell development after BMT follows many patterns that are similar to ontogenic 
development; however immune reconstitution does not appear to recapitulate human 
fetal ontogeny based on the diversity of rearranged heavy chains. The molecular 
characteristics that typify fetal repertoires, such as the use of DHQ52 and the paucity 
of N nucleotides [28;45-52], are more reliable markers for the distinction between 
fetal and adult repertoires [53]. In our studies [Chapter 3; 19] and others [10;11;54], 
the CDR3s exhibit none of these fetal characteristics, but rather resemble CDR3s from 
healthy adults. 
Somatic mutation deficit 
The hypothesis that an abnormal restriction of the antibody repertoire contributed to 
the observed immunodeficiencies proved to be wrong. However, the results described 
in Chapter 3 provide some indication of possible mechanisms contributing to poor 
antibody responses in BMT recipients. Rearrangements in BMT recipients exhibited 
much less somatic mutation than did rearrangements from healthy subjects [Chapter 
3; 17-19]. The failure in the BMT recipients to accumulate somatic mutations in 
rearranged VH genes in PBL correlated with a restricted diversity in expressed IgG 
CDR3s [10], and an absence of IgD" B cells [55] and suggest that the prolonged 
deficiency of humoral immunity after transplant may be due in part to the slow 
reconstitution of memory B cells. 
The accumulation of somatic mutations is a characteristic of T cell dependent antigen 
driven responses [56]; the absence of mutation is consistent with a defect in T cell 
dependent antigen driven responses. The successful recovery of secondary B cell 
responses after transplant will therefore depend in part on the recovery of the T cell 
compartment. The B cell phenotype following BMT is consistent with several, not 
necessarily mutually exclusive, functional deficits. For example, B cell dysfunction 
could be secondary to T cell dysfunction, either due to inadequate T cell help or to 
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suppression. Alternatively, the B cells could be unable to respond to signals that 
induce mutation. However, normal levels of serum IgM, IgGi and IgG3 one year post 
transplant indicate that T cells are able to provide at least some help [36;57-59], 
although the reconstitution of CD4+T cells is delayed post transplant [60]. As detailed 
in Chapter 5, T lymphocytes from some patients are able to provide adequate T cell 
help to healthy subject B cells in vitro [61], which is consistent with earlier reports 
that post transplant CD4+ T cells are qualitatively normal [62-65], and suggests that 
the B cell defect seen in BMT patients is not exclusively the result of defects in the T 
cell compartment. Moreover, B cells from BMT recipients one-year post transplant 
failed to accumulate mutations in vitro. This could not be overcome by co-cultures 
with healthy subject T cells, suggesting that the defect seen in BMT recipients is 
intrinsic to the B cells [Chapter 5; 61]. The inability of the healthy subject T cells to 
induce mutation in BMT B cells is probably not due to an MHC mismatch between 
recipient B cells and healthy T cells, since heterologous cell combinations of healthy 
HLA disparate individuals accumulate mutations as well as autologous combinations 
do [Chapter 5; 61]. MHC mismatched resting T cells did not drive accumulation of 
somatic mutation suggesting that the mutation seen in this culture system is not driven 
by an allogeneic reaction [Chapter 5; 61]. 
In vitro model of germinal center reactions 
Several in vitro models have been described that mimic germinal center reactions [66-
69]. In the system reported in Chapters 4 and 5, we used a system in which freshly 
isolated, activated CD4+ T cells drive naive B cell differentiation over a 14 day 
culture period [61;70]. In this system, healthy subject B cells accumulate large 
numbers of V segment mutations, presumably as a consequence of activation of the 
somatic mutator mechanism. However, there are other possible mechanisms that 
might account for the observed accumulation of somatic mutation. Therefore the 
question as to whether mutation is actually occurring during the culture period must 
be addressed. One of the possibilities is that T cells regulate differential outgrowth of 
mutated (or mutating) B cells compared to unmutated B cells by selectively driving 
the previously mutated B cells to grow out, or that T cells are selectively killing naive 
(i.e. unmutated) B cells allowing the mutated cells to grow out. Several studies of 
tonsillar B cells [71-73] as well as of peripheral blood B cells [74-78] have indicated 
that somatically mutated IgM or IgD memory cells occur, albeit at a low frequency. 
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Recently, a rare population of cells has been described that is CD27+IgD+ [79], and 
may be comprised of a novel population of highly mutated memory cells [80]. 
In the experiments described in Chapters 4 and 5, 1000 B cells were plated. Plating 
efficiency in this system is approximately 10% (G.V. Pinchuk and E.C.B. Milner 
unpublished results), therefore roughly 100 clones would grow out in these cultures. 
Nearly 40 percent of all the B cells express a VH3 containing Ig (E.H.N, van Montfort 
and E.C.B. Milner, unpublished results), which would lead to 40 VR3 expressing B 
cell clones. Twenty to 35% of the VH3 expressing B cell clones are derived from the 
V3-23 gene, therefore 8 to 14 V3-23 clones would grow out. Our sequence data are 
consistent with this prediction [70] and (A.M. Glas, E.H.N, van Montfort and E.C.B. 
Milner, unpublished results), supporting the conclusion that mutation occurs in the 
cultures. However, it cannot be excluded that the IgD+CD27+memory cells may be 
selectively permitted to proliferate in the T cell supported cultures, but not the 
CD40L-supported cultures. However, preliminary results show that sorted IgD+CD27" 
cells, and cord blood cells, which are IgD+CD27" [79], accumulate mutation in this 
system, suggesting that IgD+CD27+ memory cells are not the sole contributor of the 
mutations seen in this system (A.M. Glas, E.H.N, van Montfort and E.C.B. Milner, 
unpublished results). 
Origins ofB cell dysfunction following transplant 
Two results described in this thesis, lack of somatic mutation in vivo and inability to 
accumulate mutations in vitro, are consistent with the hypothesis that B cells from 
BMT recipients have an "intrinsic" inability to acquire somatic mutations. Unmutated, 
naive B cells have the phenotype CD19+ IgM+ IgD+. This phenotype is exhibited 
among healthy subjects by approximately 80% of B cells, and among BMT recipients 
by more than 95% of B cells [3]. Thus, by both cell surface phenotype and the extent 
of somatic mutation, the B cell repertoire post-BMT resembles the pre-immune 
component of the B cell repertoire of a healthy adult. Simply because of population 
dynamics it would seem logical that the B cell repertoire post BMT would be 
primarily naive. However, the finding that these B cells cannot be driven to acquire 
somatic mutations suggests that additional processes are at work. The failure of the 
cells to accumulate somatic mutations did not seem to parallel a failure to class switch 
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[Chapter 5; 61]. Taken together the data are most easily explained by postulating that 
there is a deficit in the capacity of BMT recipient B cells to respond to signals that 
activate the somatic mutator mechanism. 
Because the marrow donors are themselves healthy subjects whose B cells are capable 
of acquiring mutations, this post-transplant deficit must be developmentally 
determined. GVHD is a strong suppressor of immune function, however, the lack of 
somatic mutation cannot be attributed directly to GVHD because nine of the 13 
subjects studied were free of GVHD [Chapters 3 and 5; 17;18]. There were no 
obvious differences in the diversification of the repertoire between patients with or 
without GVHD. The patients are usually treated with immunosuppressive drugs, such 
as cyclosporine, to prevent GVHD; the immunosuppressive treatment might be 
expected to delay recovery of immunocompetency. However, in most patients studied 
[Chapter 5; 61], the therapy was terminated at least 180 days prior to our studies, and 
is unlikely to explain the lack of mutation in these patients. 
Memory responses are dependent on germinal center formation. The kinetics and 
quality of restructuring the architecture of the secondary lymphoid organs after 
transplant will have a significant impact on reconstitution of the B cell repertoire. One 
hypothesis is that during the pre-transplant conditioning regimen a critical cellular 
function may be disrupted that is not restored by marrow transplant. Irradiation and 
immunosuppression could affect each of the cell types in germinal center formation: T 
cells, B cells, and follicular dendritic cells (FDCs). As described above, T cells are 
unlikely to be the sole contributor to the inability to acquire mutations. Consistent 
with this hypothesis is the fact that histological analysis of spleen and lymph nodes 
from non-surviving patients of allogeneic BMT revealed a reduced number of B 
lymphocytes, and absence of lymph node follicles [81-84]. 
In normal B cell differentiation, newly formed transitional B cells are recruited into a 
long-lived preimmune B cell pool. The lymphocytes are selected in a process that is 
thought to be competitive and is dependent on survival signals delivered in secondary 
lymphoid organs [85;86]. The majority of the newly formed B lymphocytes however, 
do not enter the mature repertoire. The critical molecular interactions and micro 
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environments that select which clones will be successfully recruited are poorly 
understood. It is hypothesized that B lymphocytes move away from the T cell zone 
towards the follicles in response to a chemotactic gradient that originates in the 
follicular stroma or in the marginal zone [85]. This process is thought to be 
competitive; the chemotactic gradient is reduced when the follicles are saturated, 
either because abundant receptors consume the gradient or because of reduced 
production [85]. The involvement of chemokines in the migration of the B cells 
towards the follicles has been recognized recently (reviewed in [87;88]). It is thought 
that the survival of the B cells that have migrated towards the follicles depends on 
rescue from apoptotic death by trophic factors produced by the FDCs [85]. 
Irradiation and immunosuppression could affect the ability of the B cells to receive 
the appropriate signals (trophic factors), the generation of such signals by other cells, 
such as the FDCs, or the generation and maintenance of the chemotactic gradient. The 
lymphoid architecture may be disrupted because of the pre-transplant conditioning 
[81-83], and it has been shown that the FDCs are missing [84;89]. The absence of 
FDCs could possibly disrupt the chemotactic gradient in BMT patients and as a result 
the B cells would be unable to migrate towards the follicles to receive survival 
signals. Alternatively, if the gradient is unaffected by the pretransplant conditioning, 
the survival signals could be missing and the cells die by apoptosis. If one or more of 
these possibilities were true, then BMT recipients may fail to select a long-lived naive 
B cell compartment. The implication of this is that the B cell compartment in BMT 
recipients is comprised primarily of transitional B cells. Transitional B cells are newly 
emerged from the bone marrow and are thought to be short lived [90]. We postulate 
that this transitional B cell population can participate in primary immune responses 
and can be driven to differentiate into plasma cells, but cannot participate in a 
germinal center reaction and cannot acquire mutations. 
Concluding remarks 
The B cell deficits in BMT recipients are hypothesized to be due to a failure to recruit 
mature cells into the long-lived B cell pool, and the failure to generate a memory 
response through a germinal center reaction. Immunohistological analysis of lymph 
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nodes and spleen at multiple time points after transplant would provide insight in the 
recovery of germinal centers after transplant. However, such a procedure is invasive 
and not justifiable. A more preferable analysis would be to determine the time point at 
which BMT recipients have regained their ability to somatically mutate. 
Finally, the question remains: what is the signal (or signals) that B cells need in order 
to activate their mutational mechanism? Do well known ligands and receptors play a 
role in a novel context, or is one as yet unknown ligand and receptor involved in the 
activation of the somatic mutation process? Revealing the deficit in BMT recipients 
could provide insight into the somatic mutation process in healthy subjects. 
Conversely, elucidation of the mechanism that activates the somatic mutation process 
in normal B cells would be of help in understanding the B cell deficit after BMT. 
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ABSTRACT 
The bone marrow is the major haematopoietic organ and is critically involved in the 
production of all formed blood elements in postnatal life. The bone marrow contains 
rapidly dividing cells and therefore is sensitive to DNA damaging agents. In certain 
types of cancers where a high dose of radiation and chemotherapeutic agents are 
needed, a bone marrow transplant is necessary to "rescue" the patient from the lethal 
side effects of radiation and chemotherapy. However, the immune system of 
transplant recipients must be regenerated from the transplant inoculum, and it is not 
surprising that many transplant recipients are deficient in generating specific antibody 
responses to exogenous stimuli. In this thesis experiments are described which are 
aimed at a further understanding of the nature of the B cell defects leading to the 
humoral deficiency in bone marrow transplant (BMT) recipients. 
The possibility that an abnormal restriction of the potential antibody repertoire in B 
cells from BMT recipients could contribute to the deficiency seen in BMT patients is 
explored in Chapter 3. The results showed that the processes involved in generating 
and selecting the antibody repertoire are largely functional within the first few months 
following BMT, and the immunodeficiencies common among BMT recipients 
probably are not due to the failure to utilize appropriate V region genes in generating 
the pre-immune antibody repertoire. Rearrangements in BMT recipients, however, 
exhibited much less somatic mutation than did rearrangements obtained from healthy 
subjects. 
In Chapter 2, the correlation between motif-specific hybridizations and nucleotide 
sequence variation is described as an approach to identify individual VH genes. This 
method is highly specific and allows for the detection of somatic mutation in these 
genes by sequential hybridization. By using this method, a large number of genes can 
be analyzed without sophisticated instrumentation. 
Somatic mutation of rearranged immunoglobulin genes is a powerful diversifier of the 
antibody repertoire and an important requisite in the formation of memory B cells. 
The precise mechanism responsible for turning on the mutational process is unknown. 
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To dissect the role of different components of the germinal center in this mechanism, 
we have used a system in which freshly isolated, activated CD4+ T cells drive naive B 
cell differentiation over a 14 day culture period. In this system, healthy subject naive 
B cells accumulate large numbers of V segment mutations, presumably as a result of 
activation of the somatic mutation mechanism (Chapter 4). This system is used in 
Chapter 5 to determine whether the lack of somatic mutation seen in BMT recipients 
is an intrinsic B cell deficit or secondary to a T cell deficit. The results showed that 
BMT recipient B cells lack the capacity to accumulate somatic mutation in a T cell 
dependent manner. This appears to be a B cell autonomous deficit because T cells 
from some patients were able to support accumulation in heterologous healthy subject 
B cells, however, they were unable to support the accumulation of mutations in 
autologous naive cells. 
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SAMENVATTING 
Het beenmerg is het voomaamste orgaan dat zorgt voor de productie van alle bloed 
cellen. Het beenmerg bevat cellen die zich snel delen en is daarom zeer gevoelig voor 
DNA-beschadigende agentia. Bij bepaalde kankertherapieen waarbij gebruik gemaakt 
wordt van een hoge doses straling en cytostatica is een beenmergtransplantatie (BMT) 
noodzakelijk om de patient te redden van de fatale neven effecten. Het immuun 
systeem van de patienten moet echter geregenereerd worden van het getransplanteerde 
inoculum, en het is daarom niet verrassend dat vele patienten geen specifieke 
antilichamen kunnen maken tegen lichaamsvreemde binnendringers. In dit 
proefschrift worden experimenten beschreven die er op gericht zijn om de aard van de 
gebreken in BMT patienten te verhelderen. 
De mogelijkheid dat een abnormale beperking van het potentiele antilichaam 
repertoire zou kunnen bijdragen aan de afwijking in BMT patienten is onderzocht in 
hoofdstuk 3. De resultaten laten echter zien dat, binnen de eerste paar maanden na de 
transplantatie, het proces van het genereren en selecteren van het antilichaam 
repertoire functioneel is en dat de afwijkingen niet voort komen uit een verkeerd 
gebruik van VH gen segmenten. Opvallend was dat de gerecombineerde VH genen 
minder somatische mutaties bevatten in vergelijking met gerecombineerde VH genen 
in gezonde mensen. 
In hoofdstuk 2 is de relatie tussen motief-specifieke hybridisaties en de variatie in 
nucleotide sequenties beschreven, om de VH gen segmenten te bepalen in 
gerecombineerde VH genen. Deze methode is zeer specifiek en kan ook gebruikt 
worden voor het bepalen van somatische mutaties in de VH genen. Tevens heeft deze 
methode als voordeel dat in korte tijd vele gerecombineerde VH genen geanalyseerd 
kunnen worden zonder geavanceerde apparatuur. 
Somatische mutatie in gerecombineerde immunoglobuline genen zorgt voor een 
uitgebreid repertoire van antilichamen specifiek voor vele lichaamsvreemde 
binnendringers, en is een belangrijke vereiste voor het generen van de zogenaamde 
"memory" cellen. Het precieze mechanisme dat verantwoordelijk is voor het 
aanzetten van het mutatie-mechanisme is nog onbekend. Om het mutatie-mechanisme 
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te onderzoeken is, in hoofdstuk 4, een in vitro systeem ontwikkeld waarin vers 
gei'soleerde en geactiveerde CD4+ T cellen de differentiatie van naieve B cellen 
bevorderen in een culture van 14 dagen. In dit systeem hopen zich vele mutaties op in 
de gerecombineerde VH genen van B cellen van gezonde mensen, waarschijnlijk als 
resultaat van de activatie van het mutatie-mechanisme. Dit systeem is in hoofdstuk 5 
gebruikt om te bepalen of het defect in het somatische mutatie-mechanisme in BMT 
patienten een gevolg is van een afwijking specifiek voor B cellen of dat het een direct 
gevolg is van een defect in de T cellen. De resultaten laten zien dat de B cellen van 
BMT patienten een afwijking in het T eel afhankelijke somatische mutatie 
mechanisme hebben. Dit blijkt een afwijking specifiek voor B cellen te zijn, omdat T 
cellen van sommige patienten niet in staat zijn om mutaties te ondersteunen in hun 
eigen B cellen, maar wel in B cellen van gezonde personen. 
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ABBREVIATIONS 
BMT bone marrow transplant 
CD40L CD40 ligand 
CDR complementarity determining region 
CML chronic myelogenous leukemia 
FDC follicular dendritic cell 
FHCRC Fred Hutchinson Cancer Research Center 
FITC fluorescein isothiocyanate 
FR framework region 
GVHD graft versus host disease 
H heavy chain 
HLA human leucocyte antigen 
HS healthy subject 
Ig immunoglobulin 
IVIG intravenous immunoglobulin 
L light chain 
MC mononuclear cells 
MNC mononuclear cells 
NK natural killer cells 
PB peripheral blood 
PBL peripheral blood lymphocytes 
PCR polymerase chain reaction 
PE phycoerythrin 
RA rheumatoid arthritis 
R/S ratio ratio of replacement to silent substitutions 
SLE systemic lupus erythematosis 
TMACL tetramethylammoniumchloride 
V variable region 
VH immunoglobulin heavy chain variable region 
VMRC Virginia Mason Research Center 
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